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Abstract 
1 Abstract 
Constituting an effective barrier against environmental challenges such as pathogen 
invasion, UV-radiation or prevention of extensive water loss, the epidermis as the outermost 
layer of the human skin has to be constantly regenerated in order to maintain its protective 
function. During this highly elaborate and delicate process of epidermal rejuvenation, 
progenitor keratinocytes conduct a terminal differentiation program which is accompanied 
by fluctuating expression of differentiation proteins and ultimately results in tightly 
agglutinated, dead and flattened cells that are embedded in an extracellular lipid layer.  
In light of these profound alterations in gene expression, it is not surprising that epidermal 
homeostasis is controlled by an extensive network of signaling pathways, transcription 
factors and more recently also the involvement of long non-coding RNAs (lncRNAs) for this 
vital process has been uncovered. One of these regulatory lncRNAs might be the 326 nt 
spanning transcript SPRR5_326, which was initially identified from full transcriptome 
sequencing as a lncRNA that is induced over the course of keratinocyte differentiation and 
at the same time suppressed in squamous cell carcinoma samples. According to this 
particular expression pattern, a dual role of SPRR5_326 for both these processes seemed 
promising and the impact of sustained SPRR5_326 expression on skin carcinogenesis was 
tested by an in vitro invasion assay and an in vivo tumor formation assay with inconclusive 
results. Surprisingly, a subsequent in-depth isoform characterization for the novel SPRR5 
locus revealed that the assumed SPRR5_326 transcript was not final but part of a longer 
(726 nt) SPRR5 transcript that is controlled by the transcription factor p63 and seems to be 
primarily localized in the cytoplasm of differentiated keratinocytes.  
In contrast to the results from the conducted tumor formation assays, an indispensable 
functional impact of SPRR5 for keratinocyte differentiation could be established for in vitro 
differentiated keratinocytes as well as in regenerated organotypic epidermal tissue. 
Additionally, a global RNA-sequencing experiment ultimately proved the necessity of 
SPRR5 for a proper terminal differentiation program and hinted towards an epigenetic 
mechanism. Therefore, an Assay for Transposase Accessible Chromatin (ATAC-Seq) as 
well as a Chromatin Immunoprecipitation (ChIP-Seq) experiment for the histone marks 
H3K27me3, H3K4me1 and H3K27ac was conducted in SPRR5 deficient and control 
keratinocytes, however the results from these experiments could not support this initial 
assumption. 
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Interestingly, the SPRR5 transcript also encloses an open reading frame for a putative 
SPRR5 protein, which shares a high degree of similarity to the human small proline-rich 
protein (SPRR) family. On the other hand, a subsequent phylogenetic analysis uncovered 
the separate evolution of SPRR5 apart from the other SPRRs and thus suggests a different 
mode of action for SPRR5. Based on these observations, the actual presence of the predicted 
SPRR5 protein was investigated and only minor protein amounts could be detected with a 
highly targeted and sensitive mass spectrometry approach, raising the question whether 
SPRR5 functions as a protein, a lncRNA or a combination of both. Eventually this enigma 
should be solved by rescue experiments, though unfortunately the siRNA-mediated SPRR5 
depletion lead to inconclusive results and also the generation of a homozygous SPRR5 
knockout cell line was unsuccessful, precluding a final statement about the functional 
SPRR5 molecule in keratinocytes.   
In conclusion an in-depth characterization of the human SPRR5 locus, including the 
detection as well as the functional testing of minor SPRR5 protein amounts has been 
conducted and the hypothesized necessity of SPRR5 for epidermal homeostasis could be 
ultimately confirmed during this work.  
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2 Introduction 
2.1 The human skin 
With a surface area of almost two square meters and a portion of 15- 20% of the total body 
weight, the human skin is not only the largest but probably also the most important organ of 
the human body since it defends the body against a plethora of hazardous environmental 
challenges on a daily basis1,2. However, the protective function of the skin is not limited to 
interception of external influences such as microbial invasion, ultraviolet radiation, 
mechanical or chemical assaults but also comprises regulation of the body temperature or 
prevention of extensive water loss3,4. The secret in accomplishing all these duties lies in the 
sophisticated composition of the human skin, which can be divided into three layers  
(Figure 1). The innermost hypodermis consists mainly of fat tissue and is essential for 
thermal insulation, whereas the dermis as middle layer retains water, provides stability and 
includes sensory receptors, sweat glands, hair follicles and blood vessels which are crucial 
for oxygen and nutrient supply of epidermal cells5–7. Furthermore, the connective tissue of 
the dermis provides a specialized anchor platform for epidermal cells, called basement 
membrane, which separates the dermis from the overlying epidermis5,7. 
2.1.1 Composition and regeneration of the human epidermis  
Although keratinocytes are the dominant cell type within the epidermis (90-95% of cells), 
interspersed neuroendocrine Merkel cells, specialized cells of the immune system as well as 
pigment-producing melanocytes are also present in the human epidermis and are crucial for 
a fully functional skin barrier7. Upon UV-B radiation for example, melanocytes produce 
melanin which has a photoprotective effect against tissue damages from reoccurring 
exposure to ultraviolet radiation7,8.  
As the outermost layer of the human skin, the epidermis is the first and most effective barrier 
against external influences and is composed of four different strata, which can be 
distinguished by the presence of keratinocytes in distinct differentiation states  
(see Figure 1)6,7.  
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Figure 1: Cross section of the human skin and schematic overview of the epidermal layers 
Schematic overview of the human skin, showing the three layers, hypodermis, dermis and epidermis as well as 
the therein included appendages (left; modified after9). Furthermore, a magnification of the epidermis, 
comprising the basal layer, spinous layer, granular layer and the stratum corneum is shown on the right 
(modified after10). 
 
The deepest of the four epidermal strata is the basal layer, which mainly contains 
undifferentiated keratinocytes that upon cell division undergo a terminal differentiation 
program as they migrate through the spinous and the granular layer until they eventually 
reach the stratum corneum, where they undergo apoptosis and form an impenetrable 
protective barrier6,11. Due to its exposed position within the human body, this barrier is 
constantly weakened by environmental influences or ruptured by mechanical stress and thus 
has to be continuously renewed by succeeding keratinocytes. In humans, this highly 
elaborate process, balancing the reservoir of progenitor cells and terminally differentiating 
keratinocytes takes 28 days and is also known as epidermal homeostasis12.   
The process of epidermal homeostasis starts in the basal layer with undifferentiated 
keratinocytes, which are characterized by the expression of keratin 5 and keratin 14. In the 
classic model for epidermal regeneration those keratinocytes are claimed to be stem cells 
which give rise to short-lived progenitors known as transit-amplifying cells (TA cells)10,11. 
Upon several rounds of cell division, these TA cells would eventually withdraw from the 
cell cycle and conduct a terminal differentiation program as the cells migrate to the apical 
site of the epidermis13,14. Recent studies however contradict this model and claim that one 
uniform population of committed progenitor keratinocytes undergoes symmetric and 
asymmetric cell divisions with a fixed probability15. Whereas the cells from the symmetric 
cell division maintain the pool of committed progenitor cells, the progeny from asymmetric 
cell division is committed to terminal differentiation10,14. Activation of this differentiation 
program is initially triggered by increasing calcium concentrations in combination with 
signals from cell-cell contacts and becomes first apparent in the spinous layers, where the 
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existing keratins 5 and 14 are replaced by newly synthesized keratin 1 and keratin 10 
filaments as well as involucrin16–18. By the time the differentiating keratinocytes reach the 
granular layer they express structural proteins such as loricrin, trichohyalin, small 
proline-rich proteins (SPRRs) and late cornified envelope proteins (LCEs) as well as 
profilaggrin, a highly phosphorylated oligomer of filaggrin repeats, which is stored together 
with keratins and loricrin in electron-dense keratohyalin granules7,11,19–21. Furthermore, 
lamellar bodies, a second type of lipid-filled granules containing mainly glycosphingolipids, 
free sterols and phospholipids can also be detected in granular cells22.   
During the transition from the granular layer to the stratum corneum keratinocytes undergo 
drastic changes and even apoptosis to eventually form a protective skin barrier. For that 
matter, increasing intracellular calcium levels trigger the release of profilaggrin from the 
keratohyalin granules, which ultimately becomes dephosphorylated and cleaved into 
filaggrin monomers that are subsequently bundled with the present keratin into macrofibrils, 
resulting in gradual flattening of the cells11,23. Concomitantly, transglutaminases 1, 3 and 5 
introduce isopeptide bonds between these macrofibrils and other structural proteins like 
members of the S100 protein family, loricrin, LCEs, SPRRs and involucrin forming a rigid 
protein shell termed “cornified envelope”11,20,24,25. Finally, the lamellar bodies fuse with the 
plasma membrane and secrete the enclosed lipids into the extracellular space, generating a 
lipid lamella which is crucial for maintaining the epidermal water barrier24.   
As a result of this process, the cornified envelopes of terminally differentiated keratinocytes 
are tightly connected via modified desmosomes and embedded in extracellular lipid 
lamellae, providing the indispensable barrier against external challenges and loss of essential 
body fluids20,26. 
2.1.2 Regulation of epidermal homeostasis 
Since generation of a functional epidermis is accompanied by profound alterations in gene 
expression, multiple regulatory mechanisms are required to orchestrate those changes.   
By far the most important stimulus for keratinocyte differentiation arises from increasing 
levels of extra- and intracellular calcium concentrations, which is not only crucial because 
several differentiation proteins are stabilized by Ca2+-ions or require Ca2+ for their proper 
function but also multiple calcium-dependent signalling pathways are involved over the 
course of keratinocyte differentiation16,17,27,28. In addition to that, cell-cell contacts which 
initiate a signaling cascade via the E-cadherin–catenin complex or the activated form of 
vitamin D3 (1,25(OH)2D3) are also fundamental regulators of keratinocyte 
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differentiation4,29,30. Amongst other effects, all these stimuli lead to increased activity of 
phospholipase C which hydrolyzes phosphatidylinositol bisphosphate (PIP2) to the second 
messengers inositol trisphosphate (IP3) and diacylglycerol (DAG)
27,31. Next, IP3 releases 
calcium from intracellular storage granules and might even stimulate the influx of 
extracellular calcium which further expedites the differentiation program27. DAG on the 
other hand activates protein kinase C, which triggers intracellular signaling pathways 
including the mitogen-activated protein kinase (MAPK) pathway and ultimately results in 
the activation of transcription factors and thus induction of gene expression27,32.  
Apart from the described exemplary mechanism, several other signaling pathways are 
crucial for keratinocyte differentiation (including Notch, TGF-β and IKK/NF-κB), however 
almost all signaling pathways lead to the activation of specific transcription factors that 
ultimately induce the expression of differentiation genes33,34. Over the years, many 
transcription factors (for example members of the c-jun/c-fos family, GRHL3, Klf4, 
MAF:MAFB, OVOL1/2 or ZNF750) have been identified as fundamental mediators of 
keratinocyte differentiation but p63 was revealed as the master regulator of keratinocyte 
differentiation humans and mice33,35–39. Besides its direct effect on keratinocyte 
differentiation, p63 also controls the proliferative capacity of keratinocytes in the basal layer 
of the epidermis, which contributes to its stimulatory effect on keratinocyte differentiation 
and impressively accentuates its pivotal role for keratinocyte propagation and 
maturation40,41. Moreover, loss of p63 in keratinocytes results in severe defects in 
keratinocyte cell adhesion, basement membrane formation as well as epidermal 
stratification40,42,43. All these effects can be either reasoned by a direct p63-mediated 
induction of differentiation gene expression or the p63-dependent regulation of several 
chromatin modifiers, resulting in an epigenetic control of keratinocyte differentiation43. 
Furthermore, p63 is able to recruit the histone deacetylases 1 and 2 (HDAC1/2) in order to 
omit the expression of cell cycle arrest genes or alters the accessibility of epidermal 
enhancers in combination with the BAF chromatin remodeling complex44,45.   
Finally, keratinocyte differentiation is also regulated by several epigenetic mechanisms 
including chromatin remodeling or DNA methylation by DNMT1 or GADD45A/B for 
example46,47. Additionally, several histone modifications have been identified as regulators 
of keratinocyte differentiation. The repressive histone mark H3K27me3 for example is 
established in a conjoined action of the polycomb repressive complex (PRC) and its 
methyltransferase subunits EZH1 and EZH2, whereas target gene repression is restored by 
the demethylases JMJD3 and UTX46,48–50. 
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A fourth layer of epigenetic regulation originates from large scale nuclear remodeling during 
which the size of the nucleus decreases and the epidermal differentiation complex (a 
genomic region on the human chromosome 1 encoding many differentiation genes) is 
relocated to the nuclear periphery and becomes associated with active nucleoli for induction 
of differentiation gene expression51.   
In conclusion, a conjoined effort of a plethora of intracellular signaling pathways, 
transcription factors as well as epigenetic mechanisms is mandatory to orchestrate the 
profound changes in the gene expression pattern during epidermal homeostasis. 
2.1.3 The human epidermal differentiation complex and the SPRR 
protein family 
Spanning 1.9 Mb on the human chromosome 1 and encoding roughly sixty proteins essential 
for proper keratinocyte differentiation and epidermal barrier formation, the epidermal 
differentiation complex (EDC) is indispensable for epidermal homeostasis52,53. Interestingly, 
gene distribution within the EDC is not random but genes encoding for proteins with similar 
functional and structural properties are clustered accordingly into distinct genomic locations 
(Figure 2). Flanked by the family of S100 proteins which are characterized by two 
calcium-binding EF-hands are the S100-fused type proteins containing profilaggrin, 
trichohyalin or repetin as well as the clusters for the late cornified envelope (LCE) and small 
proline-rich proteins (SPRR)54,55. In combination with the interspersed genes for loricrin and 
involucrin, the LCE and SPRR cluster account for the majority of proteins present in the 
cornified envelope of terminally differentiated keratinocytes53.  
As the result of a series of intra- and intergenic gene duplications from a single gene 
progenitor, today the human SPRR protein family comprises 10 protein-coding genes as well 
as one pseudogene (SPRR2C) and is massively induced during the course of keratinocyte 
differentiation by cyclic-AMP, retinoids, phorbols, interferon-γ, UV-radiation as well as the 
conjoined action of several transcription factors56–58.   
 
 
 
 
 
 14 
Introduction 
 
 
 
Figure 2: Overview of the human epidermal 
differentiation complex and its encoded genes 
The human chromosome 1 is shown on the left 
and the respective cytogenetic bands are 
indicated. Furthermore, the area of the epidermal 
differentiation complex with its encoded genes 
(according to the RefSeq release 2016) is 
magnified and the main gene clusters are 
indicated on the right.
Given the evolution from a common ancestor, SPRR proteins as well as their respective 
genes share a high degree of similarity. However, based on their sequence conservation two 
major subfamilies for the human SPRR genes can be identified: the SPRR2 subfamily 
(SPRR2A-G) and a second group comprising SPRR1A, SPRR1B, SPRR3 as well as the 
most recently identified SPRR457,59. Moreover, close examination of the SPRR amino-acid 
sequences reveals a characteristic composition, as their N- and C-termini are rich in 
glutamine and lysine residues that are used for protein-protein crosslinking and thus ensures 
the mechanical resistance of the epidermis. In contrast to this, their central domain consists 
of varying proline-rich repeats, allowing the formation of a flexible and non-organized 
structure which is essential for epidermal elasticity11,57. It is this combination of features that 
render the “spring-like” 6-18 kDa SPRR proteins excellent crosslinkers for other cornified 
envelope proteins like loricrin, LCEs, filaggrin or involucrin and it is therefore not surprising 
that this is also the best described function for SPRR proteins11,57,59. Apart from that, SPRR 
proteins are also able to detoxify reactive oxygen species (ROS) by building intra- and 
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intermolecular disulfide bonds between cysteine residues, which was first reported as an 
essential function of SPRRs in injured skin tissue60. Further studies eventually uncovered 
the SPRR2A mediated deacetylation of the p53, providing a mechanistic link between SPRR 
proteins and cell migration during wound healing57,61. Later, the antioxidant effect of small 
proline-rich proteins was also identified in non-wounded tissue and SPRRs were inferred as 
part of an effective antioxidant defense mechanism within the epidermis62. Interestingly, the 
recently identified SPRR4 exhibits the highest antioxidant potential and is induced upon 
UV-radiation, suggesting a specialized role of SPRR4 during the adaptive UV-response in 
epidermal tissue59,62. Furthermore, compared to the other human SPPR proteins, SPRR4 has 
the highest DNA binding capacity, which is directly controlled by the concentration of 
reactive oxygen species but unfortunately exact target sites as well as the functional 
significance of this DNA binding in vivo remain elusive63.  
Aberrant expression of SPRR proteins is also described for various forms of cancer, 
including breast, colorectal, esophageal as well as several types of skin cancer. Depending 
on the analyzed cancer type, the corresponding expression levels were found to be either up- 
or downregulated, leading to an inconclusive picture of their role during cancer development 
and progression. Additionally, several skin diseases are marked by altered expression of 
SPRR proteins, highlighting their importance and particular role for skin development in 
general but surprisingly no defective epidermis development or aberrant epidermal 
differentiation program in SPRR knockout mice has been reported so far57,64,65. 
2.1.4 Defective epidermal homeostasis results in skin cancer progression 
Given the complex composition and the highly elaborate regulatory networks involved in 
epidermal homeostasis, one can easily visualize that already incremental changes within this 
process lead to cancer development. Moreover, the three major forms of skin cancer occur 
in the epidermis and arise either from keratinocytes like the basal cell carcinoma (BCC) and 
the squamous cell carcinoma (SCC) or from pigment producing melanocytes in the case of 
melanoma66,67. Common risk factors for skin cancer include alcohol consumption, fair skin 
pigmentation, chronic cutaneous infection and immune suppression but by far the most 
prevalent factor is the continuous exposure to UV-light and accompanying reoccurring sun 
burns66–68.   
Although less common than the keratinocyte derived BCC and SCC, melanoma accounts for 
a higher number of deaths and in general correlates with a poor prognosis. However, if 
recognized and treated prior to metastasis, melanoma is almost always curable by surgical 
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excision, which is the reason for focusing clinical efforts mainly on early melanoma 
detection and removal66,69,70.  
Basal cell carcinoma on the other hand, is the most common type of skin cancer and is 
frequently found in sun-exposed areas of skin, especially heaped in areas on and around the 
nose67. As the name already indicates, BCC arises from nonkeratinizing progenitor 
keratinocytes located in the basal layer of the epidermis and is characterized by slow growing 
and rarely metastasizing cells. Nevertheless, BCC patients frequently suffer from major 
tissue damage resulting in serious mutilating deformations and loss of vital structures66,67,71. 
From a mechanistic point of view, BCCs often include a characteristic mutation in the 
patched 1 tumor suppressor gene (PTCH1) but also other activating mutations in the sonic 
hedgehog signaling pathway have been reported, which might offer a promising therapeutic 
opportunity for BCC besides surgical excision66,72. Interestingly, signaling via the sonic 
hedgehog pathway in BCC patients also activates the Ras/Raf signaling pathway by 
increasing the expression of the platelet-derived growth factor receptor α (PDGFRα)73.  
Activation the Ras/Raf pathway is also commonly detected in cutaneous squamous cell 
carcinoma (SCC), which is only the second most common form of skin cancer in the USA 
but at the same time the one with the highest metastatic potential and the highest mortality 
after formation of aggressive metastasis66,74,75. Apart from greatly increased incidences of 
SCC in patients receiving immunosuppressive therapy, which is presumably caused by 
concomitant human papilloma virus infection and a number of heritable conditions favoring 
SCC development, UV-radiation-mediated mutagenesis is thought to be the major 
environmental factor promoting this type of cancer66. Thus, it is not surprising that 
UV-induced p53 loss of function mutations are the key event in cutaneous SCC 
carcinogenesis75. Moreover, mutations in the CDKN2A locus are frequently observed in 
SCC samples and result in an unleashed cell cycle control which is at least partly caused by 
loss of p16 mediated inhibition of cyclin-dependent kinase 4 (Cdk4) activity. Additionally, 
increased expression of Cdk4 is often associated with SCC development, which is especially 
interesting since Cdk4 overexpression is sufficient to induce SCC neoplasms in human 
epidermis when it is co-expressed with oncogenic forms of Ras proteins66,76. Consistent with 
this, release of the cell cycle control by a blockade in the NF-κB signaling pathway and 
simultaneous expression of oncogenic Ras can also transform human epidermis into a highly 
aggressive invasive neoplasia which presents itself indistinguishable from SCC77,78.  
In light of this central role of Ras proteins in SCC samples one can easily envision that 
expression of constitutively active Ras variants might be sufficient to cause SCC 
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development. Surprisingly however, expression of oncogenic Ras proteins alone drives 
keratinocytes into senescence and only the combination of oncogenic Ras and an unleashed 
cell cycle, for example by blocking the NF-κB signaling pathway or overexpressing Cdk4 
(see above), result in SCC generation77,79,80. Despite this fundamental involvement of 
constitutively active Ras proteins in SCC generation, it is astonishing that amplification of 
Ras genes or activating mutations have only been reported for the minority of SCC samples, 
hence the observed increased levels of active GTP-bound Ras in the majority of human SCC 
tissues are presumably caused by the faulty activation of several upstream factors like 
receptor tyrosine kinases for example66,75,81. Histologically and biochemically, the 
keratinocyte derived SCC cells can be distinguished from healthy keratinocytes by their 
altered proliferative capacity as well as their reduced expression of keratinocyte 
differentiation proteins. In fact, suppression of gene expression for several key 
differentiation genes is a hallmark of SCC development and was frequently reported over 
the past years82–84.  
Apart from the above described proteins, several miRNAs have been reported as important 
stage specific biomarkers in the diagnosis of SCC and others were found to be gradually 
increased or decreased, implicating a crucial gene regulatory function for miRNAs during 
SCC progression85,86. Ultimately, even members of the novel class of long non-coding 
RNAs, which are essential regulators of fundamental cellular processes and tissue 
development have been implicated in SCC carcinogenesis (for details see 2.2.4)87–91. 
 
 
2.2 Long non-coding RNAs 
 
2.2.1 Identification and classification of long non-coding RNAs 
 - DNA is transcribed into RNA, which is eventually translated into a functional protein. -  
For years, this sentence has been the irrevocable central dogma of molecular biology.  
With fundamental cellular functions ranging from energy metabolism to structural 
components, over signal transduction to being key regulators of gene expression, proteins 
were attributed great scientific attention while the RNA was contemplated as the inevitable 
intermediary required for protein production. However, this picture changed dramatically as 
high-throughput sequencing data revealed that more than two-thirds of the human genome 
are actively transcribed into RNA but only <2% actually encodes for proteins92,93. Although 
a role of ncRNAs for several basic cellular functions like translation (transfer RNAs, 
 18 
Introduction 
ribosomal RNAs), RNA editing (small nucleolar RNAs) or splicing (small nuclear RNAs) 
has been known for quite a long time and the more recently identified shorter ncRNAs 
(20-30 nt in length) including microRNAs, endogenous short-interfering RNAs or 
piwi-associated RNAs as crucial regulators of gene expression were also identified, another 
tremendous piece of the ncRNA puzzle seemed to be missing94–97. Ultimately, this gap was 
closed with the identification of the novel class of long non-coding RNAs (lncRNAs), which 
has gained increasing scientific interest over the past few years and we are only beginning 
to appreciate their exigency and significant role for cellular processes as well as tissue 
homeostasis98–100.  
Per definition lncRNAs are over 200 nucleotides in length, can be spliced, capped and/or 
polyadenylated and are localized either in the nucleus or the cytoplasm of the cell87,92,101. 
Furthermore, lncRNAs in general lack a protein-coding potential, although recent reports 
about lncRNAs associating with ribosomes and translation of small functional peptides from 
lncRNA templates challenge this rather strict classification102–104. One of the first reports 
about those bifunctional RNAs was SRA1 and its protein counterpart steroid receptor RNA 
activator protein (SRAP), which are both co-regulators of steroid receptors as well as MyoD, 
a transcription factor important for skeletal myogenesis105–107. More recently, the peptide 
DWORF was identified in the lncRNA LOC100507537 and many additional putative 
peptides are predicted to arise from lncRNAs. In contrast to this, other global studies indicate 
that the majority of lncRNAs is not translated and thus indeed non-coding102,103,108–110.  
Scattered all over the genome, lncRNAs can either emerge as divergent transcripts from a 
neighboring gene promotor or from completely autonomous genomic loci (intergenic). 
Additionally, they can represent the overlapping antisense transcript of a protein-coding 
gene or originate from an intronic region. Depending on the overlap and the orientation to 
the host gene, this rather general classification can be further refined into several more 
defined subclasses111,112. Apart from being included into other transcriptional units, 
lncRNAs themselves can host protein-coding genes or other ncRNAs like the recently 
identified circular RNAs (circRNAs), tRNAs, miRNAs and especially snoRNAs98,113–117. 
This high degree of complexity in lncRNA loci is even further increased by the presence of 
an average of 2.3 to 3.9 different isoforms per gene locus, resulting from a combination of 
alternative splicing, alternative polyadenylation and employing alternative transcription start 
sites, which highlights the requirement for a careful lncRNA locus 
characterization98,100,118,119.  
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Interestingly, many lncRNAs feature a strict cell-type and also differentiation state specific 
expression pattern which already implies a central function during different cellular 
processes. And indeed, lncRNAs have been proven essential regulators for fundamental 
processes such as cellular differentiation, epigenetic imprinting, cell cycle control, apoptosis, 
X-chromosome inactivation, promoter-specific gene regulation and nuclear import88,120–127. 
Furthermore, aberrant lncRNA signatures are a hallmark of several severe diseases including 
numerous types of cancer, which impressively highlights their tremendous significance on 
almost every aspect of the life cycle87,128. 
2.2.2 Molecular mechanisms of lncRNA function 
Although we are aware of several thousand different lncRNAs in humans today and new 
lncRNAs are identified on a regular basis, only a small number of lncRNAs has been 
mechanistically characterized in detail129. What we know today is that in general lncRNAs 
can either act as guides or decoys for other RNAs and proteins, exert a signaling function, 
or act as a scaffold during the assembly of larger ribonucleoprotein complexes130. By 
employing solely one of the above described archetypes or a combination of those, lncRNAs 
are able to fulfill their multifaceted functions which are mostly reasoned by a regulatory 
function on gene expression at both, the transcriptional and the posttranscriptional level. 
Furthermore, depending on the localization of the lncRNA gene in respect to the position of 
transcriptional control, cis- (the lncRNA regulates gene expression in the vicinity of its own 
locus) or trans-acting (spatial separation of lncRNA expression and transcriptional control) 
lncRNAs can be distinguished130,131.  
One of the best studied examples for transcriptional gene regulation in cis is the lncRNA 
X-inactive-specific transcript (XIST), which is crucial for mammalian dosage compensation. 
To this end, XIST is exclusively expressed from one of the two X-chromosomes in females, 
subsequently coats this chromosome and triggers a series of events that lead to 
conformational reorganization, chromatin modifications and ultimately transcriptional 
silencing of this X-chromosome132,133. In contrast to this, dosage compensation in flies is 
achieved by transcriptional activation of the single X-chromosome in males. During this 
process, the functionally redundant lncRNAs roX1 and roX2 target the male-specific lethal 
complex to the X-chromosome, where hypertranscription is achieved by increasing H4K16 
acetylation134,135. Another well-characterized lncRNA is the 2.2 kb HOX transcript antisense 
RNA (HOTAIR), which was the first identified lncRNA featuring a trans-acting mechanism. 
HOTAIR is expressed from the HOXC locus but represses transcription of the distant HOXD 
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locus by scaffolding and guiding the polycomb repressive complex 2 (PRC2) as well as the 
LSD1/CoREST/REST complex to the HOXD cluster, resulting in H3K27 trimethylation and 
H3K4 demethylation
120,122. Besides the above-mentioned histone and chromatin 
modifications, lncRNAs were also found to directly control Pol II activity, associate with 
transcription factors and exert coregulatory functions during transcriptional regulation of 
gene expression136.   
Moreover, lncRNAs are also able to control gene expression on a post-transcriptional level 
by regulating RNA splicing, RNA editing, mRNA stability, mRNA translation efficiency as 
well as miRNA-mediated mRNA destabilization136,137. The antisense lncRNA BACE1-AS 
for instance, is upregulated in Alzheimer's disease and increases the stability of its antisense 
transcript BACE mRNA, by masking its binding sites for miR-485-5p138. Apart from 
competing for miRNA binding sites in other transcripts, lncRNAs - in this context also 
known as miRNA sponges or competing endogenous RNAs (ceRNAs) - can efficiently 
sequester miRNAs themselves like Linc-MD1 for example, which activates muscle-specific 
gene expression in human and murine myoblasts via sponging miR-133 and miR-135139. 
2.2.3 LncRNAs control tissue homeostasis and organ development 
Given the largely cell-type and also differentiation state specific expression pattern of 
lncRNAs, it is not surprising that lncRNAs are crucial regulators of organ and tissue 
development and homeostasis87,140. Besides the already mentioned functions of the 
bifunctional SRA1 and linc-MD1 during muscle development, skeletal muscle 
differentiation and regeneration is also promoted by the lncRNAs H19, SENCR, MUNC or 
lnc-mg. Furthermore, the small peptide DWORF, which is encoded on the lncRNA 
LOC100507537, enhances muscle contractility by stimulating SERCA mediated 
Ca2+-uptake into the sarcoplasmic reticulum110,140. Along this line, even the homeostasis of 
the most important muscle – the heart – is orchestrated by several lncRNAs. One of the first 
discovered examples for this was Braveheart, which activates a core cardiovascular gene 
network and possibly mediates epigenetic regulation of cardiac commitment by interacting 
with components of the PRC2 complex141. Additionally, proper murine heart development 
is ensured by the recruitment of the histone modifying complexes PRC2 and TrxG/MLL 
through the lncRNAs Fendrr and Carmen142,143.  
Moreover, several lncRNAs are exclusively expressed in the brain and the nervous system 
and ensure proper brain development, synapse formation and function, stress responses and 
age-associated changes. Evf2 for example recruits transcription factors in cis and trans 
 21 
Introduction 
during murine ventral forebrain development, while Pinky regulates neurogenesis in the 
embryonic and postnatal brain in combination with the splicing factor PTBP1124,144. 
Interestingly, a recent single-cell analysis of the lncRNA signature from human neocortex 
cells at different developmental stages revealed numerous cell type-specific lncRNAs, 
suggesting a highly complex regulatory lncRNA network that is essential for brain 
development145.  
Apart from the indispensable roles during muscle, heart and brain development, lncRNAs 
are also well-established regulators of literally every organ, including bones, lung, liver, fat 
as well as intestinal tissue and even the homeostasis of the largest human organ – the skin – 
is tightly controlled by several lncRNAs140. 
2.2.4 Roles of long non-coding RNAs in epidermal tissue homeostasis and 
skin diseases 
The 3.7 kb terminal differentiation-induced ncRNA (TINCR) was one of the first lncRNAs 
featuring a crucial function for maintenance of epidermal homeostasis. During this highly 
complex process, TINCR regulates differentiation gene expression via a post-transcriptional 
mechanism in which it forms short double stranded RNA duplexes with several 
differentiation protein mRNAs. Specific interactions in this instance are mediated by short 
25 nt TINCR-box motifs, which become subsequently bound by the protein Staufen1, 
ultimately resulting in mRNA stabilization and therefore sustained expression of 
differentiation genes88. Whereas TINCR is essential for keratinocyte differentiation, the 
anti-differentiation ncRNA (ANCR) has an opposing effect on keratinocyte differentiation 
(Figure 3). ANCR is widely expressed in progenitor keratinocytes and was found to be 
significantly downregulated upon induction of the terminal differentiation program. 
Furthermore, loss of ANCR in undifferentiated keratinocytes induced ectopic expression of 
differentiation markers, ultimately proving that ANCR is essential for maintaining the 
undifferentiated cell state within the epidermis146. Interestingly, a recent study was able to 
show that TINCR and ANCR both control the transcription factors MAF and MAFB and 
thus exert their regulatory function in epidermal homeostasis at least partially via the same 
pathway. While TINCR potentiates the differentiation state through enhancing MAF/MAFB 
mRNA stability, ANCR suppresses MAF/MAFB expression in association with the PRC2 
component EZH236.   
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Figure 3: Expression pattern of several mammalian lncRNAs in the skin 
Schematic overview of the epidermis, depicting keratinocytes in varying differentiation states and their 
occurrence in the corresponding four epidermal strata (left). Furthermore, the expression pattern of the two 
antagonizing lncRNAs TINCR (red) and ANCR (green), controlling keratinocyte differentiation are shown 
next to the psoriasis affecting lncRNA PRINS (blue) as well as lncRNAs featuring altered expression in SCC 
(black) or melanoma (brown) (modified after147). diff. = differentiation 
 
However, not only proper keratinocyte differentiation is maintained by lncRNAs but also 
generation and progression of several skin diseases and cancer types are accompanied by 
aberrant lncRNA expression (Figure 3). TINCR as well as the recently identified lncRNA 
SMRT-2 (SCC misregulated transcript 2) for example are not only crucial factors for normal 
keratinocyte differentiation but both exhibit reduced expression in cutaneous squamous cell 
carcinoma (SCC) samples88,89. Given the fact that keratinocyte derived SCC represents the 
second most common cancer in the United States and has the highest metastatic potential 
amongst all forms of skin cancer, it is surprising that besides the above-mentioned examples 
and the recently identified PICSAR as well as the murine AK144841, only a handful of 
lncRNAs have been functionally characterized in SCC89,90. Also in melanoma, the most 
dangerous form of skin cancer originating from melanocytes, several lncRNAs like 
SPRY4-IT1, MALAT1, HOTAIR, PTENP1 or SLNCR1 feature an aberrant expression 
pattern, indicating a lncRNA involvement in melanoma progression69,147,148. Another well-
known example for a melanoma lncRNA is the 693 bp BRAF-regulated lncRNA (BANCR), 
which controls the migratory capacity of melanoma cells and hence directly correlates with 
their metastatic potential149. Further studies addressing the mechanistic details of BANCR-
mediated melanoma progression were able to unravel that BANCR controls the MAPK 
pathway activity and leads to upregulation of Notch2 via sponging of miR-204150,151. 
Moreover, diverging lncRNA signatures have been found in several other skin diseases. The 
primate-specific lncRNA PRINS (psoriasis susceptibility-related RNA gene induced by 
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stress) for example affects psoriasis susceptibility as well as the innate immune response of 
the skin and generally functions in the keratinocyte stress response152,153.  
In summary, lncRNAs have been proven to be crucial regulators of epidermal homeostasis 
and their aberrant expression is tightly linked to several skin diseases, including multiple 
forms of skin cancer. Thus, lncRNAs are not only valuable markers for skin diseases or 
keratinocyte differentiation but expanding our knowledge about the underlying modes of 
action might also offer novel angles for the development of therapeutic approaches for skin 
diseases. 
 
2.3 Detection of SPRR5_326 and preliminary results 
Initially identified from full transcriptome sequencing of differentiated versus 
undifferentiated keratinocytes, SPRR5_326 was discovered as a novel long non-coding 
RNA which is encoded within the epidermal differentiation complex, drastically induced 
during keratinocyte differentiation and suppressed in SCC samples as compared to 
site-matched tissue control samples from the same donors88,89,146. Since no annotation for 
this lncRNA was present at the time of identification, RACE analyses were conducted and 
overlaid with the results from the performed RNA-Seq experiments, leading to the prediction 
of a 326 nt long transcript lacking an open reading frame, which was hence termed 
SPRR5_326. Furthermore, given the facts that lack of differentiation is a hallmark of SCC 
cells, SPRR5_326 is induced during keratinocyte differentiation, repressed in SCC samples 
and is encoded within the human epidermal differentiation complex where many essential 
differentiation genes are clustered, SPRR5_326 seemed to control both epidermal 
homeostasis as well as SCC progression. 
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3 Objective 
Given the proposed dual function of SPRR5_326 during regular keratinocyte differentiation 
as well as its dysregulation in human squamous cell carcinoma, the aim of this PhD project 
was to shed more light on the exact role of SPRR5_326 throughout those processes. To this 
end, first the impact of sustained SPRR5_326 expression on cancer progression should be 
assessed. Furthermore, this novel and previously uncharacterized lncRNA gene locus will 
be characterized in more detail with respect to its upstream regulating transcription factors, 
all of its expressed isoforms as well as their expression pattern during keratinocyte 
differentiation. Surprisingly, results from these studies indicated that the previously 
anticipated SPRR5_326 transcript is not the dominant transcript but instead a longer isoform 
spanning 762 nt, from now on termed SPRR5, is massively induced in differentiating 
keratinocytes and also comprises a predicted open reading frame. Due to these findings, the 
actual presence of the predicted SPRR5 protein had to be tested and its functional relevance 
was probed in rescue experiments in order to decipher whether SPRR5 functions as a 
lncRNA, a protein or a combination of both.  
Finally, the impact of SPRR5 deficiency on epidermal homeostasis should be evaluated and 
insights from these studies should be used to postulate and test a hypothesized molecular 
mechanism of SPRR5 during the course of keratinocyte differentiation. 
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4 Results 
4.1 Linking SPRR5 and neoplasia 
The fact that SPRR5_326 is downregulated in human squamous cell carcinoma samples 
compared to their site matched healthy tissue controls already implies an important function 
for SPRR5_326 in either cancer onset or development and lead to the hypothesis that 
sustained SPRR5_326 expression might prevent neoplasia or tumor progression. In order to 
test this hypothesis, two experiments were performed in collaboration with the Stanford 
University School of Medicine in the laboratory of Prof. Dr. Paul Khavari. First, the impact 
of sustained SPRR5_326 expression was studied in an invasive three-dimensional 
organotypic neoplasia tissue model, which recapitulates natural features of tumor 
progression and second the influence of SPRR5_326 on tumor development was assessed 
by an in vivo tumor formation assay154.  
Since for both experiments adequate and long-lasting SPRR5_326 overexpression was 
essential, this was ensured in a preliminary experiment during which the observed 
overexpression lasted over the entire time period of more than two weeks and SPRR5_326 
expression was increased by 27- to 77-fold as compared to the lacZ control (Supplementary 
Figure 1). Next, the effect of this overexpression was analyzed in an invasive organotypic 
neoplasia tissue model. To this end, primary keratinocytes were transformed into 
“tumorigenic keratinocytes” by forced overexpression of oncogenic human HRasG12V and 
simultaneous overexpression of Cdk4 in order to omit the reported onset of cellular 
senescence caused by the single overexpression of oncogenic Ras variants76,79,80. Next, these 
tumorigenic keratinocytes, with either lacZ or SPRR5_326 overexpression, were seeded 
onto a dermal matrix with embedded fibroblasts and the resulting tissue was harvested six 
or eight days after seeding when invasion of keratinocytes into the dermal matrix was 
analyzed by immunofluorescence analyses76,154. Figure 4A clearly shows that the 
transformation into tumorigenic keratinocytes was successful as lacZ and SPRR5_326 
overexpressing cells exhibited identical and elevated expression of oncogenic Ras as well as 
Cdk4 as compared to wild type cells. Furthermore, these tumorigenic keratinocytes were 
also invasive, since they crossed the degraded basement membrane and could be detected 
within the dermal matrix which is a distinct feature of tumorigenic keratinocytes (an 
exemplary picture is given in Figure 4C). With roughly 35-fold higher levels as compared 
to the lacZ control, also the overexpression of SPRR5_326 was satisfactory (Figure 4B). 
Thus, the invasion depth of keratinocytes into the dermal matrix was analyzed as an indicator 
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for the neoplastic potential, since this process never occurs in healthy epidermal tissue but 
represents a hallmark feature of skin cancer progression154–156. 
 
 
Figure 4: Generation and analysis of invasive neoplastic tissue 
Western blot confirms that tumorigenic keratinocytes showed similar and adequate overexpression for 
HRasG12V and Cdk4 as compared to wild type (WT) cells (A). Furthermore, the obtained overexpression of 
SPRR5_326 in tumorigenic cells utilized for generation of invasive neoplastic tissue was analyzed by 
RT-qPCR (n=2), normalized to L32 and compared to expression in lacZ overexpressing cells (B). (C) shows 
an exemplary picture from the performed evaluation of measuring the invasion depth of tumorigenic 
keratinocytes into the dermis at five different sites per section (shown in white). Keratin5 (marker for 
keratinocytes) is shown in red, nuclei are shown in blue and collagen VII (marker for the basement membrane) 
is depicted in green. Mean and standard deviation of all measured invasion depths for all biological replicates 
per group (n=3) and timepoint were calculated and plotted for each timepoint. OE = overexpression 
 
Regarding the results from this experiment (Figure 4D), it is striking that no tumor 
suppressive effect of SPRR5_326 overexpression could be detected, since the invasion depth 
for SPRR5_326 overexpressing keratinocytes was almost identical to the invasion depth in 
the lacZ control at both assessed timepoints. Taking the thickness of the overlying epidermis 
into account and analyzing the ratio of invasion depth to epidermis thickness did also not 
show a clear difference between lacZ and SPRR5_326 overexpression (data not shown).  
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In a second experiment, the influence of SPRR5_326 overexpression on tumor formation 
and growth should be addressed in vivo. Therefor the same tumorigenic keratinocytes as 
described above, with additional overexpression of a luciferase-YFP fusion protein, were 
injected into the flank of immunodeficient mice and tumor growth was monitored over time 
by in vivo luciferase measurements and volumetric tumor measurements.   
Since all eight mice showed growing nodules after tumor cell injection, the tumor formation 
in general was successful, however at the end of the experiment only three tumors in the 
SPRR5_326 overexpression group were detectable (see Supplementary Figure 2), which is 
the reason why only the three biggest tumors from each group were used for data evaluation. 
Examination of the obtained tumor volumes as well as estimates on the tumor mass  
(Figure 5) showed the slight tendency that forced SPRR5_326 overexpression lead to slower 
tumor growth in vivo compared to the lacZ control. Nevertheless, it should be mentioned 
that the standard deviation of the mean tumor sizes was very high and that tumor sizes varied 
dramatically, which can also be seen by the size of the explanted tumors and the in vivo 
luciferase signal measurements (see Supplementary Figure 2A+C). Moreover, the evaluation 
of the mean luciferase signal for each group lead to no conclusive result, as at first 
SPRR5_326 overexpressing tumors showed slower tumor progression as compared to the 
lacZ control but on day 47 this trend was inverted, which is why luciferase measurements 
were only recorded until day 64 (see Supplementary Figure 2B).   
In summary, no indication for a tumor suppressive effect of SPRR5_326 can be deduced 
from the performed experiments and subsequent studies with more replicates are required, 
which could not be done in Regensburg due to the missing infrastructure and permissions. 
 
 
Figure 5: Tumor growth over time 
Tumor size was monitored by caliper measurements and the corresponding tumor mass (A) as well as the tumor 
volume (B) were calculated for the three biggest tumors for each group (lacZ or SPRR5_326 OE) and mean 
and standard deviation were plotted against the time after injection. OE = overexpression 
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4.2 Transcript characterization for SPRR5 
4.2.1 Subcellular localization of SPRR5 
Unravelling the cellular localization of a given lncRNA might already give insights into its 
possible modes of action, which is why a subcellular fractionation approach followed by 
RT-qPCR analysis was chosen to reveal the localization of SPRR5 in differentiated 
keratinocytes (Figure 6).   
 
 
Figure 6: Subcellular localization of SPRR5 
Analysis of nuclear and cytoplasmic RNA fractions of day 6 differentiated keratinocytes by RT-qPCR. The 
localization of cytoplasmic markers (GAPDH and β-actin), nuclear markers (U6 and 7SK) as well as SPRR5 
was assessed and the enrichment in each fraction relative to the other fraction was calculated and plotted. 
 
Regarding the enrichment of the assessed marker transcripts clearly indicates a decent 
cytoplasmic fraction since the cytosolic markers GAPDH as well as β-actin are roughly 
16-fold enriched in the cytosolic over the nuclear fraction, whereas the nuclear markers U6 
and 7SK are not enriched in the cytosol (see Figure 6A). The inverse analysis (enrichment 
in nuclear over cytoplasmic fraction) however showed only a slight enrichment of the 
nuclear marker 7SK in the nuclear fraction and no clear enrichment of U6 (Figure 6B). Given 
the facts, that almost all subcellular fractionation approaches are not able to completely 
separate the cytosolic and nuclear fraction and that the primary function of differentiated 
keratinocytes is the formation of a tightly sealed cornified envelope which impedes with 
their separation prior to the cellular fractionation, no perfect separation into a nuclear and 
cytosolic fraction was anticipated in this experiment and the depicted results are the best 
results after numerous protocol optimization iterations. Furthermore, the expected pattern 
for the cytosolic and nuclear marker transcripts could be observed in general and thus the 
localization of SPRR5 could be analyzed in this experiment.   
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Figure 6A shows that SPRR5 is enriched in the cytosolic fraction (when compared to the 
nuclear fraction) with similar enrichment values as the cytoplasmic markers GAPDH and 
β-actin. Hence, SPRR5 is presumably mainly localized in the cytoplasm of differentiated 
keratinocytes, which matches the results from previous fractionation experiments (data not 
shown).  
Complementary to this subcellular fractionation approach, RNA fluorescence in situ 
hybridization (RNA-FISH) was performed by Bianca Förstl as a second method to study the 
localization of SPRR5. In principal, this method was applicable to differentiated 
keratinocytes since the utilized positive controls repeatedly exhibited the expected 
subcellular localization and the negative control was characterized by a complete lack of 
signal. Despite various attempts with different labelling reagents, amplification strategies 
and numerous variations of the applied protocol however, no conclusive results for SPRR5 
could be obtained by RNA-FISH. Thus, it appears that RNA-FISH for this particular 
transcript is especially challenging and no final statement for the SPRR5 localization can be 
made since due to the technical difficulties of the subcellular fractionation approach, results 
from this analysis should be interpreted as a first indication rather than a final proof of the 
SPRR5 localization. 
 
4.2.2 p63 controls SPRR5 expression 
The initial transcriptomic screen of undifferentiated versus differentiated keratinocytes (2.3) 
indicated a strong induction of SPRR5 during terminal differentiation, raising the question 
about the accountable factor for SPRR5 induction. Thus, upstream transcription factors for 
SPRR5 were predicted with the ARCHS4 website, resulting in p63 as the most likely 
regulator of SPRR5 expression in keratinocytes (Figure 7A)157. Furthermore, analysis of 
GEO deposited p63 ChIP-Seq peaks from Kouwenhoven et al. and Bao et al. indicated p63 
binding sites in the vicinity of the SPRR5 transcript (Figure 7C)44,158–160. Eventually, p63 
could be confirmed as a regulator of SPRR5 expression by pan-p63 knockdown in 
keratinocytes, resulting in decreased SPRR5 amounts on D3 of differentiation (Figure 7B).
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Figure 7: p63 controls SPRR5 expression 
Based on the ChEA algorithm, ARCHS4 predicted p63 as most likely upstream transcription factor for SPRR5 
(A), which was further supported by the presence of p63 ChIP-Seq peaks in the vicinity of SPRR5 (C). 
Knockdown of pan-p63 in keratinocytes (n=4) and assessing SPRR5 levels on day 3 of differentiation 
eventually confirmed p63 as a regulator of SPRR5 expression.  
 
4.2.3 Recent annotations are not valid for the SPRR5 locus 
At the beginning of this project, no annotation was present for the SPRR5 gene locus and 
the assumed SPRR5_326 transcript was based on the distribution of RNA sequencing reads 
and confirmed by RACE analyses. However, during progression of the project first a second 
lncRNA, LINC01527 which is encoded from the opposite strand as SPRR5_326 was 
annotated for this gene locus. Later, the potential protein-coding SPRR5 transcript appeared 
in the Ensembl genome browser and in the recently published FANTOM5 dataset a similar 
but unspliced transcript with a different 5’end was annotated (ENCT00000012178)161,162. 
Furthermore, a third, longer and partially SPRR5 overlapping transcript 
(MICT00000021193) was included into the FANTOM5 dataset, necessitating an exact 
characterization of the transcripts arising from the genomic SPRR5 locus (an overview of 
all annotations is given in Figure 8). 
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Figure 8: Overview of the recently annotated and self-identified transcripts from the SPRR5 locus 
The assumed transcript SPRR5_326 as well as recent annotations from the Ensembl genome browser and the 
FANTOM5 dataset are included, highlighting the imperative of careful isoform characterization. 
 
Regarding the question whether LINC01527 is expressed in keratinocytes, mapped 
sequencing reads from full transcriptome sequencing of organotypic epidermal tissue (4.4.3) 
were analyzed first, showing that they do not match the LINC01527 transcript (Figure 9 
lower panel). To omit the possibility of missing indications of LINC01527 expression due 
to an unsuitable timepoint of differentiation or the assessment of solely one sample, the same 
analysis was repeated for an already published RNA-Seq dataset of undifferentiated, day 3 
and day 6 differentiated keratinocytes from Kretz et al. leading to the same result (data not 
shown)88. Furthermore, LINC01527 could not be detected by northern blot analyses with 
different DNA oligo probes or by RT-qPCR measurements using three different primer sets, 
one of which was already published by Gao et al. for LINC01527 detection (data not 
shown)163. In summary, LINC01527 expression can be neglected for keratinocytes.  
Deciphering which sense transcript arises from the SPRR5 locus commenced again with 
analysis of RNA-Seq read distribution from day 4 differentiated keratinocytes and the 
differentiation time course from Kretz et al. (Figure 9 lower panel, data from Kretz et al. not 
shown). This data shows that RNA-Seq reads cover solely the second exon of the annotated 
SPRR5 transcript, rendering ENCT00000012178 and MICT00000021193 very unlikely 
isoforms in keratinocytes. On the other hand, the SPRR5_326 transcript was supported by 
RNA-Seq reads but at least a second, longer isoform had to be present in order to explain 
the complete coverage of the second exon of the Ensembl annotated SPRR5. For the purpose 
of addressing this hypothesis, northern blot analyses with different probes were performed 
(Figure 9 top panel), which consistently showed one band at roughly 900 nt for all utilized 
probes, proving the presence of one dominant isoform in keratinocytes that is longer than 
the previously anticipated SPRR5_326 transcript. Furthermore, the presence of two exons 
as proposed by the Ensembl annotation of SPRR5 but with a shorter first exon was indicated 
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by northern blot analysis, as the probe Out_Exon1_SPRR5 did not show a signal at all, 
whereas the Exon1_SPRR5 probe was able to detect this first exon of SPRR5. For this 
reason, the actual 5’ end of the verified SPRR5 transcript was inferred from the FANTOM5 
annotated ENCT00000012178, for which a strong CAGE signal from keratinocytes was 
present and the predicted length of the first exon as well as the complete SPRR5 transcript, 
including its assumed exon-intron structure, could be verified by a novel RACE analyses 
with the Expand Long Template PCR system from Roche (work by Bianca Förstl). 
 
Figure 9: Isoform detection for the SPRR5 locus 
Overview of the genomic localization of possible transcripts from the SPRR5 gene locus as well as the verified 
SPRR5 isoform. The lower panel shows aligned and scaled sequencing reads from full transcriptome 
sequencing of day 4 organotypic epidermal tissue with and without SPRR5 knockdown and the localization of 
possible transcripts. The top panel illustrates the location of utilized antisense DNA oligo probes with respect 
to the possible SPRR5 sense transcripts as well as the obtained northern blot signals for the depicted probes 
next to the ethidium bromide staining of the respective blots as a loading control. Summarizing the results, in 
contrast to the Ensembl annotation the verified SPRR5 transcript is shorter on the 5’ end, which could also be 
confirmed by RACE analysis (red stars).  
 33 
Results 
In summary, one dominant SPRR5 transcript could be identified in keratinocytes (the 
complete sequence and genomic coordinates are given in the appendix 9.2.2 and Table 37), 
which contains a predicted open reading frame and features some characteristics of the 
Ensembl SPRR5 and some of the FANTOM5 ENCT00000012178 annotation. With the 
verified SPRR5 transcript structure in hand, the challenge whether the included open reading 
frame gives rise to a functional protein or if SPRR5 acts as a lncRNA remained and will be 
addressed in the next chapter. 
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4.3 SPRR5 – protein or lncRNA? 
4.3.1 SPRR5 is presumably protein-coding but evolved differently than 
other human SPRRs 
Considering the observed discrepancies between the hitherto annotations for the SPRR5 
gene locus and the eventually verified SPRR5 transcript (4.2.3), the possible translation from 
the predicted SPRR5 open reading frame was also examined in more detail in order to 
elucidate whether this hypothesized open reading frame is indeed translated or solely a 
misleading annotation. As a first step in this analysis, bioinformatic predictions about the 
coding potential of the SPRR5 transcript were performed. Both, iSeeRNA and the Coding 
Potential Calculator, predict that the SPRR5 transcript is indeed protein-coding  
(Figure 10A+B)164,165. Furthermore, PhyloCSF showed a positive score matching the 
predicted SPRR5 open reading frame (Figure 10C, PhyloCSF+2 track)166. Since a positive 
PhyloCSF score is an indicator for high frequencies of silent or synonymous codon 
substitutions and low frequencies of missense or nonsense substitutions, it helps to 
distinguish protein-coding from non-coding transcripts and in this case PhyloCSF predicts 
that SPRR5 represents a protein-coding transcript. 
 
 
 
Figure 10: Bioinformatic approach to unravel the coding potential of SPRR5 
The tools iSeeRNA (A) and Coding Potential Calculator (B) predict that SPRR5 is a protein-coding transcript, 
which is supported by inspection of PhyloCSF tracks in UCSC (C), where a positive score in the PhyloCSF+2 
track matches the predicted SPRR5 open reading frame (ORF), indicating a strong conservation and thus 
coding potential for the putative SPRR5 ORF. 
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Due to the fact that the SPRR5 transcript was only recently annotated, very limited data 
about the transcript itself as well as the potential protein is available and therefore literature 
research for both molecules was not very productive in general. However, one study by 
Sendoel et al. addressing the translational landscape during tumor development included 
ribosome profiling data from in vivo mouse skin and since SPRR5 has a mouse homolog, 
this dataset could be utilized for addressing the question whether the SPRR5 transcript is 
indeed translated in vivo (Figure 11)167.  
 
 
 
Figure 11: Mouse epidermal ribosome profiling data indicates translation of SPRR5 
The mouse homolog of SPRR5 (2310046K23Rik-201) is shown in blue with its intron (thin line with arrows), 
both exons (blue bars) and the open reading frame (indicated by a thicker blue bar with white arrows inside). 
Additionally, the coverage of RNA-Seq reads (top) and ribosome profiling reads (middle) from mouse 
epidermis, extracted from a study by Sendoel et al. is depicted, indicating translation from the open reading 
frame of 2310046K23Rik-201. 
 
While the whole 2310046K23Rik-201 transcript (mouse homolog of the human SPRR5 
transcript) is covered by RNA-Seq reads (Figure 11 top), the ribosome profiling reads 
(Figure 11 middle) mainly cover the open reading frame, indicating translation of 
2310046K23Rik-201 in mouse epidermis. In combination with the results from the 
bioinformatic coding potential predictions, these findings suggest the translation of a human 
SPRR5 protein in keratinocytes and raised the question about similarities between SPRR5 
and other members of the adjacently encoded human SPRR protein family.   
The human SPRR protein family counts 11 genes giving rise to 10 SPRR proteins (SPRR2C 
is a pseudogene) and all of these proteins share a very characteristic composition, featuring 
a glutamine- and lysine-rich N- and C-terminus which is used for protein-protein 
crosslinking, and a central domain consisting of varying proline-rich repeats57. Since the 
predicted SPRR5 protein would have a similar composition like the other SPRRs and its 
gene locus is directly adjacent to the human SPRR gene cluster, the annotation as a novel 
small proline-rich protein seems reasonable, although the existence of the SPRR5 protein 
was never shown. Apart from those similarities, a striking functional difference for SPRR5 
and the other SPRRs exists, as the best described function of epidermal SPRR proteins is  
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contributing to the generation of a cornified envelope, by being crosslinked to other 
differentiation proteins like loricrin, involucrin or keratins for example168. Although some 
recent publications claim a protective effect of SPRR proteins against reactive oxygen 
species and an involvement in wound healing and cell migration, no effect on keratinocyte 
differentiation or an abnormal epidermis development in SPRR knockout mice has been 
reported so far60,64,65. Given the induced expression of the SPRR5 transcript during 
keratinocyte differentiation and the observed keratinocyte differentiation deficiency upon 
SPRR5 depletion (4.4), SPRR5 seems to be strikingly different from other human SPRR 
proteins.   
In order to address this assumption, a phylogenetic analysis of the coding sequences from 
all human SPRR proteins, including the newly identified SPRR5 was conducted, unravelling 
that SPRR5 is drastically different from the other members of the human SPRR family, as 
SPRR5 clusters separately (Figure 12, bioinformatic analysis by Prof. Dr. Rainer Merkl). 
Thus, SPRR5 presumably originated from gene duplication of an SPRR ancestor but evolved 
in a different direction.  
 
 
Figure 12: Phylogenetic tree of human SPRR-coding sequences 
Molecular phylogenetic analysis by maximum likelihood method of coding sequences for all known human 
SPRRs indicating a common ancestor of SPRR5 and the other SPRRs but a separate evolution of SPRR5. 
 
Taken together, bioinformatic analysis indicate that SPRR5 might be a protein-coding 
transcript, which evolved differently from other human SPRRs and additionally its murine 
homolog (2310046K23Rik-201) seems to be translated in mouse epidermis which might be 
an indicator that the predicted SPRR5 protein is indeed expressed in the human skin. 
Nevertheless, recent publications revealed striking differences between gene expression in 
murine and human169. One example for this is the transcription factor forkhead box C1 
(FOXC1) which is expressed in the murine hair follicle but absent from the surrounding 
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epidermal tissue170. In contrast to this, FOXC1 is not only expressed in the human epidermis 
but exerts an important function as a vital regulator of the keratinocyte differentiation 
program171. Thus, the existence of the predicted SPRR5 protein in human keratinocytes as 
well as its potential functional relevance on epidermal homeostasis had to be investigated, 
since the SPRR5 transcript itself could still function as a lncRNA rather than serving as a 
blueprint for the predicted SPRR5 protein.  
4.3.2 Small amounts of SPRR5 protein are detectable in keratinocytes 
Predictions, annotations and phylogenetic analysis are a first indication but no proof for the 
actual presence of a SPRR5 protein in keratinocytes. So, in order to address this topic, two 
polyclonal antibodies against two peptides from the predicted SPRR5 protein were generated 
in cooperation with Eurogentec. Unfortunately, neither of them was able to detect the 
endogenous SPRR5 protein and both antibodies showed only weak binding to overexpressed 
and tagged SPRR5 protein variants (data from Katrin Hartinger; data not shown).   
Since the generated antibodies were not suitable to detect endogenous SPRR5 protein, mass 
spectrometry was chosen as an alternative approach to identify the predicted protein within 
differentiated keratinocytes. Therefor protein lysates from keratinocytes on day 5 of 
differentiation were separated on an SDS-PAGE because a high expression of the SPRR5 
transcript at this timepoint (Figure 19) should maximize the chances for the detection of the 
hypothesized SPRR5 protein. Following the protein separation step, samples from sections 
1-14 (corresponding to a size range of roughly 5 to 20 kDa) were analyzed by mass 
spectrometry, as the predicted SPRR5 protein with its molecular weight of 11.9 kDa should 
be included in this part of the gel (Figure 13). However, once again no evidence for the 
SPRR5 protein in keratinocytes was found as not a single peptide from the predicted SPRR5 
protein could be found within the analyzed sections. To exclude the possibility that the 
employed mass spectrometry approach was unsuitable for the detection of SPRR proteins in 
general, the obtained dataset was revaluated and several SPRR proteins like SPRR1A  
(9.9 kDa), SPRR2G (8.2 kDa) or SPRR3 (18.2 kDa) for example were amongst the measured 
proteins, proving that SPRR proteins with similar sizes as SPRR5 were detectable in this 
experiment.  
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Figure 13: Schematic overview of the 
obtained mass spectrometry gel 
Picture of the coomassie stained SDS-PAGE 
after separation of protein lysate from day 5 
differentiated keratinocytes. A rough size 
estimation can be obtained in comparison to 
the utilized protein standard (indicated on the 
left) and the cutting sites as well section 
identifiers for each gel section are given on 
the right. kDa = kilo Dalton
As a final experiment, single reaction monitoring (SRM) measurements were performed 
because they feature an increased sensitivity during the analysis due to the prior calibration 
of the mass spectrometer with corresponding heavy labelled peptides. For this purpose, four 
labelled SPRR5 peptides were ordered and tested (sequence and location are given in 9.2.3) 
but only the N-terminal peptide was suitable for quantification as the other peptides were 
not detectable during preliminary mass spectrometry measurements. In order to omit the 
possibility of missing any SPRR5 derived peptide due to the limitation to sections 1-14, this 
time samples from the whole gel (molecular weight between 5 and 250 kDa, sections 1-27) 
were analyzed and now the SPRR5 protein could be detected in sections 13 and 14. 
Surprisingly, the protein standard indicates a molecular weight of roughly 20 kDa for these 
sections, which is considerably higher than the predicted 11.9 kDa for the SPRR5 protein. 
However, this size discrepancy was also observed for tagged SPRR5-variants during 
antibody testing (data not shown) and thus presumably originates from an aberrant protein 
migration behaviour.   
Despite an increased sensitivity, single reaction monitoring also offers the possibility of 
protein quantification since the number of spiked-in peptides is known. Thus, subsequent 
quantification with the utilized spiked-in heavy peptide was performed and resulted in 
roughly 3,000 SPRR5 protein molecules per cell, which represents a rather low expression 
level for a human protein172. In summary, only small amounts of SPRR5 protein could be 
detected in human keratinocytes and only with a highly specific and targeted mass 
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spectrometry approach, which leaves the question whether those small amounts of protein 
exert the molecular function of SPRR5 during the course of keratinocyte differentiation or 
are solely the product of pervasive translation and the actual functionality arises from the 
SPRR5 transcript itself. 
4.3.3 Rescue experiments for SPRR5 
In order to determine whether SPRR5 exerts its cellular function as a protein or a lncRNA, 
rescue experiments in SPRR5 depleted keratinocytes were performed because SPRR5 
deficiency results in differentiation defects (see 4.4) and thus introducing the functional 
SPRR5 molecule should rescue this phenotype. To this end, overexpression of either the 
wild type SPRR5 transcript (SPRR5_WT), which could function as a lncRNA and could be 
translated into a protein, or the same RNA with a destroyed start codon to obtain only the 
potential lncRNA function (SPRR5_Mut) were utilized. Furthermore, functional relevance 
of the SPRR5 protein was tested by introducing only the SPRR5-coding sequence 
(SPRR5_ORF) and the identical RNA sequence with a mutated start codon 
(SPRR5_MutORF) was used to exclude the possibility of a functional relevance of the RNA 
sequence alone (an overview of the overexpressed transcripts is given in Figure 14). 
 
 
Figure 14: Overview of overexpressed SPRR5 transcripts 
The SPRR5 wild type mRNA is depicted at the top, untranslated regions are shown in light blue, whereas the 
open reading frame for the SPRR5 protein, including its start codon (AUG), is indicated in dark blue. 
Overexpressed transcripts were either wild-type SPRR5 (top), wild-type RNA with a mutated start codon so 
that no functional protein could be made (SPPR5_Mut; 2nd from the top), the protein-coding open reading 
frame without any flanking RNA elements (SPRR5_ORF; 3rd from the top) or the open reading frame with no 
start codon (SPRR5_MutORF; bottom). WT = wild type, Mut = mutated, ORF = open reading frame 
 
As a reference for the effect of SPRR5 depletion, lacZ (for the full-length transcripts) or a 
luciferase-YFP protein (for the short transcripts) were overexpressed in SPRR5 depleted 
keratinocytes, since these transcripts should not affect keratinocyte differentiation. 
Comparing the expression of several differentiation markers in keratinocyte differentiation 
cultures from SPRR5 depleted (siSPRR5) and control keratinocytes (siCtrl) however showed 
no clear differentiation defect upon SPRR5 depletion neither for the lacZ nor the 
luciferase-YFP control (Figure 15A-C). This rather unexpected result (one would expect a 
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lack of differentiation after SPRR5 depletion) was presumably due to the high cellular stress 
levels induced by the siRNA treatment in combination with the lentiviral transduction (see 
also 5.3.2) and made a conclusion about a potential rescue effect of either of the employed 
overexpressed SPRR5 constructs from this dataset impossible (Figure 15A-C).  
 
 
Figure 15: SPRR5 knockdown and rescue in calcium-induced keratinocyte differentiation 
Expression of differentiation genes was quantified on day 3 of calcium-induced keratinocyte differentiation 
and a fold change between SPRR5 depleted (siSPRR5) and control (siCtrl) cells was calculated and plotted for 
keratinocytes with simultaneous overexpression of the indicated transcripts. (A) The possible rescue effect of 
the wild-type SPRR5 transcript (SPRR5_WT) is tested, whereas (B) depicts overexpression of the same RNA 
with a mutated start codon (SPRR5_Mut); both shown next to values obtained for the lacZ control (n=2-5). (C) 
Only the protein-coding region of the SPRR5 transcript is tested (SPRR5_ORF) and compared to the same 
RNA with a mutated start codon (SPRR5_MutORF) as well as the luciferase-YFP control (n=2-3).   
 
 
Due to the inconclusive results with in vitro differentiated keratinocytes (Figure 15), the 
rescue experiment was repeated in organotypic epidermal tissue cultures since these 
represent a more natural environment for keratinocyte differentiation and hence might 
exhibit the anticipated differentiation defect upon SPRR5 depletion even in this experimental 
rescue setting. Surprisingly, once again no reduced differentiation rate between SPRR5 
deficient and control keratinocytes with luciferase-YFP overexpression could be observed 
(Figure 16B). In fact, it appeared that SPRR5 depletion in this setup lead to increased 
expression of differentiation genes and these elevated transcript levels were not drastically 
altered by overexpression of SPRR5_ORF or SPRR5_MutORF, although introducing the 
latter seemed to slightly intensify this effect (Figure 16B).   
SPRR5 depletion in keratinocytes overexpressing lacZ eventually resulted in the expected 
differentiation defect and thus a potential rescue of the full-length SPRR5 transcripts could 
be analyzed (Figure 16A). Whereas overexpression of the lncRNA version SPRR5_Mut did 
not rescue the effect of SPRR5 depletion, introducing the SPRR5 wild type transcript 
(SPRR5_WT) reversed the differentiation defect for SPRR5 depleted keratinocytes and even 
lead to an increased expression of differentiation genes (Figure 16A). Therefore, it seemed 
that the SPRR5 protein is the functional molecule in keratinocytes.  
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Figure 16: SPRR5 rescue experiment in organotypic epidermal tissue on day 3 of differentiation 
Differentiation marker levels in regenerated organotypic epidermal tissue (D3) were assessed by RT-qPCR for 
SPRR5 depleted (siSPRR5) and control (siCtrl) cells with simultaneous overexpression of the indicated 
transcripts and the fold change between siSPRR5 and siCtrl was calculated and plotted for each condition. (A) 
The potential rescue effect of wild-type SPRR5 transcript (SPRR5_WT) and same RNA with a mutated start 
codon (SPRR5_Mut) was analyzed and compared to the lacZ control (n=2). (B) The SPRR5 protein-coding 
region with an intact (SPRR5_ORF) or a destroyed start codon (SPRR5_MutORF) as well as the 
luciferase-YFP control were tested for their potential to rescue SPRR5 deficiency (n=3). 
 
 
To exclude the possibility, that the observed SPRR5_WT-mediated rescue was simply due 
to an incomparable differentiation program in this experimental setting, differentiation 
marker mRNA levels for the knockdown control samples (“siCtrl”) with simultaneous 
overexpression of lacZ, SPRR5_WT or SPRR5_Mut were compared to the lacZ 
overexpression control (Figure 17).  
 
 
Figure 17: Effect of overexpressing full-length SPRR5 transcripts in organotypic epidermis 
Expression of differentiation genes in day 3 organotypic epidermal tissue obtained from knockdown controls 
(cells treated with a scrambled siRNA control) was measured by RT-qPCR and the expression levels after 
overexpression of either lacZ, the wild-type SPRR5 transcript (SPRR5_WT), or the same RNA with a 
destroyed start codon (SPRR5_Mut) were evaluated in relation to the expression in cells overexpressing lacZ 
(n=2). Ctrl = control 
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This analysis clearly showed, that overexpression of SPRR5_Mut had only a negligible 
effect on epidermal regeneration, whereas SPRR5_WT overexpressing cells exhibited a 
dramatically reduced terminal differentiation state (Figure 17), indicating that the attenuated 
differentiation rate in SPRR5_WT overexpressing cells might be the reason for the observed 
rescue effect of SPRR5_WT. In fact, the reduced differentiation in SPRR5_WT 
overexpressing cells could not be further decreased by SPRR5 depletion and hence the 
difference between SPRR5 depleted keratinocytes and their respective knockdown controls 
was abolished, which misleadingly appeared like a genuine rescue effect during the previous 
analysis (Figure 16). Moreover, the decreased differentiation rate for the SPRR5_WT 
overexpressing cells once more highlights the fluctuating differentiation programs caused 
be simultaneous siRNA treatment and lentiviral transduction of primary keratinocytes. 
Additional support for this assumption comes from evaluation of the previous rescue 
experiments (Figure 15 and Figure 16), where no differentiation defects could be observed 
after SPRR5 depletion which is in sharp contrast to the general necessity of SPRR5 for 
proper keratinocyte differentiation (4.4).   
In summary, no conclusion about the identity of the functional SPRR5 molecule can be 
drawn from the conducted rescue experiments due to the fluctuating differentiation program 
in this particular experimental setting. 
4.3.4 Generation of SPRR5 knockout cell lines 
Due to the inconclusive results from the conducted knockdown-based rescue experiments 
(4.3.3), another approach for SPRR5 depletion was inevitable and SPRR5 knockout cells 
were chosen as a substitute. However, primary keratinocytes were unsuitable for this 
approach since they possess only a very limited number of cell doublings in vitro173,174. Thus, 
the immortalized HaCaT keratinocyte cell line which is described to differentiate properly 
in an epidermal environment was utilized for the generation of SPRR5 knockout cell lines. 
As a first step towards the generation of a SPPR5 knockout cell line, the ability of HaCaT 
cells to differentiate in our calcium-induced keratinocyte differentiation cultures as well as 
in regenerated organotypic epidermal tissue cultures was assessed175. This pilot experiment 
clearly indicated that HaCaT cells are a suitable model as they express SPRR5 and conduct 
a similar differentiation program like primary keratinocytes, although with a slightly reduced 
expression of differentiation markers and absence of loricrin protein expression 
(Supplementary Figure 3).  
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In theory, knockout cell line generation works as described in the following: After 
transfection of a plasmid encoding chimeras of the desired gRNAs and the required 
trans-activating CRISPR RNA (tracrRNA), the gRNAs should target the Cas9 endonuclease 
(also encoded on the plasmid) to the intended genomic cutting sites via base 
complementarity between the gRNA and the DNA176,177. Next, Cas9 cleaves the DNA 
specifically at the targeted sites and the resulting DNA double-strand breaks are repaired 
either via non-homologous end joining (NHEJ) or the homology-directed repair (HDR) 
mechanism176. In this case however only the NHEJ of two cutting sites flanking the SPRR5 
locus would generate the desired genomic SPRR5 deletion, as HDR with potentially 
remaining wild type alleles would reconstitute the initial state with no genomic alteration. 
Since the introduction of double-strand breaks is a crucial step in this process, two guide 
RNAs on each side of the intended genomic deletion were used simultaneously to increase 
the chances of a successful SPRR5 knockout. Furthermore, it should be mentioned that at 
the time of SPRR5 knockout cell line generation, the first exon of SPRR5 was not known 
and hence only the large second exon, including the open reading frame, was targeted by the 
deletion approach (Figure 18).  
 
 
 
Figure 18: Localization of gRNAs and screening primers at the SPRR5 locus 
The genomic SPRR5 locus and its transcript (light blue) is shown. Additionally, the localization of the utilized 
gRNAs for SPRR5 knockout (black bars), as well as the position of the employed screening primers for the 
detection of knockout alleles (orange arrows) and the forward primers for the detection of wild-type alleles 
(red arrows) are depicted. up = upstream, down = downstream, KO = knockout, WT = wild type 
 
The results from the PCR-based screening of potential SPRR5 knockout cell lines, obtained 
by transient transfection of a plasmid encoding all four gRNAs and the Cas9 endonuclease 
and subsequent generation of a clonal cell line, are summarized in Table 1. Considering that 
during the first round of transfection only 3.5% of screened clones were heterozygous for 
genomic SPRR5 deletions and no homozygous knockout cell line was obtained, it became 
evident, that the genomic editing was not very efficient. For this reason, three heterozygous 
cell lines from the first experiment, were subjected to another cycle of transfection and 
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single-cell seeding in order to eventually get a homozygous SPRR5 knockout cell line but 
despite screening of 402 clones, no homozygous SPRR5 knockout clone was found  
(Table 1).  
Table 1: Results from SPRR5 knockout cell line screening (transient approach) 
 1st round 2nd round 
Heterozygous SPRR5 knockout 24 (3.5%) n.d. 
Homozygous SPRR5 knockout - - 
Total number of generated cell lines 692 402 
 
Since the transient transfection approach did not yield any homozygous SPRR5 knockout 
cell lines, a lentiviral delivery system was chosen for stable genomic integration of the four 
gRNAs as well as the Cas9 endonuclease into wild type HaCaT cells which would ensure 
prolonged and constant expression of Cas9 as well as the gRNAs and thus might increase 
the probability for genomic deletions. And indeed, after only one cycle of infection, selection 
and clonal expansion, the portion of heterozygous clones could be raised from 3.5% to 13.4% 
but once more no homozygous SPRR5 knockout cell line could be identified  
(Table 2). Therefore, six heterozygous clones from the first lentiviral infection cycle were 
chosen and the presence of any remaining SPRR5 wild type alleles was assessed after 
repeating the lentiviral-based knockout procedure. Surprisingly, even this rather drastic 
treatment did not result in one single homozygous SPRR5 knockout cell line (Table 2) which 
is the reason for ceasing this subproject. 
Table 2: Results from SPRR5 knockout cell line screening (lentiviral approach) 
 1st round 2nd round 
Heterozygous SPRR5 knockout 41 (13.4%) n.d. 
Homozygous SPRR5 knockout - - 
Total number of generated cell lines 306 435 
 
In summary, the identity of the functional SPRR5 molecule in differentiated keratinocytes 
could not be ultimately deciphered. Although bioinformatic predictions indicate that SPRR5 
does not act as a non-coding transcript, only minor amounts of the SPRR5 protein could be 
detected in differentiated keratinocytes and phylogenetic analyses show that SPRR5 differs 
drastically from other human SPRR proteins. Furthermore, the conducted rescue 
experiments as well as the generation of an SPRR5 knockout cell line were inconclusive, 
leaving the question whether SPRR5 exerts its function as a protein or lncRNA unsolved.  
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4.4 Epidermal homeostasis is controlled by SPRR5 
4.4.1 SPRR5 is required but not sufficient for keratinocyte differentiation 
Despite the ambiguity about the functional molecule, the role of the SPRR5 transcript for 
keratinocyte differentiation could be assessed, since the level of both molecules (lncRNA 
and protein) depends on the available amount of SPRR5 RNA.   
As a first step towards this functional characterization, SPRR5 transcript amounts were 
monitored over the course of keratinocyte differentiation, demonstrating a strong induction 
of SPRR5 during terminal differentiation (Figure 19A+B), which already implied a 
functional importance of SPRR5 for keratinocyte differentiation. In order to test this 
hypothesis, siRNA-mediated knockdown of SPRR5 was performed in keratinocyte 
differentiation cultures and the expression of several key differentiation markers was 
assessed by RT-qPCR as well as western blot analysis (Figure 20). 
 
 
Figure 19: SPRR5 induction during keratinocyte differentiation 
SPRR5 transcript levels were analyzed by RT-qPCR and compared to the transcript levels in undifferentiated 
keratinocytes in four different primary keratinocyte isolates (KC1-4; n=2), revealing a strong SPRR5 induction 
during keratinocyte differentiation (A). Furthermore, induction of SPRR5 was confirmed by northern blot 
analysis, using GAPDH as a loading control (B). KC = keratinocyte, undiff. = undifferentiated,  
Diff. = differentiation, GAPDH = glyceraldehyde 3-phosphate dehydrogenase 
 
For all three timepoints of differentiation, an efficient knockdown of SPRR5 transcript levels 
was obtained (<5% SPRR5 remaining), which resulted in a reduced expression of the 
evaluated differentiation marker mRNAs small proline-rich protein 3 (SPRR3), keratin 1 
(KRT1), as well as filaggrin (FLG) (Figure 20A+B). Furthermore, also the protein levels of 
keratin 1 (KRT1) and loricrin (LOR) were diminished upon SPRR5 depletion (Figure 20C), 
proving that SPRR5 is essential for proper terminal keratinocyte differentiation. 
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Figure 20: SPRR5 depletion leads to differentiation defects 
Depletion of SPRR5 by siRNAs (A) leads to a decreased expression of differentiation marker mRNAs (B) 
as obtained by RT-qPCR (n=3-4). Western blot analysis reveals a reduction of differentiation protein levels 
upon SPRR5 knockdown (C). Ctrl = control, Diff. = differentiation  
 
Whether SPRR5 alone is sufficient to ectopically induce the keratinocyte differentiation 
program was examined by overexpression of SPRR5 followed by RT-qPCR analysis of 
differentiation marker mRNA levels. Compared to the lacZ control, a moderate 
overexpression of roughly threefold higher SPRR5 levels was achieved (Figure 21A), 
however no elevated transcript levels for the small proline-rich protein 3 (SPRR3), keratin 1 
(KRT1) or filaggrin (FLG) could be detected and the mRNA amounts of the late cornified 
envelope proteins 1E and 3A (LCE1E and LCE3A) were only slightly increased on day 3 
and day 4 of differentiation (Figure 21B). Thus, the SPRR5 transcript is essential but not 
sufficient for proper keratinocyte differentiation. 
 
 
Figure 21: Effect of SPRR5 overexpression on keratinocyte differentiation  
SPRR5 (or lacZ as a control) was overexpressed in keratinocytes and differentiation was monitored on day 3 
and day 4 by evaluating overexpression levels of SPRR5 (A) and the resulting effect on mRNA amounts for 
key differentiation markers by RT-qPCR (B) (n=2-3). OE = overexpression, KC = keratinocyte, Ctrl = control 
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4.4.2 Epidermal tissue homeostasis necessitates SPRR5 
Since SPRR5 regulates keratinocyte differentiation in vitro (4.4.1), it was interesting to test 
whether SPRR5 also promotes keratinocyte differentiation in a mature tissue environment 
and hence SPRR5 knockdown was conducted in epidermal tissue cultures. 
 
 
Figure 22: SPRR5 controls epidermal tissue homeostasis on day 3 of differentiation 
Efficient depletion of SPRR5 in organotypic epidermal tissue cultures (A) results in diminished expression of 
differentiation marker mRNAs (B) as obtained by RT-qPCR analysis (n=4). Exemplary pictures of 
immunofluorescence analysis of cross sections from the corresponding regenerated epidermal tissue (C) 
reveals reduced amounts of the differentiation proteins loricrin and filaggrin (red) in SPRR5 depleted tissue. 
Collagen VII (green) is depicted for orientation purposes as it separates the epidermis from the beneath lying 
dermis, nuclei are shown in blue and the scale bar (white) indicates 50 µm. Diff. = differentiation, Ctrl = control 
 
On day 3 of differentiation, SPRR5 transcript levels were efficiently diminished down to 5% 
(as compared to the control) (Figure 22A), resulting in an extensive loss of differentiation 
marker expression as illustrated by the reduced expression of several members of the late 
cornified envelope proteins (LCEs), small proline-rich proteins (SPRRs), keratins (KRTs) 
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as well as filaggrin (FLG) and loricrin (LOR) (Figure 22B). Moreover, cross sections from 
the obtained epidermal tissue also revealed decreased levels for the differentiation proteins 
filaggrin and loricrin, whereas no stratification defect or aberrant epidermis thickness was 
observed (Figure 22C). Additionally, analysis of SPRR5 depleted organotypic epidermal 
tissue on day 4 of differentiation lead to similar results (Supplementary Figure 4), proving 
that SPRR5 is not only required for in vitro differentiation of keratinocytes but also essential 
for maintaining epidermal tissue homeostasis. 
4.4.3 SPRR5 regulates keratinocyte differentiation on a global level 
In order to obtain a comprehensive picture of the global impact of SPRR5 knockdown on 
epidermis development, a full transcriptome sequencing approach of SPRR5 depleted and 
control tissue was performed. To this end, three to five biological replicates of regenerated 
organotypic epidermis with and without SPRR5 depletion were harvested on day 3 or on 
day 4 of differentiation and the isolated RNA was subjected to a poly-A enrichment followed 
by library preparation and next generation sequencing. With 24 to 33 million mapped reads 
per sample, a sufficient sequencing depth was received and the subsequent principal 
component analysis proved comparability between the transcriptomes of the biological 
replicates for each timepoint and nice clustering in a control and SPRR5 depletion group 
(Supplementary Figure 5). Thus, differential gene expression analysis was done for each 
timepoint (work by Dr. Nicholas Strieder) using a customized DeSeq2 script and the 
obtained results were successfully verified by RT-qPCR for selected transcripts, confirming 
the validity of the obtained RNA-Seq analysis (Supplementary Figure 6).  
First, the efficient knockdown of SPRR5 with 3% and 9% remaining transcript amounts on 
day 3 or day 4 respectively (Figure 23B) should be emphasized which ultimately resulted in 
numerous differentially expressed genes (-0.5 > log2(fold change) > 0.5 and an adjusted 
p-value < 0.05; lists of differential expressed genes are included in the appendix). Whereas 
on day 3 of differentiation a total of 249 genes was differentially expressed and 209 genes 
were downregulated and 40 genes upregulated upon SPRR5 depletion (Figure 23C), a 
similar pattern could be observed for the day 4 samples as with 323 downregulated and 56 
upregulated genes, the majority of the 379 total regulated genes showed decreased 
expression upon loss of SPRR5 (Figure 23D). In combination with the results from the 
previous studies that indicated a reduced differentiation pattern upon SPRR5 depletion (4.4.1 
and 4.4.2), it seemed reasonable to proceed only with the downregulated genes and test 
whether differentiation genes are enriched within this subset. 
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Figure 23: SPRR5 depletion severely alters the transcriptome in epidermal tissue 
Workflow of the performed RNA-Seq experiment (A) and the obtained knockdown efficiency of SPRR5 for 
each timepoint of differentiation as obtained from the RNA-Seq analysis (B). Heatmaps of genes with a 
significantly altered expression (adjusted p-value < 0.05 and -0.5 > log2 fold change > 0.5) for day 3 (C) and 
day 4 of differentiation (D) reveal that SPRR5 depletion changes the expression of a plethora of genes.  
log2FC = log2(fold change), padj = adjusted p-value, Ctrl = control, up = upregulated, down = downregulated 
 50 
Results 
And indeed, functional annotation clustering of the genes with decreased expression upon 
SPRR5 depletion showed highly significant enrichment for gene ontology terms like 
“cornified envelope”, “keratinocyte differentiation” or “epidermis development”  
(Figure 24), ultimately proving that SPRR5 is indispensable for proper keratinocyte 
differentiation in an epidermal tissue environment. In contrast to this, a functional annotation 
clustering of genes that are upregulated upon SPPR5 knockdown did not disclose any 
significant enrichment for a gene ontology term or reveal any conclusive link between the 
subset of upregulated genes (data not shown).  
 
Figure 24: GO-Term analysis of genes with decreased expression upon SPRR5 depletion 
GO-Term enrichment analysis was done for significantly downregulated genes after SPRR5 knockdown with 
the DAVID tool and the negative decadic logarithm of the 5 most enriched GO-terms of the classes “biological 
process” and “cellular compartment” is plotted for day 3 (A) and day 4 (B) of differentiation.   
GO = gene ontology 
 
Interestingly, analysis of the genomic distribution of SPRR5 regulated genes revealed only 
one significant hit, namely chromosome 1 cytogenetic band 21, which is especially striking 
as this represents the genomic localization of the human epidermal differentiation complex 
(EDC) where many keratinocyte differentiation genes as well as SPRR5 itself are encoded. 
Thus, a more detailed analysis of the SPRR5 regulated genes within the EDC was performed, 
revealing the regulation of almost the complete late cornified envelope protein (LCE) gene 
cluster on day 3 of differentiation and the small proline-rich protein cluster (SPRR) on day 4, 
so precisely those gene clusters flanking the genomic SPRR5 locus (Figure 25A). 
Furthermore, it seemed like SPRR5 mainly regulated a specific subset of genes for each 
timepoint of differentiation individually and only a smaller set of concordantly regulated 
genes. This initial assumption could be confirmed as only 87 genes (16%) are regulated by 
SPRR5 at both timepoints, whereas SPRR5 controls 162 (30%) genes exclusively on day 3 
and 292 genes (54%) only on day 4 of differentiation (Figure 25B). In conclusion, SPRR5 
is not only essential for keratinocyte differentiation but controls different gene clusters 
during the course of differentiation indicating a possible epigenetic mechanism of SPRR5.  
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4.4.4 Investigating the potential epigenetic mechanism of SPRR5 
Given the observed regulation of adjacent gene clusters by SPRR5 (4.4.3) and the numerous 
reports about epigenetic control of keratinocyte differentiation46,49,178–180, an epigenetic 
mechanism for SPRR5 seemed promising. In order to address this hypothesis, the effect of 
SPRR5 depletion on the accessibility of genomic regions was probed with ATAC-Seq in 
SPRR5 depleted and regular keratinocytes for day 4 of differentiation as well as in 
undifferentiated cells (in collaboration with Katrin Hartinger and the AG Rehli).  
 
Figure 25: SPRR5 regulates different 
subsets of genes and gene clusters 
within the epidermal differentiation 
complex 
Schematic overview of the human 
epidermal differentiation complex on 
chr1q21 with highlighted genes that are 
controlled by SPRR5 in organotypic 
epidermis on day 3 (yellow), day 4 (blue) 
or at both timepoints (green), reveals the 
regulation of the LCE gene cluster on 
day 3 and the SPRR gene cluster on 
day 4. The genomic localization of 
SPRR5 is indicated by a red star (A).
 Venn diagram of SPRR5 
regulated genes on day 3 and day 4 (B) 
indicates that SPRR5 mainly regulates 
different subsets of genes for each 
timepoint of differentiation.  
LCE = late cornified envelope,  
SPRR = small proline-rich protein 
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Figure 26: Knockdown efficiency for ATAC-Seq replicates 
SPRR5 knockdown efficiencies in undifferentiated (D0) and differentiated (D4) keratinocytes as obtained by 
RT-qPCR for the biological ATAC-Seq replicates 1 (A) and 2 (B). 
 
As a first step in this analysis successful depletion of SPRR5 was validated for both 
biological replicates (Figure 26), followed by a quality control of the obtained sequencing 
data, revealing an overall satisfying data quality with only few mitochondrial reads. 
Nevertheless, it should be mentioned that with 6.6 to 73.8 million reads per sample, the total 
number of sequencing reads per sample varied drastically (Table 3).  
Table 3: Quality control of ATAC-Seq data (FRIP = fraction of reads in called peak regions) 
Sample Total 
reads 
Mapped 
reads 
Mitochondrial 
reads 
Unique 
reads 
FRIP 
D0_siCtrl_1 29.2 mio 94.2% 0.71% 18.1 34.5% 
D0_siCtrl_2 6.9 mio 95.9% 3.38% 5.1 40.2% 
D0_siSPRR5_1 16.5 mio 88.5% 0.67% 11.8 37.8% 
D0_siSPRR5_2 73.8 mio 96.2% 2.27% 31.5 41.9% 
D4_siCtrl_1 12.2 mio 93.9% 0.67% 8.5 29.7% 
D4_siCtrl_2 6.6 mio 95.9% 0.56% 5.1 22.3% 
D4_siSPRR5_1 33.7 mio 95.1% 0.67% 20.3 28.2% 
D4_siSPRR5_2 46.4 mio 96.4% 0.67% 29.5 22.7% 
 
Additionally, current standards for ATAC-Seq data from the ENCODE consortium were 
applied and with two biological replicates, over 80% mapped reads, >20% fraction of reads 
in called peak regions (FRIP) and over 100,000 called peaks for each timepoint also met in 
general181,182. However, the ENCODE required sequencing depth of over 25 million unique 
reads was not reached for almost all samples (Table 3) and further criteria were not 
investigated because replicate reproducibility for example was analyzed via principal 
component analysis (PCA). Since in these PCA plots the second biological control replicate 
(siCtrl_2) did cluster far away from all the other samples and since siCtrl_2 was the sample 
with the lowest amount of sequencing reads for each timepoint, this sample was excluded 
during further analysis (Figure 27 A+B). Rerunning the PCA analysis without siCtrl_2 
showed no drastic differences in terms of chromatin accessibility for undifferentiated 
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samples (D0) but a nice clustering for day 4 of differentiation, matching the observation that 
SPRR5 is preferably crucial for gene expression in differentiated keratinocytes  
(Figure 27 C+D). Since in undifferentiated cells no noteworthy changes in chromatin 
accessibility due to SPRR5 depletion were detectable (data not shown), only the results from 
day 4 of differentiation are shown here. 
 
 
Figure 27: Principal component analysis of ATAC-Seq samples 
Principal component analysis of ATAC-Seq samples on D0 (A) and D4 (B) showed a drastic difference for the 
control replicate 2 (siCtrl_2), which is why this was excluded for subsequent analysis. Repeating the PCA 
analysis without siCtrl_2 for D0 (C), indicates that all three samples are similar, whereas for D4 (D) the SPRR5 
depleted samples cluster separately. Ctrl = control, PC = principal component 
 
 
Regarding the changes in genomic accessibility upon SPRR5 depletion in differentiated 
keratinocytes (Figure 28, left), no clear difference between opened and closed regions on a 
genome wide level could be detected, although the vast downregulation of differentiation 
gene expression identified by RNA-Seq (4.4.3) would suggest more closed regions upon 
SPRR5 depletion. To omit the possibility that SPRR5 does control accessibility of the 
adjacent LCE and SPRR gene clusters but fails to regulate chromatin accessibility on a 
global level, the analysis was restricted to the epidermal differentiation complex resulting in 
four opened and four closed regions (Figure 28, right).  
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Figure 28: SPRR5 controls genomic accessibility 
Regions exhibiting altered accessibility in SPRR5 deficient keratinocytes for the whole genome (left) or solely 
the epidermal differentiation complex (EDC; right) on day 4 of keratinocyte differentiation are shown. SiCtrl_2 
was excluded for this analysis and opened regions (blue) were defined by a log2(fold change) higher than 0.5, 
whereas closed regions (orange) had to meet a log2(fold change) lower than -0.5. 
 
 
Given the formulated hypothesis that SPRR5 could control gene expression of the LCE and 
the SPRR gene clusters, SPRR5 depletion should result in an enrichment of closed chromatin 
in these areas. However, only one of the four closed regions localized to the SPRR gene 
cluster whereas the remaining regions were found roughly 470 kbp upstream and 220 kbp 
downstream of the LCE or the SPRR cluster. In combination with the finding that 50% of 
the opened regions were present within the genomic LCE and SPRR region, no evidence for 
an epigenetic regulation of chromatin accessibility for those gene clusters by SPRR5 could 
be observed. 
Apart from opening or closing parts of the genome, SPRR5 might affect the distribution of 
histone modifications and exert its regulatory function via this epigenetic mechanism. Thus, 
the occurrences of the repressive histone mark H3K27me3 as well as the activating marks 
H3K4me1 and H3K27ac were compared between regular and SPRR5 depleted keratinocytes 
with ChIP-Seq (in collaboration with Katrin Hartinger and the AG Rehli)183,184.  
 
 
 
 
Figure 29: SPRR5 knockdown efficiency for 
ChIP-Seq 
The SPRR5 knockdown efficiency in 
undifferentiated (D0) and differentiated (D4) 
keratinocytes is shown for the cells utilized for 
ChIP-Seq sample generation.  
Ctrl = control
Similar to the ATAC-Seq analysis, successful SPRR5 knockdown validation (Figure 29) 
was followed by a general quality control of the obtained sequencing data (Table 4). With 
total numbers of reads ranging from 13.9 to 38.4 million and 69 to 77% unique reads (after 
removal of duplicate reads and low-quality mapping reads), the current ENCODE standards 
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for ChIP-Seq demanding 20 to 45 million reads, over 90% unique reads and biological 
duplicates were not completely matched181,185. Nevertheless, the obtained data quality was 
high enough to get a first impression about a possible involvement of SPRR5 in modifying 
the histone code in keratinocytes.  
Table 4: Quality control of ChIP-Seq samples (FRIP = fraction of reads in called peak regions) 
Sample Total reads Mapped reads Unique reads FRIP 
D0_siCtrl_Input 31.7 mio 97.7% 75.0% n.d. 
D0_siCtrl_H3K4me1 24.0 mio 98.2% 77.0% 21.9% 
D0_siCtrl_H3K27me3 17.6 mio 98.2% 76.7% 27.3% 
D0_siCtrl_H3K27ac 25.0 mio 97.4% 69.0% 31.0% 
D0_siSPRR5_Input 38.4 mio 97.4% 72.6% n.d. 
D0_siSPRR5_H3K4me1 30.0 mio 97.9% 74.2% 19.7% 
D0_siSPRR5_H3K27me3 25.2 mio 98.2% 74.8% 29.5% 
D0_siSPRR5_H3K27ac 22.4 mio 98.0% 74.9% 29.9% 
D4_siCtrl_Input 26.2 mio 97.5% 74.6% n.d. 
D4_siCtrl_H3K4me1 15.9 mio 97.8% 76.7% 8.2% 
D4_siCtrl_H3K27me3 13.9 mio 97.6% 77.0% 17.5% 
D4_siCtrl_H3K27ac 17.7 mio 97.6% 75.7% 29.6% 
D4_siSPRR5_Input 28.5 mio 98.1% 76.2% n.d. 
D4_siSPRR5_H3K4me1 20.4 mio 98.6% 76.0% 9.1% 
D4_siSPRR5_H3K27me3 15.1 mio 98.2% 75.0% 13.8% 
D4_siSPRR5_H3K27ac 19.3 mio 98.4% 75.0% 33.3% 
 
Moreover, with about 20 to 30%, the fraction of reads in called peak regions (FRIP) was 
satisfactory for almost all samples, however a clearly lower FRIP was obtained for 
H3K4me1 and H3K27me3 on day 4 of differentiation. For this reason and as an additional 
second quality control, the obtained ChIP-Seq data for control samples on day 4 of 
differentiation were compared to already analyzed and published ChIP-Seq data from Bao 
et al. (an exemplary view is given in Supplementary Figure 7)44. Since both datasets nicely 
correlated for the called peaks, the overall distribution of obtained reads as well as for the 
observed signal-to-noise ratio, a subsequent analysis of genome wide alterations in histone 
mark deposition upon SPRR5 depletion was performed with DeSeq2.  
Table 5: Results from ChIP-Seq analysis with DeSeq2 
(only regions that met -0.5>log2(fold change) or log2(fold change)>0.5 are shown, siSPRR5 compared to siCtrl) 
 
Sample Total altered regions Increased signal Decreased signal 
D0_H3K4me1 361 228 113 
D0_H3K27me3 1,049 247 802 
D0_H3K27ac 494 147 347 
D4_H3K4me1 11,657 4,381 7,276 
D4_H3K27me3 9,787 7,354 2,433 
D4_H3K27ac 5,484 3,535 1,949 
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The results of this global analysis (Table 5) revealed that SPRR5 affects the histone 
landscape mainly in differentiated cells because in undifferentiated keratinocytes the number 
of total altered regions is drastically lower than at day 4 of differentiation. Furthermore, in 
differentiated cells the majority of altered regions for the active chromatin mark H3K4me1 
exhibited a decreased signal whereas the repressive mark H3K27me3 predominantly was 
enriched upon SPRR5 depletion, matching the observed differentiation deficiency upon 
SPRR5 depletion. Surprisingly, the other active chromatin mark H3K27ac showed also more 
enriched regions in SPRR5 deficient cells as compared to the control sample.   
In order to test whether SPRR5 directly regulates the histone marks at the LCE and SPRR 
gene cluster, the analysis was restricted to the epidermal differentiation complex (EDC) and 
only the results for differentiated keratinocytes are shown here, since the previous analysis 
for undifferentiated cells revealed only minor changes in their histone marks (Table 5). 
 
 
 
Figure 30: Altered histone modifications upon SPRR5 depletion within the EDC 
Histone modifications exhibiting changes upon SPRR5 depletion on day 4 of keratinocyte differentiation and 
are included within the epidermal differentiation complex (EDC) are depicted. A decreased signal (orange) is 
defined by a log2(fold change) lower than -0.5, whereas an increased signal (blue) had to meet a log2(fold 
change) above 0.5. Altered signals for the histone modification H3K4me1 are shown on the left, next to 
H3K37me3 (middle) and H3K27ac on the right. 
 
This close examination of the altered histone marks within the EDC revealed no clear 
difference between increased and decreased deposition of H3K4me1 but a strong increase 
in H3K27me3 and H3K27ac sites in SPRR5 deficient cells (Figure 30). Similar to the results 
from the global analysis, this increase in H3K27 acetylation in SPRR5 deficient 
keratinocytes would rather contradict the positive effect of SPRR5 on keratinocyte 
differentiation but since almost all altered peaks were not within the LCE or the SPRR gene 
cluster, this histone mark could be neglected for studying the possible epigenetic regulation 
of SPRR5 for those two gene clusters. Interestingly, SPRR5 depletion led to exclusively  
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more deposition of the repressive histone mark H3K27me3 within the EDC (Figure 30 
middle), suggesting an involvement of SPRR5 for prevention this modification during 
keratinocyte differentiation. However, an analysis of the exact location of the identified 
increased H3K27me3 signals revealed only two sites within the LCE cluster, none for the 
SPRR cluster and no overlap with the recently identified enhancer regions of the EDC, 
rendering an epigenetic control of those regions by SPRR5 rather unlikely54,186,187.   
Given the inconclusive results from the analysis above and the observed rather small signal 
changes for histone mark signals, the analysis was repeated with another analysis pipeline 
for ChIP-Seq data called HOMER188. Surprisingly, this second analysis lead to strikingly 
different and partially completely contrary results in the distribution of histone marks upon 
SPRR5 depletion (results not shown). Thus, no evidence for an epigenetic regulation of 
SPRR5 during keratinocyte differentiation could be obtained from the analyzed ATAC-Seq 
and ChIP-Seq data sets and the molecular mechanism of SPRR5 remains elusive. 
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5 Discussion and Outlook 
5.1 Linking SPRR5 and neoplasia 
Considering the vast amount of lncRNAs featuring an aberrant expression pattern in cancer 
and in particular in skin cancer progression (examples given in 2.1.4), we are only beginning 
to realize their significant role for carcinogenesis. Interestingly, a recent study from 
Piipponen et al. unraveled that the lncRNA PICSAR promotes growth of cutaneous 
squamous cell carcinoma (SCC) by regulating ERK1/2 activity90. Additionally, the 
identification of seven annotated but uncharacterized lncRNAs that are differentially 
expressed in SCC impressively highlights that lncRNAs are crucial regulators of SCC 
progression and that our current knowledge about their numbers and molecular modes of 
action is very limited89. Furthermore, a dual role during proper keratinocyte differentiation 
on the one hand and in SCC generation on the other hand seems to be characteristic for 
several skin specific lncRNAs such as TINCR and SMRT-2, which have been reported to be 
involved during both processes and are induced during the course of keratinocyte 
differentiation and suppressed in SCC samples88,89. SPRR5_326 exhibits the exact same 
expression pattern and since lack of differentiation is a hallmark of skin cancer, sustained 
SPRR5_326 expression might prevent neoplasia. In order to test this hypothesis, an invasion 
assay for tumorigenic keratinocytes in neoplastic epidermal tissue cultures and an in vivo 
tumor formation assay were conducted as valid metrics for tumorigenesis (4.1)154–156. 
Surprisingly, no effect of forced SPRR5_326 expression could be observed for the invasion 
depth of tumorigenic keratinocytes at both assessed timepoints (Figure 4D). One possible 
explanation for this result could be insufficient SPRR5_326 overexpression levels. Although 
an initial upregulation of roughly 35-fold more SPRR5_326 was obtained, overexpression 
levels might have been too low to see an effect on invasion depth. Furthermore, no data is 
available for the SPRR5_326 overexpression at the time point of tissue harvest but 
long-lasting overexpression was detected during preliminary experiments, which would 
suggest reasonable SPRR5_326 overexpression levels over the entire experiment. In 
addition to that, the timepoint of tissue harvest might have been not optimal and choosing 
an earlier timepoint, grasping commencing invasion might reveal the hypothesized tumor 
protective effect of SPRR5_326. Nevertheless, one of the most likely explanations for the 
undetectable tumor suppressive effect of SPRR5_326, is presumably that SPRR5_326 
corresponds solely to the 3’ half of the entire SPRR5 transcript, which was not known at that 
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time. Thus, the experiment has to be repeated with the full length SPRR5 transcript and with 
more timepoints in order to draw a final conclusion about its link to carcinogenesis.  
The in vivo tumor formation assay as second method to study the effect of SPRR5_326 on 
tumor development showed only a slight reduction in tumor mass and volume for 
SPRR5_326 overexpressing tumors but inconclusive luciferase signals and drastically 
varying tumor sizes after explantation, which might have been caused by commencing tissue 
necrosis (Figure 5 and Supplementary Figure 2). As discussed above for the invasion assay, 
the obtained overexpression might have been to weak and possibly not high enough over the 
entire duration of this experiment. Furthermore, not the whole SPRR5 transcript was 
employed which might explain the partially mixed results. Strikingly, the formed tumors in 
this experiment did grow drastically slower than anticipated for tumors overexpressing 
oncogenic Ras and Cdk4. Whereas in the initial publication from Lazarov et al. the tumors 
reached volumes >500 mm3 28 days after injection, it took over 70 days for the control 
tumors to reach that size during this experiment76. Hence, the observed slow tumor growth 
might also be an indication for aberrant tumor development in this particular setting, which 
in combination with overexpression of a partial SPRR5 version, might have masked the 
tumor suppressive effect of SPRR5. To finally answer whether SPRR5 controls tumor 
development, both experiments (generation of invasive neoplastic tissue and the in vivo 
tumor formation assay) need to be repeated with a stronger overexpression of the full length 
SPRR5 and more biological replicates, which was not possible in Regensburg due the 
lacking infrastructure and permission for animal experiments as well as for the missing 
requirements to overexpress oncogenic Ras variants. Unfortunately, a repetition at the 
Stanford University was also not an option due to a strict time limitation of the short research 
visit to four weeks.   
To shed further light on the possible link between SPRR5 and carcinogenesis, the commonly 
used colony formation assay, scratch assay or a transwell invasion assay might be applied in 
the future189,190. Interestingly, preliminary results from a transwell migration assay in two 
SCC cell lines already indicated a reduced invasive capacity of SCC cells upon 
overexpression of the full-length SPRR5 transcript, encouraging the supposed tumor 
suppressive effect of SPRR5 (data not shown, work from Kunal Das Mahapatra, in 
collaboration with the Pivarcsi lab, Karolinska Institute, Sweden). 
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5.2 Transcript characterization for SPRR5 
Unravelling the cellular localization of a lncRNA is not only part of a comprehensive 
transcript characterization but might also shed first light on the molecular mechanism of a 
given lncRNA. To this end, subcellular fractionation in combination with RT-qPCR was 
employed during this project, hinting towards a cytoplasmic localization of SPRR5 (4.2.1). 
Regarding the results from this analysis however, only preliminary conclusions should be 
drawn, since no satisfying enrichment of the nuclear markers was obtained from 
differentiated keratinocytes. Given the formation of a tightly connected cornified envelope 
during the course of keratinocyte differentiation, this was presumably due to insufficient 
separation of differentiated keratinocytes in combination with inevitable cell damage prior 
to fractionation. On the other hand, employing undifferentiated keratinocytes would 
facilitate the cell separation prior to the fractionation but would have the drawback of low 
SPRR5 abundance and additionally a switch in the subcellular localization of SPRR5 during 
the course of keratinocyte differentiation could not be excluded.   
In general, it appears that subcellular fractionation is a common obstacle in the keratinocyte 
field, since other reports about lncRNA localization in skin utilized single molecule fish 
analysis for example rather than a biochemical fractionation approach88. Unfortunately, so 
far RNA-FISH for SPRR5 lead to inconclusive and partly contradictory results, despite the 
proven applicability of this method for differentiated keratinocytes (as in our hands other 
transcripts like Klf4 could be reproducibly detected in the expected cellular compartment 
and the employed negative controls showed no signal at all). Even numerous RNA-FISH 
protocol optimization steps and different signal amplification strategies were unable to 
finally reveal the subcellular localization of SPRR5 (work by Bianca Förstl). Therefore, the 
more promising single molecule FISH approach should be employed in future experiments 
but since this approach demands a high resolution microscope in combination with a cooled 
CCD-camera it could not be used in this study191. Additionally, both conventional 
RNA-FISH as well as the conducted subcellular fractionation should be further adapted in 
order to eventually unravel the subcellular localization of SPRR5 in differentiated 
keratinocytes. 
SPRR5 regulates epidermal homeostasis but what controls SPRR5 expression? By 
answering this question, it might be possible to integrate SPRR5 into the complex regulatory 
network of keratinocyte differentiation and furthermore roughly infer the unacquainted 
promotor region for SPRR5. Hence a bioinformatic prediction of upstream transcription 
factors was performed, leading to p63 as the most likely regulator of SPRR5 expression 
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(Figure 7), which was further supported by the presence of p63 ChIP-Seq peaks in the 
vicinity of the human SPRR5 locus and ultimately confirmed via p63 knockdown in primary 
keratinocytes44,158. In light of the already well-established role of p63 as a master regulator 
of murine and human epidermal homeostasis, the observed regulation of SPRR5 by p63 once 
more supported the hypothesized involvement of SPRR5 during keratinocyte 
differentiation39,40.  
Interestingly, the area of the upstream p63 ChIP peak also exhibited a polymerase II as well 
as a ChIP-Seq signal for the transcriptional co-activator p300, indicating that this area might 
represent the promotor for SPRR544,192. Furthermore, the assumed SPRR5 promotor region 
was investigated for additional ChIP signals of known epidermal transcription factors 
revealing overlapping ChIP peaks for ZNF750 and KLF4 but not MAF or MAFB which 
suggests a specialized role of the p63-ZNF750-KLF4 axis for SPRR5 regulation (data not 
shown)35,36. Since KLF4 is controlled by ZNF750, which in turn is a downstream target of 
p63, and loss of either p63, ZNF750 or KLF4 in keratinocytes results in disrupted epidermal 
differentiation, the occurrence of ChIP signals for all three transcription factors at the 
hypothesized SPRR5 promotor accentuates its inevitable necessity for epidermal 
homeostasis because its expression seems to be directly regulated by all three members of 
the p63-ZNF750-KLF4 axis individually35,40,193,194.  
With the advance in sequencing technologies over the recent years, numerous novel lncRNA 
transcripts have been identified and it became evident that several lncRNA isoforms can 
arise from one gene locus through a combination of alternative splicing, polyadenylation or 
promotor usage100,119,129,195. With SPRR5 being a novel lncRNA locus whose transcript has 
only been provisionally annotated as a 326 nt long lncRNA and the recent miscellaneous 
annotations for this gene locus in the latest Ensembl and FANTOM5 release, an exact 
isoform characterization for SPRR5 became indispensable161,162. Surprisingly, this analysis 
was not only able to disprove all public annotations for this gene locus but revealed that the 
previously anticipated SPRR5_326 was indeed part of the dominantly expressed, longer 
SPRR5 transcript rather than representing a discrete alternative isoform (Figure 9). But why 
was the longer SPRR5 RNA not detected earlier? As no annotation for this gene locus was 
present at the time of identification, isoform detection commenced with inspection of the 
initially obtained RNA-Seq reads from differentiated versus undifferentiated keratinocytes, 
revealing one large pile-up of reads spanning roughly 60% of the second exon of SPPR5 
(≈500 nt) and the exact same 3’ end as for SPRR588,146. Thus, in order to elucidate the start 
and end point of the transcript with single nucleotide resolution, RACE analyses with a 5’cap 
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dependent and a 3’ poly-A based strategy were conducted. Interestingly, results from these 
experiments confirmed the assumed 3’end and reproducibly detected a 5’start site 
corresponding to the 326 nt long SPRR5_326 (work by PD Dr. Markus Kretz, Dr. Sonja 
Hombach and Bianca Förstl). Due to the commonly used unstranded RNA-Seq approach, 
integration of RACE and RNA-Seq data lead to the presumed SPRR5_326 transcript and the 
prediction of a second antisense transcript which would explain the presence of RNA-Seq 
reads across the 5’end of SPRR5_326. This antisense transcript however was never 
detectable by northern blots and in combination with the results from the herein conducted 
stranded RNA-Seq experiment (4.4.3), the presence of an antisense transcript could be 
eventually declined.   
At the same time, this recent RNA-Seq experiment raised again the assumption that 
SPRR5_326 might not be the exclusive transcript from the SPRR locus but a second, longer 
isoform had to be present in order to account for the observed RNA-Seq reads outside of the 
SPRR5_326 boundaries (Figure 9). For this reason, RACE studies were repeated with 
several protocol iterations and finally the use of a specialized polymerase revealed the 
presence of two exons and an upstream 5’end for SPRR5 explaining the observed RNA read 
distribution. So in retrospective, previous RACE analyses supposedly were hampered by a 
combination of the utilized DNA polymerase and a GC-rich region directly upstream of the 
5’end of SPRR5_326, which has been described to impede with proper DNA 
amplification196. In conclusion, mainly one dominant capped and polyadenylated SPRR5 
transcript spanning 762 nt is expressed in human keratinocytes, which could be ultimately 
confirmed by a series of northern blots with probes targeting different parts of SPRR5. 
Recapitulating the obtained insights into the SPRR5 transcript characterization, the 
dominant isoform as well as the involvement of several epidermal transcription factors for 
SPRR5 could be revealed. However, the hypothesized direct regulation by KLF4 and 
ZNF750 need to be biochemically verified and also the possible promotor of SPRR5 has to 
be confirmed in future luciferase experiments. Moreover, it will be fascinating to uncover 
how SPRR5 expression is interlaced into other processes controlling epidermal homeostasis. 
Given the transcriptional control of TINCR and ANCR on the epidermal transcription factors 
MAF/MAFB and the recently identified induction of SPRR5 upon decreased levels of the 
progenitor specific lncRNA LINC00941, there seems to be a highly complex and elaborate 
network of lncRNAs and transcription factors regulating each other and in a conjoined effort 
controlling epidermal tissue homeostasis (Ziegler & Graf et al., under review)36.   
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5.3 SPRR5 – protein or lncRNA? 
Originally defined as transcripts longer than 200 nucleotides with no protein-coding 
capacity, recent studies revealed that several lncRNAs associate with ribosomes and do serve 
as ribosomal templates for the expression of small functional peptides102–104. Although the 
extent of this lncRNA translation is under current debate, a few elaborate reports could 
already confirm the existence of bifunctional lncRNAs acting as both RNA as well as 
through the encoded small peptide102,103,107–110. Moreover, based on large RNA-Seq studies 
numerous transcripts might have been misleadingly annotated as lncRNAs but their true 
function is serving as a mRNA for functional protein synthesis. Thus, it remains a 
challenging task in the lncRNA field to discriminate whether transcripts containing a 
predicted open reading frame, act as a coding or non-coding transcript or as a combination 
of both. Interestingly, this obstacle also occurred for the herein verified SPRR5 transcript 
which includes an annotated open reading frame for a putative SPRR5 protein consisting of 
108 amino acids and a molecular weight of 11.9 kDa. This putative protein also reasons the 
name of the SPRR5 transcript, since it might represent a novel family member of the human 
small proline-rich proteins, whose gene cluster is directly adjacent to the genomic 
localization of SPRR5 and strikingly the predicted SPRR5 protein shares compositional 
similarities with other SPRR proteins as it contains a central proline-rich domain built from 
a repeating amino acid motif that is flanked by a N- and C-terminal domain, harboring 
several glutamine and lysine residues197. Nevertheless, the question whether the SPRR5 
protein is indeed expressed in keratinocytes remained and was first addressed by applying 
several bioinformatic coding potential calculations (Figure 10). Concordantly, all employed 
methods predicted a coding nature of SPRR5 which was even further supported by the 
presence of translating ribosomes at the potential open reading frame of the mouse SPRR5 
homolog in a ribosomal profiling study in murine keratinocytes167. Moreover, the observed 
cytoplasmic localization of the SPRR5 transcript would be in agreement with a potential 
translation of SPRR5.   
As already indicated above, the putative SPRR5 protein might be a novel member of the 
human SPRR protein family. In order to shed some light on their evolutionary relationship 
a phylogenetic analysis of their coding sequences was performed, revealing that SPRR5 
seems to have evolved differently than other SPRRs. This finding might already explain the 
significantly different phenotype observed after SPRR5 depletion. Whereas no epidermal 
defects for SPRR knockout mice have been reported so far, loss of SPRR5 clearly disrupts 
proper keratinocyte differentiation as shown above (4.4)64,65.  
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Besides the acquisition of this novel gene function by SPRR5, its separate evolution apart 
from the other SPRR proteins might have also resulted in a different mode of action, in that 
SPRR5 exerts its molecular function as a lncRNA rather than as a functional SPRR5 protein. 
Interestingly, a recent report from Hezroni et al. supports this hypothesis, since it estimates 
that 5% of conserved mammalian lncRNAs arose from remnants of protein-coding genes198. 
5.3.1 Small amounts of endogenous SPRR5 protein are detectable 
Of course, deciphering whether SPRR5 acts as a lncRNA or as a protein implies the actual 
presence of detectable SPRR5 protein amounts within keratinocytes. To this end, a global 
mass spectrometry driven approach was chosen, which was unable to detect a single peptide 
from the predicted SPRR5 protein (4.3.2). However, employing a highly sensitive and 
targeted approach using synthetic heavy labelled SPRR5 peptides for instrument calibration 
prior to the analysis of protein lysate from differentiated keratinocytes revealed the presence 
of roughly 3,000 SPRR5 protein molecules per cell. This rather low protein level might also 
explain the unsuccessful attempt to detect the endogenous SPRR5 protein in 
immunofluorescence analysis of epidermal tissue cross sections or in western blot analysis 
utilizing two polyclonal SPRR5 antibodies which have been proven to detect SPRR5 
peptides in a preliminary dot blot experiments172. Furthermore, even the detection of 
overexpressed and tagged SPRR5 variants turned out to be a challenging endeavour, since 
only weak signals were obtained for both SPRR5 antibodies as well as antibodies 
recognizing the utilized protein tags which might be an evidence for an unstable SPRR5 
protein (antibody testing was done in collaboration with Katrin Hartinger; data not 
shown)199. Of note, during all these studies, the SPRR5 protein was consistently and 
exclusively detected between 20 and 25 kDa, which is in contrast to the predicted molecular 
weight of 11.9 kDa but a slower migration pattern during SDS-PAGE is a known 
phenomenon for proline-rich proteins200,201.   
Considering the well-described function of other human SPRR proteins as flexible 
protein-crosslinkers during the formation of the cornified envelope, detection of at least 
some SPRR5 peptides in the higher molecular weight fractions was anticipated11,57. 
Although high-molecular weight protein complexes (drastically crosslinked aggregations of 
SPRR proteins and other differentiation proteins) might have been segregated during the 
performed centrifugation over a 100 kDa cut off spin column or the detection of potential 
SPRR5 peptides from these fractions might have been hampered by the aberrant peptide 
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mass after massive protein-protein crosslinking, at least sporadic SPRR5 peptides should 
have been observed. For instance, peptides from crosslinked SPRR5 proteins could arise 
from initial two-protein crosslinking intermediates, where SPRR5 would have been 
crosslinked to another differentiation protein like loricrin or involucrin for example. Peptides 
from these complexes should then have been measured in the targeted mass spectrometry 
approach within higher molecular weight fractions since the introduction of a protein 
crosslink solely in the area of the detectable SPRR5 peptide seems highly unlikely. Once 
more, these results indicate merely the presence of uncrosslinked SPRR5 protein in 
differentiated keratinocytes and additionally substantiate a potential novel function of 
SPRR5 apart from other human SPRR proteins.   
In conclusion, only relatively small amounts of uncrosslinked human SPRR5 protein were 
detectable in human keratinocytes and solely with an extremely sensitive mass spectrometry 
approach, hinting towards either low protein stability or accidental translation of SPRR5. 
Moreover, this observation raised serious doubts whether those low amounts of SPRR5 
protein are sufficient to account for the detected effect on keratinocyte differentiation. 
However, future experiments should address the subcellular localization of the SPRR5 
protein in differentiated keratinocytes in order to omit the possibility of higher SPRR5 
protein levels that might have been masked in this semi-quantitative approach by being 
crosslinked to other differentiation proteins at the cellular membrane.  
5.3.2 Rescue experiments for SPRR5 lead to inconclusive results 
Up to now, the gold standard in deciphering the functionality of a given molecule remains 
in rescuing its phenotypic effect by reintroducing the molecule of interest into a depletion 
background202. Thus, siRNA-mediated SPRR5 transcript depletion, resulting in defective 
keratinocyte differentiation (4.4.3), should be rescued by introducing either the SPRR5 
protein or the SPRR5 lncRNA (4.3.3). Surprisingly, for in vitro differentiated keratinocytes 
no differentiation defect upon SPRR5 depletion was detectable, despite the reproducible lack 
of differentiation after siRNA-mediated SPRR5 depletion without simultaneous 
lentiviral-based overexpression (4.4.1). Furthermore, no disrupted but a rather intensified 
differentiation marker expression was observed between SPRR5 depleted and control cells 
when the rescue experiment was conducted in epidermal tissue cultures and the shorter 
SPRR5 open reading frame constructs or the unrelated luciferase-YFP fusion protein were 
overexpressed. Unfortunately, also the initially assumed rescue of the SPRR5 wild-type 
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transcript in organotypic epidermal tissue cultures turned out to be an artefact of a faulty 
differentiation program in the knockdown control for SPRR5_WT rather than the desired 
phenotypic rescue effect. Hence, no conclusion about the functional SPRR5 molecule could 
be drawn from the conducted siRNA-based rescue experiments. Considering the reported 
induction of keratinocyte differentiation upon an increase in cellular stress levels, the 
publications about stress responses triggered by lentiviral infection and electroporation of 
keratinocytes, the siRNA-mediated knockdown in combination with the simultaneous 
lentiviral transduction of overexpression constructs presumably prohibited proper 
keratinocyte differentiation and thus foredoomed the performed rescue experiments203–205. 
 In order to reduce the cellular stress levels and eventually obtain a possible rescue 
effect by either the SPRR5 protein or the SPRR5 RNA, a CRISPR/Cas9 mediated SPRR5 
depletion strategy was employed as a substitute for the electroporation based SPRR5 
knockdown. Since primary keratinocytes were unsuitable for a SPRR5 knockout cell line 
generation due to their limited amount of cell passages, the commonly used HaCaT 
keratinocyte cell line was employed and successfully validated as a suitable model system 
for this experiment. However, neither the transient introduction of the Cas9 endonuclease 
and two guideRNAs flanking each site of the desired deletion, nor the stable genomic 
integration which prolonged the window of opportunity for genomic editing events resulted 
in a homozygous SPRR5 deletion, even though the latter approach drastically increased the 
rate of heterozygous deletions from 3.5% to 13.4%. Given the numerous reports about 
efficient genomic editing using the CRISPR/Cas9 system, it was puzzling to run into these 
kinds of trouble at first, however several parameters were identified that might have hindered 
the generation of a homozygous knockout cell line. First, the rather low portion of 
heterozygous clones should be mentioned. Although, in one study the introduction of a 
1.3 kb genomic deletion was successful for 37.5% of the analyzed alleles, another study with 
different cells aiming at a 119 bp excision reported only 1.6% deletion efficacy, accentuating 
that there might be large differences in genome editing events depending on the cell line, the 
desired genomic deletion as well as the targeted locus176,206,207. Nevertheless, the herein 
observed deletion rates were rather at the lower end of the reported range which might be 
due to an inaccessible SPRR5 locus in undifferentiated keratinocytes. This hypothesis is 
substantiated by reports about the presence of a highly condensed chromatin structure of the 
genomic SPRR5 locus in undifferentiated keratinocytes and the lack of DNAse accessible 
sites upstream of the desired SPRR5 deletion51,179,181,208–210. In addition to that, also a 
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CRISPR/Cas9 mediated endogenous tagging approach for SPRR5 failed, despite an efficient 
delivery of exogenous DNA into HaCaT cells, which once more highlights the challenging 
character of genome editing at this particular gene locus in keratinocytes (work from Karina 
Berschneider, Bianca Förstl and Sonja Hombach).   
Another important factor that should not be neglected is the reported aneuploidy of HaCaT 
cells. Strikingly, the presence of four copies of the targeted chromosome 1 did certainly not 
alleviate the intended homozygous SPRR5 knockout but might have even hampered this 
effort by serving as a template for the homology-directed repair pathway upon successful 
excision of SPRR5175,176.   
Since the applied knockout strategy did not result in the desired SPRR5 depletion so far, 
further rounds of transfection, selection and screening of already heterozygous knockout 
clones might ultimately result in a homozygous SPRR5 knockout cell line. In light of the 
reports about off-target modifications introduced by the CRISPR/Cas9 system and the 
accumulating number of random mutations over the course of clonal cell expansion and 
cultivation, it would be highly questionable whether such a cell line would still be 
comparable to the initially utilized HaCaT cells after several knockout cycles211–214. 
Alternatively, the HaCaT cells could be substituted with the immortalized N/Tert 
keratinocyte cell line which, in contrast to HaCaT cells, only contains two copies of the 
targeted chromosome 1 and hence might increase the chances of a homozygous SPRR5 
knockout215. Moreover, the recently developed enhanced Cas9 should be combined with 
guideRNAs targeting the DNAse accessible regions surrounding the SPRR5 locus in order 
to combine fair chances for a knockout cell line with a reduced number of off-target 
mutations216. Eventually, the generation of a SPRR5 knockout cell line seems inevitable, as 
the rescue experiments with the siRNA-mediated depletion background failed and 
electroporation represents the only efficient delivery method for siRNAs into keratinocytes 
in our hands. Furthermore, simple overexpression of either the protein or the lncRNA moiety 
alone did not result in any ectopic or increased differentiation marker expression in 
keratinocytes and thus was also unable to solve the mystery about the functional SPRR5 
molecule (data not shown and Figure 21). 
In conclusion, the identity of the functional SPRR5 molecule in differentiated keratinocytes 
could not be ultimately deciphered due to the inconclusive results from the performed rescue 
experiments and the unsuccessful generation of SPRR5 knockout cell lines. Nevertheless, 
bioinformatic predictions indicate the translation of SPRR5 and minor amounts of soluble 
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SPRR5 protein could be detected in differentiated keratinocytes. The drastically different 
effect of SPRR5 in comparison to other known SPRR proteins, the diminutive intracellular 
protein levels and the conducted phylogenetic analysis in combination with a report about 
lncRNA evolution from formerly protein-coding genes on the other raised serious doubts 
whether the predicted protein is indeed functional or an unstable by-product of accidental 
protein synthesis109,198,217. Based on these ambiguous findings, three conceivable scenarios 
for the SPRR5 transcript remain: Either, SPRR5 solely serves as a mRNA and its translation 
results in a functional protein, or SPRR5 exerts its regulatory role during keratinocyte 
differentiation exclusively as a lncRNA and the detected protein represents the outcome of 
pervasive translation or a combination of both applies, meaning that SPRR5 acts as a 
lncRNA and as a functional protein. Interestingly, several of these bifunctional lncRNAs 
were recently characterized, demonstrating that the strict classification into coding and 
non-coding transcripts is not appropriate anymore and might also be applicable for 
SPRR5104,106,110,218. 
5.4 Epidermal homeostasis is controlled by SPRR5 
Despite the ambiguity about the functional SPRR5 molecule, it could be shown that proper 
execution of the terminal keratinocyte differentiation program is strictly dependent on the 
presence of the SPRR5 transcript, as its depletion for in vitro differentiated keratinocytes as 
well as in organotypic epidermal tissue cultures resulted in reduced expression of several 
key differentiation markers on both mRNA and protein levels (4.4.1 and 4.4.2). Moreover, 
the global RNA-sequencing approach of SPRR5 deficient epidermal tissue versus control 
tissue revealed that SPRR5 controls gene expression for a plethora of genes and since the 
top GO-terms for genes with reduced expression upon SPRR5 depletion were associated 
with epidermal development and homeostasis, this experiment ultimately proved the 
exigency of SPRR5 for keratinocyte differentiation. Strikingly, SPRR5 apparently controls 
the gene expression of almost the whole SPRR and LCE gene cluster over the course of the 
differentiation program, suggesting a cis-regulatory role of SPRR5 on those neighboring 
gene clusters (Figure 25). According to a recent review, three distinct mechanisms for 
cis-acting lncRNAs can be distinguished with respect to their regulatory component. First, 
gene expression can be controlled by the lncRNA itself for example by guiding or 
scaffolding transcription factors to nearby gene loci. Second, the process of RNA 
transcription or splicing confers the regulatory effect or as a third possibility the presence 
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of regulatory DNA elements within the gene locus might be the mode of action for the 
expected cis-regulatory function131. Given the observed SPRR5 knockdown phenotype (4.4), 
the relevance of the SPRR5 transcript itself was unambiguously verified since siRNAs 
should mainly affect the steady-state levels of a given RNA transcript and thus, the first 
possibility seems the most promising. So, assuming that SPRR5 exerts its cellular function 
as a cis-acting lncRNA, again various modes of action are conceivable like the guidance of 
transcription factors, assembly of an active transcription machinery as well as altering the 
genomic accessibility or the histone marks at the regulated gene loci. Considering that 
analysis of the regulated genes from the RNA-Seq experiment did not hint towards a 
common transcription factor and numerous publications reported a crucial role of activating 
and repressing histone marks in epidermal differentiation, which are controlled by the 
demethylases JMJD3 and UTX, histone deacetylases 1 and 2, the PCR2 complex or the BAF 
chromatin remodeling complex (see also 2.1.2), an epigenetic mechanism for SPRR5 
seemed promising and was tested with ATAC-Seq and ChIP-Seq experiments44–46,48–50. 
5.4.1 No evidence for an epigenetic mechanism of SPRR5 
As discussed above, SPRR5 might act as a lncRNA and epigenetically control gene 
expression from the LCE and SPRR gene cluster in cis and other gene loci via a trans-acting 
mechanism but on the other hand epigenetic control of keratinocyte differentiation might 
also be accomplished by the SPRR5 protein which was an additional reason for moving 
forward into this direction. To this end, the genomic accessibility was probed with 
ATAC-Seq in SPRR5 deficient as well as in control keratinocytes at day 4 of differentiation 
as well as in progenitor cells. Surprisingly, loss of SPRR5 in differentiated keratinocytes 
resulted in no major differences in the number of opened or closed regions although the 
detected downregulation of many differentiation genes would suggest a generally more 
condensed chromatin structure in SPRR5 depleted cells. Furthermore, the observed dynamic 
range for the detected alterations was rather low as not a single region was altered by a factor 
of two or more. One reason for these findings certainly arises from the high sample 
variability within the replicates. Not only the knockdown efficiencies varied between the 
biological replicates but also gross differences in the sequencing depth as well as a high 
variance for the genomic accessibility became apparent (Figure 26, Figure 27, Table 3). 
Thus, it was also not surprising that none of the detected altered regions was statistically 
significant. On the other hand, the obtained sequencing data had an overall decent quality, 
so possibly existing fundamental alterations in the genomic accessibility upon SPRR5 
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depletion should have been detected even though with no statistical significance. Another 
important parameter might have been the sample preparation, in which the keratinocytes 
were detached and dead cells were removed via an Annexin V based depletion strategy. 
Although this step might have improved the overall data quality, exposing the cells to 
suboptimal growth conditions for such a long time (≈90 min) might have already induced 
changes into their chromatin accessibility which in turn might have masked SPRR5 
dependent alterations. To this end, future ATAC experiments should be rather performed 
according to the described approach by Bao et al., where the transposase reaction takes place 
directly in the cultivation vessel and minimizes the window of opportunity for possibly 
occurring belated chromatin alterations44. Interestingly, in one of the few publications about 
ATAC-Seq in keratinocytes, Bao et al. found roughly 12% of open and accessible chromatin 
regions to be dependent on the BAF complex, which is an unexpectedly low rate given the 
well-established chromatin remodeling role of BAF and the also reported conjoined action 
with p63, which is the master regulator of keratinocyte differentiation33,39,40,42,44. Moreover, 
the reported nucleosomal shifting rates by an average of only 20 nucleotides substantiates 
the impression that in general rather incremental changes in the genomic accessibility of 
keratinocytes appear and that these might have been masked here due to the high sample 
variance originating from sample preparation and different sequencing depths44. In 
conclusion, SPRR5 does not seem to control the chromatin accessibility during keratinocyte 
differentiation, however future experiments with more replicates and an optimized sample 
preparation are necessary to substantiate this hypothesis. 
Although no evidence for an epigenetic mechanism of SPRR5 could be deduced from the 
ATAC-Seq experiments, SPRR5 might regulate the deposition of histone marks, which was 
tested for the activating marks H3K4me1 and H3K27ac and the repressive mark H3K27me3 
(4.4.4). As anticipated, SPRR5 depletion in progenitor keratinocytes did not lead to major 
changes in the histone landscape which can be reasoned by the low SPRR5 expression level 
in progenitor cells and their dormant differentiation program. In contrast to this, for day 4 of 
differentiation either a decreased deposition of the activating marks H3K4me1 or H3K27ac 
and/or an increased signal for the repressive mark H3K27me3 would be expected in SPRR5 
deficient cells, since at this differentiation stage loss of SPRR5 results in an extensive 
downregulation of differentiation gene expression. Strikingly, this expectation was matched 
for H3K4me1 and H3K27me3 but not for the activating mark H3K27ac. Given the 
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hypothesized expression control of SPRR5 over the LCE and the SPRR cluster, in a next 
step only altered histone modifications within this area were assessed, which unfortunately 
revealed no dramatic alterations in their histone landscape. Additionally, no regulated  
(-0.5 > log2(fold change) > 0.5) histone signals were obtained within two recently 
characterized EDC enhancer regions and only sporadic and inconclusive areas were found 
within super-enhancer regions identified in the murine epidermal differentiation complex, 
excluding the possibility that SPRR5 alters histone modifications specifically in those 
enhancer regions and exerts its global gene regulation within the EDC via this 
mechanism54,186,187. Strikingly, reanalysis of the altered ATAC-Seq signals for these 
enhancer regions lead to similar results, also neglecting a SPRR5 involvement in regulating 
their accessibility. Thus, an epigenetic control of keratinocyte differentiation mediated by 
SPRR5 regulated deposition of the tested histone modifications seemed rather unlikely, 
which was further substantiated by reanalyzing the data set with the HOMER ChIP-Seq 
toolbox, leading to different and partly contradicting results188. Nevertheless, in order to 
draw a final conclusion on that, this experiment has to be repeated since no biological 
replicates were employed, which makes an estimation about the biological variance as well 
as the detection of significantly altered regions impossible. Interestingly, a recent report 
claimed that transcriptional control in keratinocytes is accompanied by modest, essentially 
quantitative changes in histone modifications rather than an all or nothing mechanism which 
highlights the indispensable requirement for biological replicates in order to detect those 
modest alterations with statistical significance180. Furthermore, it should also be considered 
that SPRR5 might alter the distribution of histone modifications during the course of 
differentiation but simply not the modifications that have been tested here. Although several 
differentiation-associated genes are known to be suppressed in progenitor cells by the 
repressive histone mark H3K27me3 and are activated by demethylation upon induction of 
the terminal differentiation program and a more recent report revealing broad differences for 
H3K4me1 and H3K27ac deposition between progenitor and differentiated keratinocytes, 
similar reports exist for the histone modifications H4K20me1 or H3K9ac for 
example45,180,219,220. In addition to that, SPRR5 might also affect the DNA methylation state, 
which has been found to be a crucial regulator of maintaining the keratinocyte progenitor 
state as loss of the DNA methyltransferase 1 (DNMT1), and thus a decreased DNA 
methylation rate at certain gene loci, leads to premature keratinocyte differentiation178.  
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In summary, it appears that SPRR5 does not exert its molecular function on keratinocyte 
differentiation by altering the chromatin accessibility or the distribution of the histone 
modifications H3K4me1, H3K27ac or H3K27me3, however several other epigenetic roles 
of SPRR5 might apply as discussed above. Furthermore, the nuclear role of SPRR5 might 
also occur on the level of higher-order genome organization since it was shown that the 
coordinated induction of EDC genes over the course of keratinocyte differentiation depend 
on an active reorganization of the EDC locus51. Recent studies in keratinocytes for instance 
unraveled spatial interactions between an AP-1 bound enhancer element and several EDC 
genes and another group identified that the formation of long-range chromatin looping by 
the lncRNA CCAT1-L, which induces expression of the transcription factor MYC in 
colorectal cancer cells186,221. In conclusion, these findings suggest that also SPRR5 might 
establish spatial contacts between distinct genomic regions within the EDC which could be 
tested by a chromosome conformation capture analysis in SPRR5 deficient keratinocytes. 
 All of the above discussed possible mechanism for SPRR5 take place in nucleus but 
the preliminary proposed cytoplasmic localization of the SPRR5 transcript would rather 
contradict a direct nuclear lncRNA mechanism. Nevertheless, a cytoplasmic regulation of 
another lncRNA or protein mediator that could then exert the epigenetic control in the 
nucleus is conceivable. On the other hand, the cytosolic localization of the SPRR5 transcript 
is in agreement with the observed translation of SPRR5 and the resulting SPRR5 protein 
might be the effector of the hypothesized nuclear function. Along this line, first experiments 
about the localization of the SPRR5 protein in HEK cells however, revealed a largely 
cytosolic localization of the overexpressed SPRR5-GFP fusion-protein and bioinformatic 
predictions failed to detect a nuclear localization signal (NLS) for the SPRR5 protein 
(overexpression done by Katrin Hartinger)222–225. Interestingly, a recent report showed that 
overexpressed SPRR4, which also lacks a predicted NLS, is predominantly localized in the 
cytosol of HeLa cells but has the ability to bind double-stranded DNA which is even further 
increased at high levels of reactive oxygen species63,222–225. In combination with another 
report from the same group about consistent nuclear detection of overexpressed 
pEGFP-SPRR1B in migrating keratinocytes, the authors envisioned a nuclear role of human 
SPRR proteins, which might also be applicable for the SPPR5 protein60,63.  
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5.4.2 Conceivable cytosolic mechanisms for SPRR5 and future directions 
Apart from the already discussed possible nuclear functions of SPRR5 (5.4.1), also a 
cytoplasmic control of gene expression is imaginable and will be discussed here under the 
assumption that SPRR5 acts as a lncRNA. First, SPRR5 might exert a post-transcriptional 
regulation of gene expression similar to the well-elaborated role of the lncRNA TINCR, in 
which TINCR stabilizes several differentiation marker transcripts together with the protein 
Staufen 188. But since no specific SPRR5-Staufen 1 association could be detected in a 
previous protein interaction study, a different mechanism seems to apply for SPRR5 
(unpublished results from the Kretz lab)88. Furthermore, SPRR5 might intervene into cellular 
signaling pathways as shown for the NF-κB Interacting LncRNA (NKILA) which would be 
especially intriguing since blockade of the NF-κB signaling pathway is one factor that is able 
to induce neoplastic tumors from epidermal keratinocytes and a functional involvement of 
SPRR5 in SCC development is assumed77,226. Finally, SPRR5 might also fine-tune the levels 
of miRNAs, which in turn regulate the expression of keratinocyte differentiation markers. 
Interestingly, several crucial miRNAs have already been reported for epidermal homeostasis 
and the lncRNA H19 was shown to regulate keratinocyte differentiation by sponging 
miR-130b-3p85,86,227–231. In light of the plethora of possible mechanism under the assumption 
that SPRR5 represents a functional lncRNA, the detection of the SPRR5 protein drastically 
augments the number of conceivable cellular mechanisms, which will not be discussed here. 
With the in-depth SPRR5 transcript characterization and the detailed functional data for the 
SPRR5 transcript, future endeavors for SPRR5 should be first focused on the elucidation 
whether SPRR5 controls epidermal tissue homeostasis as a lncRNA, a protein or a 
combination of both. To this end, rescue experiments in a keratinocyte-derived SPRR5 
knockout cell line would be highly favorable but also the lentiviral introduction of 
short-hairpin RNAs targeting SPRR5 might be applicable as a different depletion strategy. 
Once the functional SPRR5 molecule is clear, unravelling its subcellular localization might 
shed first light onto the exact mode of action, which could then be complemented by targeted 
interaction studies for protein or RNA interactors and in case of a nuclear localization also 
by assaying possible DNA interactions. Furthermore, insights from these studies might 
interlace SPRR5 into the intriguing regulatory network of epidermal homeostasis and 
possibly also hint towards its involvement in skin cancer progression or the generation of 
skin diseases. 
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6 Material 
6.1 Antibodies and beads 
6.1.1 Antibodies  
Table 6: Primary antibodies used during this thesis 
Name Source 
Dilution 
(Fixative) 
Application Supplier 
α-β-actin 
mouse, 
monoclonal 
AC-15 
1:5,000 WB 
Sigma-Aldrich, 
A1978 
α-β-actin 
mouse, 
monoclonal 
AC-15 
1:10,000 WB Abcam, ab6276 
α-Cdk4 rabbit, polyclonal 1:1,000 WB 
Santa Cruz 
Biotechnology, 
sc-749 
α-collagen VII rabbit, polyclonal 
1:400 
(dependent on 
diff. marker) 
IF staining 
Merck 
Millipore, 
234192 
α-collagen VII 
mouse, 
monoclonal 
LH7.2 
1:800 
(dependent on 
diff. marker) 
IF staining 
Merck 
Millipore, 
MAB1345 
α-collagen VII 
mouse, 
monoclonal 
clone32 
1:1,000 
(methanol/acetone
1:1) 
IF staining  
(tissue: 7.2.6) 
Merck 
Millipore, 
MAB2500 
α-Filaggrin 
mouse, 
monoclonal 
1:50 
(ethanol) 
IF staining 
Santa Cruz 
Biotechnology, 
sc-66192 
α-H3K4me1 rabbit, polyclonal 12.5 ng/µl (final) ChIP-Seq Abcam, ab8895 
α-H3K27ac rabbit, polyclonal 12.5 ng/µl (final) ChIP-Seq Abcam, ab4729 
α-H3K27me3 rabbit, polyclonal 12.5 ng/µl (final) ChIP-Seq 
Diagenode, 
C15410069 
α-Loricrin rabbit, polyclonal 
1:800  
(acetone) 
IF staining 
Covance, 
PRB-145P 
α-Loricrin rabbit, polyclonal 1: 1,000 WB 
Covance, 
PRB-145P 
α-Keratin1 rabbit, polyclonal 1:1,000 WB 
Covance, 
PRB-149P 
α-Keratin1 rabbit, polyclonal 
1:2,000 
(methanol) 
IF staining 
Covance, 
PRB-149P 
α-Keratin5 rabbit, polyclonal 
1:750 
(methanol/acetone
1:1) 
IF staining 
(tissue: 7.2.6) 
Covance, 
PRB-160P 
α-pan Ras 
mouse, 
monoclonal  
C-4 
1:1,000 WB 
Santa Cruz 
Biotechnology, 
sc-166691 
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Table 7: Utilized secondary antibodies 
Name Source Dilution Application Supplier 
Alexa Fluor 488 
goat α-rabbit IgG 
goat, polyclonal 1:300 IF staining 
Thermo Fisher 
Scientific, 
A-11008 
Alexa Fluor 488 
goat α-mouse IgG 
goat, polyclonal 1:300 IF staining 
Thermo Fisher 
Scientific, 
A-11001 
Alexa Fluor 555 
goat α-rabbit IgG 
goat, polyclonal 1:300 IF staining 
Thermo Fisher 
Scientific, 
A-21428 
Alexa Fluor 555 
goat α-mouse IgG 
goat, polyclonal 1:300 IF staining 
Thermo Fisher 
Scientific, 
A-21422 
IRDye 680RD 
goat α-mouse IgG 
goat, polyclonal 1:15,000 WB 
LI-COR 
Biosciences, 
926-68070 
IRDye 800CW 
goat α-mouse IgG 
goat, polyclonal 1:15,000 WB 
LI-COR 
Biosciences, 
926-32210 
IRDye 800CW 
goat α-rabbit IgG 
goat, polyclonal 1:15,000 WB 
LI-COR 
Biosciences, 
926-32211 
 
6.1.2 Beads 
Table 8: Overview of utilized beads 
Name Application Supplier Catalogue number 
Agencourt AMPure XP beads 
ATAC-Seq, 
ChIP-Seq 
Beckman Coulter A63880 
nProtein A Sepharose 4 Fast Flow ChIP-Seq Merck GE17-5280-04 
Sepharose CL-4B beads ChIP-Seq Merck CL4B200 
 
6.2 Buffers and solutions 
All buffers and solutions were prepared with deionized H2O unless stated otherwise. 
Table 9: Utilized buffers and solutions 
Buffer/Solution Composition  
10% APS 10% (w/v) ammonium persulfate in water 
2x RNA loading dye 20 mM 
5 mM 
1 mM 
5.9% (v/v) 
45% (v/v) 
0.01% (w/v) 
5% (v/v) 
MOPS, pH 7.0 
sodium acetate 
EDTA 
formaldehyde 
formamide 
bromophenol blue 
glycerol 
2x SSC 300 mM 
30 mM 
 
sodium chloride 
sodium citrate 
pH 7.0 
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20x SSC 3 M 
0.3 M 
 
sodium chloride 
sodium citrate 
pH 7.0 
4x Resolving gel buffer 1.5 M 
0.4% (w/v) 
 
Tris 
SDS 
pH 8.8 
4x Stacking gel buffer 0.5 M 
0.4% (w/v) 
 
Tris 
SDS 
pH 6.8 
5x laemmli buffer 300 mM 
10% (w/v) 
62.5% (v/v) 
0.1% (w/v) 
10% (v/v) 
Tris/HCl, pH 6.8 
SDS 
glycerol 
bromophenol blue 
β-mercaptoethanol, added fresh before use 
ATAC resuspension buffer 10 mM 
10 mM 
3 mM 
Tris/HCl, pH 7.4 
NaCl 
MgCl2 
Coomassie fixative 10% (v/v) 
50% (v/v) 
acetic acid 
methanol 
ChIP-Seq elution buffer 1% (w/v) 
100 mM 
SDS 
sodium hydrogen carbonate 
ChIP RIPA buffer 1% (v/v) 
0.5% (w/v) 
0.1% (w/v) 
1 mM 
add before use: 
1x 
1 mM 
10 mM 
NP-40 
sodium deoxycholate  
SDS 
EDTA 
in PBS, pH 7.8 
protease inhibitor (Roche) 
AEBSF 
sodium butyrate 
ChIP swelling buffer 100 mM 
10 mM 
15 mM 
1% (v/v) 
add before use: 
1x 
1 mM 
10 mM 
Tris/HCl, pH 7.6 
Potassium acetate 
magnesium acetate 
NP-40 
 
protease inhibitor (Roche) 
AEBSF 
sodium butyrate 
ChIP-Seq DB 20 mM 
100 mM 
2 mM 
0.5% (v/v) 
add before use: 
1 mM 
10 mM 
1x 
Tris/HCl, pH 7.4 
sodium chloride 
EDTA 
Triton X-100 
 
AEBSF 
sodium butyrate 
protease inhibitor (Roche) 
ChIP-Seq WB I 20 mM 
150 mM 
0.1% (w/v) 
1% (v/v) 
2 mM 
Tris/HCl, pH 7.4 
sodium chloride 
SDS 
Triton X-100 
EDTA 
ChIP-Seq WB II 20 mM 
500 mM 
1% (v/v) 
2 mM 
Tris/HCl, pH 7.4 
sodium chloride 
Triton X-100 
EDTA 
ChIP-Seq WB III 10 mM Tris/HCl, pH 7.4 
 77 
Material 
250 mM 
1% (v/v) 
1% (w/v) 
1 mM 
lithium chloride 
NP-40 
sodium deoxycholate  
EDTA 
DNA loading dye 0.25% (w/v) 
30% (v/v) 
bromophenol blue 
glycerol 
Hoechst solution 4 µg/ml 
 
Hoechst 33342 
dissolved in PBS 
hybridization solution 750 mM 
75 mM 
20 mM 
7% (w/v) 
0.02% (w/v) 
0.02% (w/v) 
0.02% (w/v) 
sodium chloride 
sodium citrate 
disodium phosphate, pH 7.2 
SDS 
albumin fraction V 
Ficoll400 
polyvinylpyrrolidon K30 
LB medium 1% (w/v) 
1% (w/v) 
0.5% (w/v) 
 
sodium chloride 
tryptone 
yeast extract 
pH 7.4, autoclaved before usage 
LB-Amp 0.01% (w/v) 
 
ampicillin 
added to LB medium after sterilization 
LB-(Amp)agar 1.5% (w/v) 
0.01% (w/v) 
 
agar 
ampicillin 
dissolved in LB medium 
NB wash I 750 mM 
75 mM 
1% (w/v) 
 
sodium chloride 
sodium citrate 
SDS 
pH 7.0 
NB wash II 150 mM 
15 mM 
1% (w/v) 
 
sodium chloride 
sodium citrate 
SDS 
pH 7.0 
PBS 140 mM 
2.7 mM 
10 mM 
1.8 mM 
 
sodium chloride 
potassium chloride  
disodium phosphate 
monopotassium phosphate 
pH 7.2  
protein lysis buffer 25 mM 
150 mM 
5% (v/v) 
2 mM 
0.3% (w/v) 
1 mM 
1x 
 
Tris/HCl, pH 7.5 
sodium chloride 
glycerol 
EDTA 
NP-40 
dithiothreitol, added fresh 
cOmplete, EDTA-free Protease Inhibitor 
Cocktail (Roche), added fresh 
RIPA 50 mM 
150 mM 
0.1% (w/v) 
1% (w/v) 
1% (w/v) 
1 mM 
1x 
 
Tris/HCl, pH 7.5 
sodium chloride 
SDS 
sodium deoxycholate 
NP-40 
dithiothreitol, added fresh 
cOmplete, EDTA-free Protease Inhibitor 
Cocktail (Roche), added fresh 
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RNA gel buffer 20 mM 
5 mM 
1 mM 
1.9% (v/v)  
 
MOPS 
sodium acetate 
EDTA 
formaldehyde 
pH 7.0 
siRNA annealing buffer 60 mM 
4 mM 
200 mM 
HEPES 
magnesium acetate 
potassium acetate 
TAE 8 mM 
0.2 mM 
4 mM 
Tris 
EDTA 
acetic acid 
TBS-T 10 mM 
150 mM 
0.02 % (w/v) 
Tris 
sodium chloride 
Tween-20 
TE 10 mM 
1 mM 
 
Tris 
EDTA 
pH 8.0 
TGS 25 mM 
192 mM 
0.1% (w/v) 
 
Tris 
glycine 
SDS 
pH 8.3 
TFBI 30 mM 
50 mM 
100 mM 
10 mM 
15% (v/v) 
 
potassium acetate 
manganese chloride 
rubidium chloride 
calcium chloride 
glycerol 
pH 5.8, filtered sterile through 0.2 µm pore filter 
TFBII 10 mM 
75 mM 
10 mM 
15% (v/v) 
 
MOPS sodium salt 
calcium chloride 
rubidium chloride 
glycerol 
pH 7.0, filtered sterile through 0.2 µm pore filter 
YT-medium 0.8% (w/v) 
0.5% (w/v) 
85 mM 
20 mM 
10mM  
 
tryptone 
yeast extract 
sodium chloride 
magnesium sulfate 
potassium chloride 
pH 7.5, autoclaved before usage 
western blot transfer buffer 25 mM 
192 mM 
20% (v/v) 
 
Tris 
glycine 
methanol 
pH 8.6 
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6.3 Chemicals, enzymes and peptides 
Unless stated otherwise, chemicals were purchased from Applichem (Darmstadt, Germany), 
Bio-Rad (Hercules, USA), Carl Roth (Karlsruhe, Germany), Merck (Darmstadt, Germany), 
Roche (Basel, Switzerland), Sigma-Aldrich (St. Louis, USA), Thermo Fisher Scientific 
(Waltham, USA), VWR International (Radnor, USA) and Weckert Labortechnik (Kitzingen, 
Germany).  
Radiochemicals were purchased from Hartmann Analytics (Braunschweig, Germany), 
restriction enzymes, enzymes for RNA and DNA modifications (ligases, polymerases etc.) 
and markers were purchased from Bio-Rad (Hercules, USA), Merck (Darmstadt, Germany), 
New England Biolabs (Ipswich, USA), Roche (Basel, Switzerland) and Thermo Fisher 
Scientific (Waltham, USA).   
Heavy labeled peptides for quantitative mass spectrometry were obtained from JPT Peptide 
Technologies (Berlin, Germany) and contained a 13C15N-label on the C-terminal arginine or 
lysine residue. 
Table 10: Sequences of heavy labeled peptides 
Peptide Sequence (N to C terminus) AA pos. in SPRR5 
SPRR5_peptide1 CQEPCAPK 88-95 
SPRR5_peptide2 QPCQPPPK 80-87 
SPRR5_peptide3 CPPPQQCQTSK 96-106 
SPRR5_peptide4 QCAPPQQCCPPPQQR 8-22 
 
6.4 Commercial kits 
Commercial kits were used according to their included manuals unless stated otherwise. 
Table 11: List of commercial kits 
Name Supplier Catalogue number 
Agilent High Sensitivity 
DNA Kit 
Agilent Technologies (Santa Clara, USA) 5067-4626 
Agilent RNA 6000 Pico Kit Agilent Technologies (Santa Clara, USA) 5067-1513 
Annexin V MicroBead Kit 
Miltenyi Biotec (Bergisch Gladbach, 
Germany) 
130-090-201 
Cytoplasmic and Nuclear 
RNA Purification Kit 
Norgen Biotek (Thorold, Canada) 21000 
DNase I, RNase-free Thermo Fisher Scientific (Waltham, USA) EN0521 
ERCC RNA Spike In Mix Thermo Fisher Scientific (Waltham, USA) 4456740 
Expand Long Template PCR 
System 
Sigma-Aldrich (St. Louis, USA) 11681834001 
FirstChoice RLM-RACE Kit Thermo Fisher Scientific (Waltham, USA) AM1700 
High Sensitivity D1000 
ScreenTape and reagents 
Agilent Technologies (Santa Clara, USA) 
5067- 5584;  
5067- 5585 
 80 
Material 
Human Keratinocyte 
Nucleofector Kit 
Lonza (Basel, Switzerland) VVPD-1002 
illustra MicroSpin G-25 
Columns 
GE Healthcare (Chalfont St Giles, Great 
Britain) 
27532501 
iScript cDNA Synthesis Kit Bio-Rad (Hercules, USA) 170-8890 
Lipofectamine 3000 Thermo Fisher Scientific (Waltham, USA) L3000015 
Monarch PCR & DNA 
Purification Kit 
New England Biolabs (Ipswich, USA) T1030S 
NEBNext Multiplex Oligos 
for Illumina 
New England Biolabs (Ipswich, USA) 
E7335 (Set1) 
E7500 (Set 2) 
NEBNext Ultra II DNA 
Library Prep Kit for Illumina 
New England Biolabs (Ipswich, USA) E7645 
Nextera DNA Library 
Preparation Kit 
Illumina (San Diego, USA) FC-121-1030 
Nextera Index Kit Illumina (San Diego, USA) FC-121-1011 
NucleoBond Xtra Maxi EF Macherey-Nagel (Dueren, Germany) 740424 
NucleoBond Xtra Midi Kit Macherey-Nagel (Dueren, Germany) 740410 
NucleoSpin Gel and PCR 
Clean-up Kit 
Macherey-Nagel (Dueren, Germany) 740609 
NucleoSpin Plasmid (NoLid) Macherey-Nagel (Dueren, Germany) 740499 
pGEM-T Easy Vector Kit Promega (Madison, USA) A1360 
Pierce BCA Protein Assay 
Kit 
Thermo Fisher Scientific (Waltham, USA) 23225 
PrecisionX Multiplex gRNA 
Cloning Kit 
BioCat (Heidelberg, Germany) 
CAS9-GRNA-KIT-
SBI 
QIAShredder Qiagen (Hilden, Germany) 79654 
QIAquick PCR Purification 
Kit 
Qiagen (Hilden, Germany) 28106 
Qubit dsDNA HS Assay Kit Thermo Fisher Scientific (Waltham, USA) Q32851 
RNeasy Plus Mini Kit Qiagen (Hilden, Germany) 74136 
Roti-Quant Carl Roth (Karlsruhe, Germany) K015.1 
SsoFast EvaGreen Bio-Rad (Hercules, USA) 1725200 
Takyon No ROX SYBR 
2x MasterMix blue dTTP 
Eurogentec (Luettich, Belgium) UF-NSMT-B0701 
TURBO DNA-free Kit Thermo Fisher Scientific (Waltham, USA) AM1907 
TruSeq Stranded mRNA 
Library Prep 
Illumina (San Diego, USA) 20020594 
 
6.5 Consumables, membranes and screens 
Consumables were, unless stated otherwise, purchased from Bio-Rad (Hercules, USA), Carl 
Roth (Karlsruhe, Germany), Eppendorf (Hamburg, Germany), Eurogentec (Luettich, 
Belgium), GE Healthcare (Chalfont St Giles, Great Britain), MP Biomedicals (Heidelberg, 
Germany), NeoLab (Heidelberg, Germany), Sarstedt (Nuembrecht, Germany), Thermo 
Fisher Scientific (Waltham, USA) or VWR International (Radnor, USA).  
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Table 12: List of membranes and screens 
Name Supplier Catalogue number 
Amersham Hybond-ECL 
GE Healthcare (Chalfont St Giles, Great 
Britain) 
RPN132D 
Amersham Hybond-N+ 
GE Healthcare (Chalfont St Giles, Great 
Britain) 
RPN203B 
Storage Phosphor Screen GP Kodak (Rochester, NY, USA) 1707843 
 
6.6 Eukaryotic cell cultivation 
Dermis for regenerated organotypic epidermal tissue cultures was prepared from frozen 
split-skin obtained from Biopredic International (Saint-Grégoire, France), Tissue Solutions 
(Glasgow, Great Britain) or was isolated from surgical specimens in the Khavari laboratory 
at the Stanford University School of Medicine (Stanford, USA). Utilized primary cells, cell 
lines, media components and their composition are listed below. 
Table 13: Overview of primary eukaryotic cells and cell lines 
Name Details Supplier 
HaCaT cell line Catalogue number 300493 
Cell Lines Service 
(Eppelheim, Germany) 
HEK293T cells gift from the AG Meister  
AG Meister 
(Regensburg, Germany) 
Normal Human Epidermal 
Keratinocytes (NHEK), adult 
single donor 
isolated from fresh surgical specimens at 
the University Hospital Regensburg 
AG Kretz 
Normal Human Epidermal 
Keratinocytes (NHEK), 
juvenile foreskin, pooled 
Lot numbers:  
1020401, 1040101 and 407Z001 
PromoCell  
(Heidelberg, Germany) 
Primary neonatal human 
keratinocytes 
isolated from fresh surgical specimens at 
the Stanford University 
Khavari laboratory 
(Stanford, USA) 
Primary human fibroblasts 
isolated from fresh surgical specimens at 
the Stanford University 
Khavari laboratory 
(Stanford, USA) 
 
Table 14: Reagents for eukaryotic cell cultures 
Name Supplier Catalogue number 
3,3’,5’-Triiodo-L-thryonine Sigma-Aldrich (St. Louis, USA) T0281 
Adenine hydrochloride 
hydrate 
Sigma-Aldrich (St. Louis, USA) A-9795 
100x Antibiotic-Antimycotic 
Thermo Fisher Scientific (Waltham, 
USA) 
15240-096 
Cholera toxin from Vibrio 
cholerae 
Sigma-Aldrich (St. Louis, USA) C8052 
Corning Matrigel 
Thermo Fisher Scientific (Waltham, 
USA) 
11543550 
DMSO Carl Roth (Karlsruhe, Germany) A994.1 
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Dulbecco’s Modified Eagle 
Medium, high glucose, 
pyruvate (DMEM) 
Thermo Fisher Scientific (Waltham, 
USA) 
41966-029 
Dulbecco’s Phosphate-
Buffered Saline, no calcium, 
no magnesium (DPBS) 
Thermo Fisher Scientific (Waltham, 
USA) 
14190-094 
Epidermal Growth Factor 
human  
Sigma-Aldrich (St. Louis, USA) E9644 
Fetal Bovine Serum 
Thermo Fisher Scientific (Waltham, 
USA) 
10270-106 
Ham’s F12 Lonza (Basel, Switzerland) BE12-615F 
Holo-Transferrin human Sigma-Aldrich (St. Louis, USA) T0665 
Human Keratinocyte Growth 
Supplement 
Thermo Fisher Scientific (Waltham, 
USA) 
S-001-5 
HyClone Bovine calf serum  
Thermo Fisher Scientific (Waltham, 
USA) 
SH3007303 
HyClone Characterized Fetal 
Bovine serum 
Thermo Fisher Scientific (Waltham, 
USA) 
SH3007103 
Hydrocortisone Sigma-Aldrich (St. Louis, USA) H0396 
Insulin solution human Sigma-Aldrich (St. Louis, USA) I9278 
Keratinocyte-SFM  
Serum Free Medium 
Thermo Fisher Scientific (Waltham, 
USA) 
17005-042 
Medium 154 
Thermo Fisher Scientific (Waltham, 
USA) 
M-154-500 
Opti-MEM Reduced Serum 
Medium 
Thermo Fisher Scientific (Waltham, 
USA) 
31985070 
Penicillin-Streptomycin 
(10000 U/ml) 
Thermo Fisher Scientific (Waltham, 
USA) 
15140-122 
Puromycin dihydrochloride Carl Roth (Karlsruhe, Germany) 0240.3 
Polybrene Sigma-Aldrich (St. Louis, USA) 10768910G 
Supplements for 
Keratinocyte-SFM  
Thermo Fisher Scientific (Waltham, 
USA) 
37000-015 
Trypsin-EDTA 0.05%, 
phenol red 
Thermo Fisher Scientific (Waltham, 
USA) 
25000-054 
Trypsin-EDTA 0.25%, 
phenol red 
Thermo Fisher Scientific (Waltham, 
USA) 
25200-056 
 
 
Table 15: Components and composition of cell culture medium 
Medium/Solution Composition  
50:50 medium 
500 ml 
500 ml 
5 ml 
10 ml 
1x 
Keratinocyte SFM 
Medium 154 
Human Keratinocyte Growth Supplement  
100x Antibiotic-Antimycotic 
Supplements for Keratinocyte-SFM  
Adenine stock solution 
12 mg 
6.75 ml 
 
Adenine hydrochloride hydrate 
DMEM 
adjust pH to 7.5 
Basic buffer 
0.2 M 
3 mM 
1 mM 
 
sodium chloride 
sodium azid 
EDTA 
adjust pH to 8.0 
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Cholera toxin solution 
1 mg 
1 ml 
99 ml 
Cholera toxin from Vibrio cholera 
Basic buffer 
DMEM 
Conditioned 50:50 medium  
50:50 medium which was used for cultivation of 
HaCaT cells for two days and subsequently 
filtered through a 0.2 µm pore filter 
DMEM+BCS 
500 ml 
50 ml 
5 ml 
DMEM 
BCS 
Penicillin/Streptomycin 
DMEM+FBS 
500 ml 
50 ml 
5 ml 
DMEM 
FBS (Thermo) 
Penicillin/Streptomycin 
EGF stock solution 
100 µg 
10 ml 
EGF 
ddH2O 
Hydrocortisone stock 
solution 
5 mg 
1 ml 
24 ml 
Hydrocortisone 
Ethanol 
DMEM 
Insulin stock solution 
5 mg 
1 ml  
Insulin solution human 
ddH2O 
KGM 
330 ml 
110 ml 
5 ml 
5 ml 
50 ml 
1 ml 
0.5 ml 
1 ml 
0.5 ml 
0.5 ml 
0.5 ml 
DMEM 
Ham’s F12 
Penicillin-Streptomycin 
100x Antibiotic-Antimycotic 
FBS (HyClone) 
Adenine stock solution 
Cholera toxin solution 
Hydrocortisone stock solution 
T/T3 solution 
EGF stock solution 
Insulin stock solution 
PBS+2x A/A 
10 ml 
500 ml 
100x Antibiotic-Antimycotic 
DPBS 
Polybrene solution 1 mg/ml Polybrene in PBS 
T/T3 solution 
9.9 ml 
100 µl 
Transferrin stock solution 
Triiodo-L-thyronine stock solution 
Transferrin stock solution 
50 mg 
10 ml 
Holo-Transferrin human 
DPBS 
Triiodo-L-thyronine stock 
solution 
13.6 mg 
100 ml  
3,3’,5’-Triiodo-L-thyronine 
ddH2O 
 
 
6.7 Instruments 
General laboratory instruments and devices were purchased from Beckman Coulter (Brea, 
USA), Bio-Rad (Hercules, USA), Eppendorf (Hamburg, Germany), NeoLab (Heidelberg, 
Germany) and Thermo Fisher Scientific (Waltham, USA). Particular instruments are listed 
in the table below. 
Table 16: List of instruments 
Name Supplier 
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2200 TapeStation System Agilent Technologies (Santa Clara, USA) 
Agilent 2100 Bioanalyzer Agilent Technologies (Santa Clara, USA) 
Amersham Ultrospec 3300 pro 
GE Healthcare (Chalfont St Giles, Great 
Britain) 
Centrifuge 5424 R Eppendorf (Hamburg, Germany) 
Centrifuge 5810 Eppendorf (Hamburg, Germany) 
CO2-Incubator HERAcell 240i Thermo Fisher Scientific (Waltham, USA) 
Cryostat Microm HM 500 OM Thermo Fisher Scientific (Waltham, USA) 
Electroporation Device Nucleofector II Lonza (Basel, Switzerland) 
FastPrep-24 Instrument MP Biomedicals (Heidelberg, Germany) 
Heraeus Megafuge 40R Thermo Fisher Scientific (Waltham, USA) 
Heraeus Multifuge 1S Thermo Fisher Scientific (Waltham, USA) 
HeraSafe KS Thermo Fisher Scientific (Waltham, USA) 
HiSeq 1000 Illumina (San Diego, USA) 
Hybridization oven type T 5042 Heraeus (Hanau, Germany) 
IKA MS3 Agilent Technologies (Santa Clara, USA) 
Incubator Model B6200 Heraeus (Hanau, Germany) 
Inverted microscope Axiovert 200 M Carl Zeiss (Oberkochen, Germany) 
Inverted microscope Diavert Leitz (Wetzlar, Germany) 
IVIS 100 In Vivo Imaging System PerkinElmer (Waltham, USA) 
Leica CM3050 S Cryostat Leica Biosystems (Nussloch, Germany) 
MaXis plus UHR-QTOF Bruker (Billerica, USA) 
MilliQ Q-Pod Merck (Darmstadt, Germany) 
Mx3000P Agilent Technologies (Santa Clara, USA) 
NanoDrop 1000 Thermo Fisher Scientific (Waltham, USA) 
Nanophotometer Classic Implen (Munich, Germany) 
New Brunswick Innova 44 Shaker Eppendorf (Hamburg, Germany) 
Odyssey Imaging System LI-COR Biosciences (Lincoln, USA) 
PM1002 mobile anesthesia machine Parkland Scientific (Coral Springs, USA) 
PMI Personal Molecular Imager FX Bio-Rad (Hercules, USA) 
QTRAP 4500  SCIEX (Framingham, USA) 
Qubit 2.0 Fluorometer Thermo Fisher Scientific (Waltham, USA) 
Real-Time PCR Cycler CFX96 Bio-Rad (Hercules, USA) 
S220 Focused-ultrasonicator Covaris (Woburn, USA) 
Screen Eraser-K Bio-Rad (Hercules, USA) 
Shake 'n' Stack Hybridization Oven Thermo Fisher Scientific (Waltham, USA) 
Thermomixer comfort Eppendorf (Hamburg, Germany) 
Trans-Blot SD Semi-dry transfer cell Bio-Rad (Hercules, USA) 
Transilluminator Quantum ST4 PEQLAB (Erlangen, Germany) 
UltiMate 3000 RSLCnano System 
with Acclaim PepMap100 C18 Nano-Trap column 
and Acclaim PepMap100 C18 column 
Thermo Fisher Scientific (Waltham, USA) 
UV Stratalinker 2400 Stratagene (La Jolla, USA) 
 
6.8 Mouse strain 
Immunodeficient mice (CBySmn.CB17-Prkdcscid/J) were purchased from The Jackson 
Laboratory (Bar Harbor, USA). 
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6.9 Oligonucleotides 
DNA oligonucleotides were ordered from Metabion (Martinsried, Germany) or 
Sigma-Aldrich (St. Louis, USA), siRNA Pools (mixture of 11-30 different siRNAs per 
target, exact sequences are available from siTools upon request) were designed and ordered 
from siTools (Munich, Germany) and single siRNAs were obtained from biomers.net (Ulm, 
Germany). 
Table 17: Overview of utilized siRNAs 
siRNA Sequence (5’ to 3’) 
Control_sense GUAGAUUCAUAUUGUAAGG 
Control_antisense CCUUACAAUAUGAAUCUAC 
pan_p63i_sense CGACAGUCUUGUACAAUUU 
pan_p63i_antisense AAAUUGUACAAGACUGUCG 
siCtrl siPool 
siSPRR5 siPool 
siSPRR5_326 siPool 
 
Table 18: List of sequencing primers 
Name Sequence (5’ to 3’) 
5'Cas9_seq_R CCGATGCTGTACTTCTTGTC 
CMV_F CGCAAATGGGCGGTAGGCGTG 
KO_out_F2 CCAACTCTAAGAGAGGTAAGTATG 
KO_out_R2 GTATGCAGTGTTTGCATAGACTGTC 
lentiCRISPRv2_seq_F GGACAGCAGAGATCCAGTTT 
lentiCRISPRv2_seq_R AGCCAATTCCCACTCCTTTC 
pLARTA_F5 AGAATCGCAAAACCAGCAAG 
PGK_F TGTTCCGCATTCTGCAAGCC 
pLARTA_Ins_F CGAATCACCGACCTCTCTCC 
pLARTA_R1 AAACCGTCTATCAGGGCGAT 
pX459_F TTACGGTTCCTGGCCTTTTG 
pX459_R TGTCTGCAGAATTGGCGCA 
SP6 ATTTAGGTGACACTATAG 
T7 TAATACGACTCACTATAGGG 
WPRE-rev CATAGCGTAAAAGGAGCAACA 
WT_In_F2 CCCCTCAGCTCCTGTTTTCA 
 
Table 19: List of primer sequences used for qRT-PCR 
Name Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
7SK CCTGCTAGAACCTCCAAACAAG GCCTCATTTGGATGTGTCTG 
ALOX12B AGACTGCAATTCCGGATCAC TGTGGAATGCACTGGAGAAG 
β-actin GGACTTCGAGCAAGAGATGG AGGAAGGAAGGCTGGAAGAG 
CALB1 TGGCTTTGTCGGATGGAGGG GGTTGCGGCCACCAACTCTA 
C1orf68 TTCTGGCCCCCTCTCTGTTA GGGACTGTACTAACTCTGGC 
ELOVL3 TTCGAGGAGTATTGGGCAAC GAAGATTGCAAGGCAGAAGG 
FLG AAAGAGCTGAAGGAACTTCTGG AACCATATCTGGGTCATCTGG 
GAPDH GAAGAGAGAGACCCTCACTGCTG ACTGTGAGGAGGGGAGATTCAGT 
KRT1 TGAGCTGAATCGTGTGATCC CCAGGTCATTCAGCTTGTTC 
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KRT10 GCAAATTGAGAGCCTGACTG CAGTGGACACATTTCGAAGG 
L32 AGGCATTGACAACAGGGTTC GTTGCACATCAGCAGCACTT 
LacZ GTGCGGATTGAAAATGGTCT GACCTGACCATGCAGAGGAT 
LCE1A GAAGCGGACTCTGCACCTAGAA AGGAGACAGGTGAGGAGGAAATG 
LCE1E TGAAGTGGACCTTGACTTCCTC CTCCAGGCAAGACTTCAAGC 
LCE2A TGGAGAAACTTGCAACCAGGA CCTCACAAGGTGTGTCAGCC 
LCE2D GGACGTGTCTGTGCTTTTGC CTTGGGAGGACATTTGGGAGG 
LCE3A TGTCTGCCTCCAGCTTCCT AGTTGGAGCTCTGGCAACG 
LCE3D TCTTGATGCATGAGTTCCCAGA TGGACATCAGACAGGAAGTGC 
LCE4A CCCCCTCCCAAGTGTCCTAT GAGCCACAGCAGGAAGAGAT 
LCE5A CCCAGGTGCTGAAGATGTGT ATGGAGTGAACATGGGCAGG 
LCE6A GTCCTGATCTCTCCTCTCGTCT CAAGATTGCTGCTTCTGCTGT 
Lenti_SPRR5 CCCTCAGCTCCTGTTTTCAA GCTGCCTTGTAAGTCATTGG 
LINC01527_1 GCCTCTCCTGCAAGTGTGA TCCTCATTTATGACATTTTCAGTCTC 
LINC01527_2 ACATGCCAGTGAAGTCTGTTCA AGTCATGTGAGGCAGTTCCA 
LINC01527_3 TCCCCCTACCTCTCATAGGC AGATGAACAGACTTCACTGGCA 
LOR CTCTGTCTGCGGCTACTCTG CACGAGGTCTGAGTGACCTG 
Pan-p63 GACAGGAAGGCGGATGAAGATAG TGTTTCTGAAGTAAGTGCTGGTGC 
pLEX_SPRR5 CACGCTGTTTTGACCTCCATAG CACTGCTTCTGCTTCTGCTGAG 
Puro CACCAGGGCAAGGGTCTG GCTCGTAGAAGGGGAGGTTG 
SPRR1A CAGCCCATTCTGCTCCGTAT GGCTGGCAAGGTTGTTTCAC 
SPRR2A ACACAGGGAGCTTCTTTCTCC CCAGGACTTCCTTTGCTCAGT 
SPRR2D TCGTTCCACAGCTCCACTTG CAGGCCACAGGTTAAGGAGA 
SPRR3 CCTCGACCTTCTCTGCACAG GGTTGTTTCACCTGCTGCTG 
SPRR4 AGCCTCCAAGAGCAAACAGA GCAGGAGGAGATGTGAGAGG 
SPRR5 AGCAGCTGCAGTTTCCATCT AAACAGGAGCTGAGGGGAAG 
U6 CACATATACTAAAATTGGAACG CTTCACGAATTTGCGTGTCATC 
 
Table 20: List of primers used for molecular cloning and PCR 
Name Sequence (5’ to 3’) Purpose 
3’inner TCTCAGCAGAAGCAGAAGCAGT RACE verification of SPRR5 
3’outer CAAGTCCAGCCCAGAATGTCTC RACE verification of SPRR5 
5’inner GAACCAGATCCTTGTCTGAGAT RACE verification of SPRR5 
5’outer CTGCCAGAGGAATTCTGTTTTAATTG RACE verification of SPRR5 
AfeI_CMV_R 
GATGATAGCGCTAGCTCTGCTTATATAG
ACCT 
Cloning CMV promotor and 
enhancer into lentiCRISPRv2 
KO_out_F1 CTGCATGTGTGTGTCGGTAC Screening for SPRR5 KO cells 
KO_out_F2 CCAACTCTAAGAGAGGTAAGTATG Screening for SPRR5 KO cells 
KO_out_R1 TTACTGTCGGGTGTGTGTGT Screening for SPRR5 KO cells 
KO_out_R2 GTATGCAGTGTTTGCATAGACTGTC Screening for SPRR5 KO cells 
NheI_CMV_F 
GATGATGCTAGCGACATTGATTATTGAC
TAGT 
Cloning CMV promotor and 
enhancer into lentiCRISPRv2 
SPRR5_KO_1 
AAAGGACGAAACACCGGATCCCTTCACA
GATTTAAGGTTTTAGAGCTAGAAATAGC
AAG 
Generation of a gRNA cassette 
for SPRR5 KO with Multiplex 
gRNA Cloning Kit, Block1 
SPRR5_KO_2 
GCCAAAAAGACCTGCGCAGTGGATCCAA
GGTGTCTCATAC 
Generation of a gRNA cassette 
for SPRR5 KO with Multiplex 
gRNA Cloning Kit, Block1 
SPRR5_KO_3 
GCAGGTCTTTTTGGCGTTTTAGAGCTAG
AAATAGCAAG 
Generation of a gRNA cassette 
for SPRR5 KO with Multiplex 
gRNA Cloning Kit, Block2 
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SPRR5_KO_4 
AGAGTGTGCTCTCTGAGTTCGGTGTTTCG
TCCTTTCCAC 
Generation of a gRNA cassette 
for SPRR5 KO with Multiplex 
gRNA Cloning Kit, Block2 
SPRR5_KO_5 
AGAGAGCACACTCTAGTTTTAGAGCTAG
AAATAGCAAG 
Generation of a gRNA cassette 
for SPRR5 KO with Multiplex 
gRNA Cloning Kit, Block3 
SPRR5_KO_6 
TTCTAGCTCTAAAACGGCAATTTATTCCA
GATGCCGGATCCAAGGTGTCTCATAC 
Generation of a gRNA cassette 
for SPRR5 KO with Multiplex 
gRNA Cloning Kit, Block3 
WT_In_F1 CGTCCAAGCAGAAGTAAGCC Screening for SPRR5 KO cells 
WT_In_F2 CCCCTCAGCTCCTGTTTTCA Screening for SPRR5 KO cells 
 
Table 21: DNA probes for Northern Blot Analysis 
Name Sequence (5’ to 3’) 
GAPDH #1 CATGGACTGTGGTCATGAGTCCTTCCACGATACCAAAGTT 
GAPDH #2 
GAATTTGCCATGGGTGGAATCATATTGGAACATGTAAACCATG
TAGTTGAGG 
Out_Exon1_SPRR5 
GATGCTCTGAGCCTATCTACCTTTTATATACCTCTCATCCCTGC
CTGAGG 
Exon1_SPRR5 
CAAGGTTCACCAGCGACTGGAGCAGATAGGTGTGGAGGGGTT
T 
Intron_SPRR5 
CCCACACTACTCTGCTGGATAACTTGCTGGACCCAAGATAGGT
TTGTCAC 
Exon2_SPRR5_Probe1 
CACACTGCTTCTGCTTCTGCTGAGACATTCTGGGCTGGACTTG
CAACTGG 
Exon2_SPRR5_Probe2 CAAGGCTGCTTGGTCTGTTGGGGTGGGGGGCAGTAC 
Exon2_SPRR5_Probe3 GATCACATGCCCAGGGCTTACTTCTGCTTGGACGTCTGGCAC 
Exon2_SPRR5_ProbePool_1 TGTGGAGTGTAAGATGCTGG 
Exon2_SPRR5_ProbePool_2 AGAGTAGAGCTCGAGGAAGC 
Exon2_SPRR5_ProbePool_3 CAGGGCAATGTAGATGCATG 
Exon2_SPRR5_ProbePool_4 GCCAGAGGAATTCTGTTTTA 
Exon2_SPRR5_ProbePool_5 TGCTGGCCCAGAAGGAACTT 
Exon2_SPRR5_ProbePool_6 TGGTGAGCAGGGCTTTGCTT 
Exon2_SPRR5_ProbePool_7 TGTGGCTGCATCCAGAAGCA 
Exon2_SPRR5_ProbePool_8 CCTCTCCTGCAAGTGTGAAG 
Exon2_SPRR5_ProbePool_9 ACTGCAGCTGCTAATTAAGA 
Exon2_SPRR5_ProbePool_10 GATCCTTGTCTGAGATGGAA 
Exon2_SPRR5_ProbePool_11 CATGCCGCTCATGTTTCCAG 
Exon2_SPRR5_ProbePool_12 GGTAGGAGAAGATGCCTGTG 
LINC01527_1 CACTTCACACTTGCAGGAGAGGCAGCACCAGG 
LINC01527_2 GCTGGCGGCTTCCTCGAGCTCTACTCTTCTTA 
LINC01527_3 GCAGCTGCAGTTTCCATCTCAGACAAGGATCTGG 
LINC01527_4 CATCTTTCCTGACATGCATCTACATTGCCCTG 
LINC01527_5 GGAAACATGAGCGGCATGCACAGGCATC 
 
Table 22: GRNA sequences for SPRR5 KO cell generation 
Name Sequence (5’ to 3’) 
SPRR5_down_1 ACTGCGCAGGTCTTTTTGGC 
SPRR5_down_2 AACTCAGAGAGCACACTCTA 
SPRR5_up_1 GATCCCTTCACAGATTTAAG 
SPRR5_up_2 GGCATCTGGAATAAATTGCC 
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6.10 Plasmids  
Table 23: List of plasmids 
Plasmid Properties Origin 
lentiCRISPRv2_complete 
Lentiviral transfer plasmid based on 
lentiCRISPRv2 from Addgene (#52961). The 
SPRR5 KO cassette has been inserted via 
SLIC cloning after BsmBI digest of the vector, 
encodes Cas9 from S. pyogenes 
AG Kretz/Julia Junghans 
(supervised master student) 
(University of Regensburg) 
lentiCRISPRv2_complete_
CMVCas9 
Lentiviral transfer plasmid based on 
lentiCRISPRv2_complete, with Cas9 under the 
control of a CMV promotor 
this work 
 
pCMV dR8.91 
Packaging plasmid for generation of lentiviral 
particles, encodes the viral gag, rev, tat and 
pol proteins under control of the CMV 
promotor 
gift from the  
Khavari laboratory  
(Stanford University, USA) 
pGEM-T Easy vector for TA cloning of PCR products Promega (Madison, USA) 
pLARTA_326 
Lentiviral transfer plasmid, contains the 
SPRR5_326 sequence under the control of the 
hPGK promotor, flanked by the LTR 
sequences for stable genomic integration 
AG Kretz/Bianca Förstl 
(University of Regensburg) 
pLARTA_lacZ 
Lentiviral transfer plasmid, contains the lacZ 
sequence under the control of the hPGK 
promotor, flanked by the LTR sequences for 
stable genomic integration 
AG Kretz/Johannes Graf 
(University of Regensburg) 
pLARTA_SPRR5 
Lentiviral transfer plasmid, contains the 
SPRR5 sequence under the control of the 
hPGK promotor, flanked by the LTR 
sequences for stable genomic integration 
AG Kretz/Bianca Förstl 
(University of Regensburg) 
pLARTA_SPRR5_MutDB 
Lentiviral transfer plasmid, contains the 
SPRR5 sequence with mutated start codons 
under the control of the hPGK promotor, 
flanked by the LTR sequences for stable 
genomic integration 
AG Kretz/Bianca Förstl 
(University of Regensburg) 
pLEX_Cdk4 
Based on the pLEX-MCS vector backbone 
(Thermo Scientific Open Biosystems, 
#OHS4735), lentiviral transfer plasmid for 
overexpression of human Cdk4  
gift from the  
Khavari laboratory  
(Stanford University, USA) 
pLEX_HRasG12V 
Based on the pLEX-MCS vector backbone 
(Thermo Scientific Open Biosystems, 
#OHS4735), lentiviral transfer plasmid for 
overexpression of constitutively active human 
HRasG12V protein 
gift from the  
Khavari laboratory  
(Stanford University, USA) 
pLEX_LY 
Based on the pLEX-MCS vector backbone 
(Thermo Scientific Open Biosystems, 
#OHS4735), lentiviral transfer plasmid for 
overexpression of a fusion protein of 
luciferase and YFP protein 
gift from the  
Khavari laboratory  
(Stanford University, USA) 
pLEX_SPRR5_ORF 
Based on the pLEX-MCS vector backbone 
(Thermo Scientific Open Biosystems, 
#OHS4735), lentiviral transfer plasmid for 
overexpression of SPRR5 protein 
AG Kretz/Bianca Förstl 
(University of Regensburg) 
pLEX_SPRR5_MutORF 
Based on the pLEX-MCS vector backbone 
(Thermo Scientific Open Biosystems, 
#OHS4735), lentiviral transfer plasmid for 
overexpression of the SPRR5 CDS with a 
mutated start codon 
AG Kretz/Bianca Förstl 
(University of Regensburg) 
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pUC-MDG 
Envelope plasmid for generation of lentiviral 
particles, encodes the viral VSV-G envelope 
protein under control of the CMV promotor 
gift from the  
Khavari laboratory  
(Stanford University, USA) 
pX459_complete 
Plasmid for CRISPR/Cas9 mediated knockout 
of SPRR5, based on pX459 (Addgene, #62988) 
with the insertion of a SPRR5 KO cassette via 
SLIC cloning after BbsI digest of the vector 
backbone 
AG Kretz/Julia Junghans 
(supervised master student) 
(University of Regensburg) 
 
6.11 Prokaryotic cells 
Table 24: Overview of utilized Escherichia coli strains during this work 
Strain Genotype Details 
DH5α 
F- Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 
hsdR17(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 λ- 
Propagation of plasmids 
Stbl3 
F-mcrB mrrhsdS20(rB-, mB-) recA13 supE44 ara-14 galK2 
lacY1 proA2 rpsL20(StrR) xyl-5 λ-leumtl-1 
Propagation of lentiviral 
plasmids 
 
6.12 Software 
Table 25: Software used during this work 
Name Source of supply 
2200 TapeStation Software Agilent Technologies (Santa Clara, USA) 
Agilent 2100 Expert Software B.02.08SI648 Agilent Technologies (Santa Clara, USA) 
AxioVision 4.9.1.0 Carl Zeiss (Oberkochen, Germany) 
Bio-Rad CFX Manager 3.1 Bio-Rad (Hercules, USA) 
CASAVA1.8.2 
https://biogist.wordpress.com/2012/10/23/casa
va-1-8-2-installation/ 
Galaxy server tools (indicated individually) local installation after https://usegalaxy.org/ 
gRNA design tool http://crispr.mit.edu/ 
HOMER (v4.9, 2-20-2017) http://homer.ucsd.edu/homer/ 
Integrative Genomics Viewer 2.3.90 (IGV) https://www.broadinstitute.org/igv/ 
IrfanView 4.42 http://www.irfanview.de/ 
Living Image 4.5.2 PerkinElmer (Waltham, USA) 
MASCOT 2.5.1 Matrix Science (London, United Kingdom) 
Microsoft Office Microsoft (Redmond, USA) 
MxPro QPCR Software Agilent Technologies (Santa Clara, USA) 
ND-1000 3.81 Thermo Fisher Scientific (Waltham, USA) 
Odyssey 3.0.30 LI-COR Biosciences (Lincoln, USA) 
ProteinScape4 3.1.3 461 Bruker (Billerica, USA) 
Quantity One 4.6.9 Bio-Rad (Hercules, USA) 
R version 3.3.1 https://www.r-project.org/ 
Rstudio version 1.0.136 https://www.rstudio.com/ 
R-packages (several, indicated individually) Bioconductor  
SnapGene Viewer 4.1.4 GSL Biotech LLC (Chicago, USA) 
SonoLab Software 7.2 Covaris (Woburn, USA) 
Skyline 4.1 
University of Washington (McCoss Lab) 
https://skyline.ms/project/home/software/Skyli
ne/begin.view 
Zotero https://www.zotero.org/ 
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7 Methods 
7.1 Bioinformatical data analysis 
7.1.1 Analysis of full transcriptome sequencing data 
Differential gene expression analysis for RNA sequencing (7.6.7) was done by Dr. Nicholas 
Strieder. 
Preprocessing: Quality of sequencing data from the RNA-Seq libraries was examined using 
FASTQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and size, adapter 
and quality trimming was performed using Trimmomatic232 (ver. 0.32, 
ILLUMINACLIP:TruSeq_s tranded_SE.fa:2:30:10 HEADCROP:0 TRAILING:26 
LEADING:26 SLIDINGWINDOW:4:15 MINLEN:25). Trimmed reads were aligned to the 
Homo sapiens genome (ftp://ftp.ensembl.org/pub/release-85/fasta/homo_sapiens/dna/ 
Homo_sapiens.GRCh38.dna.primary_assembly.fa.gz) extended with the ERCC spike in 
sequence information233 using STAR234. The mapped reads were then assessed on the gene 
level using featureCounts from the Rsubread R-library235 based on the annotation 
information from Ensembl161 (GRCh38.p7 release-85). Following alignment, further quality 
control was performed using QoRTs236 and aligned reads were inspected with the UCSC 
genome browser208 or the Integrative Genomics Viewer (IGV)237,238.  
Differential expression analysis: Count data at the gene level was analyzed with DESeq2239 
using ERCC spike ins for library size normalization and all comparisons were corrected for 
multiple testing using FDR240. Genes that met the indicated log2(fold change) restraint and 
had a false discovery rate < 0.05 (“padj”) were considered significantly differential 
expressed.  
Heatmap generation and functional annotation: Heatmaps for genes with altered expression 
(adj. p-value < 0.05 and -0.5 > log2FC > 0.5) were generated with pheatmap235 after variance 
stabilization transformation of count data with DeSeq2. Functional annotation clustering was 
performed using the David 6.8 database241,242 as well as the Enrichr tool243,244 for the 
GO-Term classes “biological process” and “cellular compartment”. Principal component 
analysis was done in R245 with the plotPCA function of the DeSeq2 package after variance 
stabilizing transformation of read counts per gene. 
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7.1.2 Analysis of publicly available datasets for p63 regulation of SPRR5 
For p63 regulation of SPRR5 in keratinocytes, published p63 ChIP-Seq datasets from 
Kouwenhoven et. al.158 (GSE59827) and Bao et. al.44 (GSE67382) were downloaded from 
the Gene Expression Omnibus (GEO) database159,160 and uploaded into the UCSC genome 
browser208 to visualize the peak location with respect to SPRR5. Furthermore, the prediction 
of upstream transcription factors for SPRR5 (using its former gene identifier RP1-20N18.10) 
was done with the ARCHS4 tool from the Ma'ayan Lab244. 
7.1.3 Coding potential analysis for SPRR5 
PhyloCSF166 tracks were imported into the UCSC genome browser208 by inserting 
“http://www.broadinstitute.org/compbio1/PhyloCSFtracks/trackHub/hub.txt” into the “my 
hubs” section and comparison of these tracks relative to the SPRR5 transcript246. 
Furthermore, the coding potential was assessed by running iSeeRNA165 with a gtf file of the 
SPRR5 exons and by inspection of the spliced SPRR5 transcript with the Coding Potential 
Calculator (CPC)164 by using their default settings. 
7.1.4 Data analysis for ATAC-Seq 
Data analysis for ATAC-Seq was done with a local installation of the Galaxy platform247 
and several Galaxy tools (indicated individually) with default settings unless indicated 
otherwise and the resulting output was inspected in IGV237,238. First, quality of obtained 
sequencing reads was monitored with FastQC (v. 0.70)248 and reads were aligned to the 
human genome (hg19) using Bowtie2 (v. 2.3.3.1)249,250. Next, low quality mapping reads 
(MAPQ < 10) and duplicate reads were removed with BamTools (v. 2.4.1)251 and rmDup  
(v. 2.0.1) of the SamTools252 suite respectively. Statistics about the mapped reads were 
extracted with SamTools (IdxStats and Stats) and percentages of mapped reads were 
calculated in Excel. Peak calling for each ATAC sample was done individually with the 
callpeak function of MACS2 (v. 2.1.1.20160309.0, -q 0.05, --nomodel, --shift -100, --extsize 
200)253,254 without a control sample and the resulting bedgraph files were normalized to 
10 million reads according to their corresponding read number after filtering and duplicate 
removal. A common peak set for each day of differentiation was generated by concatenating 
the individual peak files and merging overlapping and close peaks with the BedTools suite 
(v. 2.27.0.0)255 by subsequently running “SortBed” and “MergeBed” (-d 100). The resulting 
peak file was then transformed into a gtf file, which was used to count the number of reads 
(after rmDup and quality filtering) within peaks using htseq-count (v. 0.6.1galaxy3,  
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stranded = no, mode = union, ID attribute = gene_id)256 for each ATAC sample individually 
and Excel was used to calculate the fraction of reads in called peak regions (FRIP). 
Furthermore, obtained count tables were combined in Excel for each day of differentiation, 
imported into R245, differential gene expression analysis was done with DeSeq2 (v. 1.14.1)239 
and PCA plots were generated with the plotPCA function of DeSeq2 after variance 
stabilizing transformation of read counts per peak location. 
7.1.5 Data analysis for ChIP-Seq 
In general, data analysis with Galaxy247 and R245 was performed as described for ATAC-Seq 
data (7.1.4) but with the following modifications. Peak calling for ChIP-Seq datasets was 
done against the respective input controls with MACS2253,254 by “building the shifting 
model”, --mfold 2,5000, --bw 200, --broad, --broad-cutoff=0.1 and “MergeBed” was run 
with -d 300. Furthermore, HOMER (v4.9, 2-20-2017)188 was used for ChIP-Seq data 
analysis according to the HOMER documentation. Briefly, bedgraphs from filtered and 
deduplicated bamfiles were generated by “makeUCSCfile” (-res 10) and enriched peaks 
were identified with “getDifferentialPeaks” (-F 2 or -F 4), using the combined peak files 
from MACS2253,254.   
Additionally, already published ChIP-Seq datasets from Bao et al.44 (GSE67382) were 
extracted from the GEO data repository159,160 and processed as described above.  
7.1.6 Mouse ribosome profiling data analysis 
Reanalysis of mouse ribosome profiling data was done by Uwe Schwartz (University of 
Regensburg). Briefly, in vivo RNA-Seq and ribosome profiling reads from P4 mice (both 
replicate 0) from the Sendoel et al. paper167 (GSE83332) were extracted, trimmed, 
deduplicated and aligned to the mouse genome (mm10) as described in the paper and the 
obtained alignment files were inspected with IGV237,238.  
7.1.7 Phylogenetic analysis of human SPRR coding sequences 
The coding sequences for all human SPRR proteins were extracted from Ensembl161, and the 
subsequent phylogenetic analysis was done by Prof. Dr. Rainer Merkl (University of 
Regensburg). Briefly, the evolutionary history was inferred by using the Maximum 
Likelihood method based on the Tamura‐Nei model257. The tree with the highest log 
likelihood (‐761.45) is shown. The percentage of trees in which the associated taxa clustered 
together is shown next to the branches. Initial trees for the heuristic search were obtained 
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automatically by applying Neighbor‐Join and BioNJ algorithms to a matrix of pairwise 
distances estimated using the Maximum Composite Likelihood (MCL) approach and then 
selecting the topology with superior log likelihood value. A discrete Gamma distribution 
was used to model evolutionary rate differences among sites (5 categories (+G, parameter = 
5.2252)). The tree is drawn to scale, with branch lengths measured in the number of 
substitutions per site. Codon positions included were 1st+2nd+3rd+Noncoding and all 
positions containing gaps and missing data were eliminated resulting in a total of 137 
positions in the final dataset. Evolutionary analyses were conducted in MEGA7258 and 1000 
bootstrap iterations were performed. 
7.2 Cell culture methods 
All cell culture methods were performed in a biological safety cabinet under laminar air-flow 
to obtain sterile conditions. Lentiviral procedures were performed under biosafety level 2 
precautions, whereas biosafety level 1 regulations applied to the remaining methods. Cell 
culture media, trypsin and DPBS (see Table 15) were pre-warmed to 37 °C prior to use and 
cultivation of cells was performed in a humidified incubator at 37°C and 5% carbon dioxide. 
7.2.1 Cultivation of HEK293T cells and fibroblasts 
HEK293T cells and fibroblasts were cultivated in DMEM+FBS (see Table 15) and passaged 
when they reached 80-90% confluency. Therefor the medium was aspirated, cells were 
washed once with DPBS and detached using 0.05% trypsin-EDTA. DMEM+FBS was used 
to quench the trypsin, cells were resuspended to obtain a single cell suspension and after 
centrifugation (200 rcf, RT, 5 min) cells were resuspended in an appropriate volume of 
DMEM+FBS and equally distributed onto fresh cell culture dishes. 
7.2.2 Cultivation of keratinocytes 
Primary keratinocytes and HaCaT cells were cultivated in 50:50 medium (see Table 15) until 
a maximal confluency of 80% to prevent premature differentiation. For passaging of 
keratinocytes, cells were washed once with DPBS and detached using 0.05% trypsin-EDTA 
(4 min, 37 °C). After tapping the plate to lift the cells and addition of at least four volumes 
of DMEM+BCS, cells were resuspended to obtain a single cell solution and pelleted by 
centrifugation (200 rcf, RT, 5 min). Cell pellets were resuspended in 50:50 medium and 
seeded onto appropriate cell culture dishes with at least 5% confluency.   
Primary keratinocytes were not passaged more than 7 times. 
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7.2.3 Determination of cell numbers 
Cells in suspension were added to a Neubauer Counting Chamber and the cells in four 
quadrats were counted. The number of cells per milliliter cell suspension was obtained by: 
Cells per ml = 
𝐶𝑜𝑢𝑛𝑡𝑒𝑑 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
4 (# 𝑜𝑓𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑞𝑢𝑎𝑑𝑟𝑎𝑡𝑠)
 x 10,000 
7.2.4 Electroporation of keratinocytes 
Keratinocytes were nucleofected with siRNA pools or annealed siRNAs (see 7.6.1) utilizing 
the Human Keratinocyte Nucleofector Kit (Lonza). After detaching the cells with trypsin 
(see 7.2.1), the cell number was determined and six million keratinocytes were pelleted  
(200 rcf, RT, 5 min) and resuspended in 100 µl electroporation buffer. 95 µl of this 
suspension were mixed with 10 µl siRNA pool or annealed siRNAs (both 100 µM) and 
transferred to the electroporation cuvette and nucleofection was achieved with the 
Electroporation Device Nucleofector II (Lonza) and its preset program T-018 (Keratinocytes 
human, neonatal, high efficiency). Following nucleofection, the cells were transferred to 
500 µl prewarmed (37°C) 50:50 medium and after recovery at 37°C for 30 minutes, seeded 
on a 15 cm dish and recovered for at least 24 hours at 37°C with 5% carbon dioxide. 
7.2.5 Freezing and thawing of cells 
For storage of cells, 1.5 million keratinocytes or 3 million HEK293T cells were resuspended 
in 1 ml freezing medium (cultivation medium for the cell type supplemented with 10% 
DMSO) and the temperature was slowly (1°C/min) lowered to -80°C. The next day, 
cryo-stocks were transferred to the vapor phase of liquid nitrogen for long term storage.   
Cryopreserved cells were thawed in a water bath at 37°C, transferred to 10 ml cultivation 
medium (see Table 15) and DMSO was removed by aspirating the medium after 
centrifugation (200 rcf, RT, 5 min) and resuspending the cells in fresh cultivation medium 
followed by seeding the cells onto appropriate cell culture dishes. 
7.2.6 Generation of invasive three-dimensional organotypic neoplastic 
tissue 
Devitalized human dermis (see 7.2.11) was cut into 2.25 cm2 pieces and each piece was 
spread with the basement membrane side down into a 12-well tissue culture dish. After air 
drying of the dermis 1 ml DMEM+FBS was added to each well.  
In order to obtain dermis with embedded fibroblasts, fibroblasts were detached (see 7.2.1 
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and 100,000 fibroblasts in 500 µl DMEM+FBS were added to each well and centrifuged into 
the dermis (200 rcf, RT, 20 min). This step was repeated once with the opposite orientation 
of the 12-well plate during centrifugation to ensure even distribution of fibroblasts. After 
this step, fibroblasts were allowed to fully penetrate the dermis by cultivation at 37°C and 
5% carbon dioxide and medium changes every second day.  
Seven days after embedding of fibroblasts, the dermis was mechanically detached from the 
12-well plate and placed with the basement membrane side upwards onto prepared inserts 
for organotypic epidermal cultures, the bottom was sealed with 90 µl Matrigel (Thermo 
Fisher Scientific) and 500,000 “tumorigenic keratinocytes” in 20 µl KGM were seeded onto 
the dermis after addition of KGM to the bottom of the prepared setup (for details see 7.2.7). 
“Tumorigenic keratinocytes”, are primary keratinocytes that have been transduced with 
lentiviral particles to overexpress human HRasG12V and Cdk4 to unleash the cell cycle and 
either lacZ or SPRR5_326 overexpression (see 7.2.10).   
After 6 or 8 days of cultivation with medium changes every second day, the tissue was 
harvested as described in 7.2.7, however only one third was used for RNA extraction and 
two thirds were embedded into Tissue-Tek (Weckert Labortechnik) for immunofluorescence 
analysis of invasion depth. 
7.2.7 Generation of organotypic epidermal tissue 
Setups for organotypic epidermal tissue cultures consisted of an insert with a squared  
(0.8 cm edge length) cavity that rested on glass beads that have been mounted in a 6 cm cell 
culture dish. Next, devitalized human dermis was cut, placed basement membrane side 
upwards over the cavity of the insert and 90 µl Matrigel (Thermo Fisher Scientific) were 
applied to the bottom side of the dermis to seal holes. Finally, KGM was added to the setups 
until it reached the bottom of the insert and thus nutrients and fluids could diffuse through 
the dermis.  
Keratinocytes (untreated, nucleofected with siRNA or transduced with lentiviral particles) 
were detached, counted and pelleted (see 7.2.2 and 7.2.3) and 500,000 cells were 
resuspended in 20 µl KGM and equally distributed onto the dermis part covering the cavity 
of the insert. Stratification and differentiation was induced by raising the keratinocytes the 
air-liquid interface and KGM was exchanged every second day.  
Organotypic epidermal tissue cultures were harvested by lifting the insert and carefully 
removing the Matrigel and excess devitalized human dermis. The remaining regenerated 
organotypic skin tissue was cut in the middle to give rise to two equal triangles and one half 
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was embedded for immunohistological analysis (7.3.1) into Tissue-Tek (Weckert 
Labortechnik), flash frozen on dry-ice and stored at -80°C, whereas the other half was used 
for RNA extraction (see 7.6.14). 
7.2.8 Generation of SPRR5 knockout cell lines 
The utilized plasmids were prepared by Julia Junghans (master student under my 
supervision). Briefly, guide RNAs for SPRR5 KO were designed with the gRNA Design 
tool from the Zhang Lab (http://crispr.mit.edu) and the two gRNAs upstream and two 
downstream of the SPRR5 coding sequence with the highest score were chosen and 
combined into a gRNA expression cassette using the PrecisionX Multiplex gRNA Cloning 
Kit (BioCat) and subsequently inserted into pX459 or lentiCRISPRv2 (both Addgene).  
For the transient transfection-based approach, 150,000 HaCaT cells (WT or heterozygous 
KO cells) were seeded into a 6-well the day before transfection. The next day, the medium 
was changed to fresh 50:50 medium, the transfection mix was prepared according to Table 
26 and after combining plasmid and lipofectamine solution and incubation at room 
temperature for 20 minutes, this mixture was added dropwise to the cells, followed by a 
medium change, six hours post transfection.  
Table 26: Transfection mix for SPRR5 KO cell line generation 
 6-well Component 
Plasmid dilution 
125 µl 
2.5 µg 
5 µl 
Opti-MEM 
pX459_complete 
P3000 enhancer reagent 
Lipofectamine dilution 
125 µl 
7,5 µl 
Opti-MEM 
Lipofectamine 3000 reagent 
 
Selection of plasmid containing cells was achieved by changing the medium to 50:50 
medium supplemented with 1 µg/ml puromycin 48 hours and 72 hours post transfection. 
After selection, medium was exchanged to conditioned 50:50 medium and cells were 
allowed to recover for one day.  
For single cell seeding, cells were detached (7.2.2), counted (7.2.3) and diluted with 
conditioned 50:50 medium to a concentration of 0.5 cells per 100 µl and 100 µl were plated 
into a 96-well. Two weeks after seeding, 50 µl of a 1:1 mixture of fresh and conditioned 
50:50 medium was added to each well and when a clonal cell would become more than 60% 
confluent this cell line was expanded by detaching the cells with trypsin (described in 7.2.2) 
and 60% of the cells for were used for further cultivation on a 48-well and 40% for screening 
purposes.  
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In order to screen potential KO cell lines, a cell lysate was prepared by pelleting the cells  
(5 min, RT, 13,000 rcf), resuspending the pellet in 40 µl 1x ThermoPol buffer (New England 
Biolabs) supplemented with 8 µg Proteinase K (Roche) and incubation at 65°C for one hour 
followed by 15 minutes at 95°C. This lysate was then used for the PCR-based screening 
approach (see 7.6.10) and heterozygous KO cell lines were further expanded while wild type 
cells were discarded.  
The lentiviral approach was similar to the transfection-based approach, however the SPRR5 
KO cassette was stably integrated into the genome of the HaCaT cells by lentiviral 
transduction (see 7.2.10 with the transfer plasmid: lentiCRISPRv2_complete_CMVCas9) 
rather than introducing it by transient transfection. Starting with the puromycin selection, 
cells from this approach were treated as described for the transient transfection approach. 
7.2.9 Keratinocyte differentiation cultures 
Differentiation of keratinocytes in monolayers was induced by seeding the keratinocytes 
after detachment and centrifugation (see 7.2.1) at full confluency and addition of 1.2 mM 
calcium chloride to the 50:50 medium. For differentiation cultures, the medium was renewed 
every day.  
7.2.10 Lentivirus production and transduction of keratinocytes 
Transfection of HEK293T cells was performed according to the table below and only 
endotoxin free plasmid preparations (see 7.6.10) were used for transfection in combination 
with Lipofectamine 3000 (Thermo Fisher Scientific). The lentiviral transfer vectors were 
either pLEX, pLARTA or lentiCRISPRv2 with varying inserts (see Table 23) and the 
employed amount for transfection was calculated depending on the size of the lentiviral 
transfer vector to obtain a molar ratio of 1:1:1 for all three plasmids. 
Table 27: Transfection reaction mixtures for lentiviral particle generation 
 10 cm dish 15 cm dish Component 
Plasmid dilution 
1.5 ml 
7.5 µg 
3.72 µg 
varied 
35 µl 
3.5 ml 
17.5 µg 
8.68 µg 
varied 
81 µl 
Opti-MEM 
pCMV dR8.91 
pUC-MDG 
lentiviral transfer vector 
P3000 enhancer reagent 
Lipofectamine dilution 
1.5 ml 
41 µl 
3.5 ml 
95 µl 
Opti-MEM 
Lipofectamine 3000 reagent 
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Plasmid and lipofectamine dilution were mixed and incubated at room temperature for 25 
minutes. After that, the transfection reaction was applied to the 10 cm (or 15 cm) dish and 
21 million (50 million for 15 cm) HEK293T cells resuspended in 8 ml (or 18 ml for 15 cm) 
were added for reverse transfection. Six and 24 hours post transfection, the medium was 
changed to 12 ml (or 25 ml for 15 cm) DMEM+FBS and viral particles were harvested 48 
hours post transfection by filtering the virus containing medium through a 0.45 µm 
pore-sized polyethersulfone membrane.  
For lentiviral transduction 45,000 (or 250,000 per 10 cm dish) keratinocytes were seeded in 
a 6-well (or 10 cm dish) the day before infection. The next day, 2.5 ml (or 12 ml per 10 cm 
dish) transduction mix per 6-well was prepared, by diluting the viral particles in 
DMEM+FBS and addition of polybrene to a final concentration of 5 µg/ml. The optimal 
dilution was determined in preceding efficiency tests for each batch of lentiviral particles to 
ensure an adequate overexpression in combination with no cytotoxic effect. The finally 
employed dilutions can be obtained from Table 28. 
Table 28: Overview of employed lentiviral dilutions for keratinocyte transduction 
Lentiviral transfer vector Dilution 
lentiCRISPRv2_complete_CMVCas9 1:1.66 
pLARTA_326/lacZ (for 7.2.6 and 7.4.2) undiluted 
pLARTA backbone with varying inserts 
(for all procedures except 7.2.6 and 7.4.2) 
1:1.66 
pLEX_Cdk4/HRasG12V/LY 1:2/1:3/1:2 
pLEX backbone with varying inserts for 
Rescue experiments 
1:6.66 
 
Infection of keratinocytes was accomplished by exchanging the growth medium to the 
transduction mix and centrifugation at room temperature with 250 rcf for one hour. 
Afterwards, the transduction mix was aspirated, cells were washed twice with DPBS and 
recovered in 50:50 medium for at least 24 hours. 
7.2.11 Preparation of human devitalized dermis 
Human split-skin was washed twice in PBS+2x A/A and incubated in PBS+2x A/A at 37°C 
for 3-7 days until the epidermis could be mechanically detached from the dermis. Until 
further use, the dermis was stored in PBS+2x A/A at 4°C. 
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7.3 Histological analysis 
7.3.1 Immunofluorescence analysis of cryosections from epidermal 
tissue 
7 µm thick sections from embedded regenerated organotypic epidermal tissue (see 7.2.7) 
were prepared with the Cryostat Microm HM 500 OM (Thermo Fisher Scientific), 
transferred onto Polysine slides (Carl Roth) and dried for one hour at room temperature and 
stored at -20°C until staining. 
Depending on the differentiation protein to be analyzed, skin sections were fixed in 
methanol, ethanol or acetone (see Table 6) for 10 min at -20°C and after gradually replacing 
the fixative with PBS, slides were blocked for 20 min at room temperature in PBS with 10% 
BCS (Thermo Fisher Scientific). Primary antibody solution in 1% BCS in PBS was applied 
and incubated on the sections for one hour at room temperature or overnight at 4°C in a 
humidified chamber (double staining of differentiation protein and collagen VII, dilutions 
are given in Table 6). Next, sections were washed with 1% BCS in PBS (three times, 5 min 
each) and fluorescently labeled secondary antibodies (see Table 7) diluted in 1% BCS in 
PBS were applied in a dark humidified chamber for one hour at room temperature, such as 
the differentiation protein was labeled with Alexa 555 and collagen VII with Alexa 488. 
Following this step, slides were briefly rinsed in PBS and nuclei were stained by incubating 
the sections with Hoechst solution for 5 min at room temperature. Slides were washed three 
times with PBS (5 min, RT), air dried, mounted using ProLong Gold Antifade Mountant 
(Thermo Fisher Scientific) and stored at 4°C.  
Pictures from representative areas for each section were taken with the Inverted microscope 
Axiovert 200 M (Carl Zeiss) in combination with the AxioVision software (Carl Zeiss) by 
overlaying pictures from the DAPI, GFP and Cy5 channel taken at 20x magnification. 
7.3.2 Immunofluorescence analysis of cryosections from neoplastic 
tissue 
Invasive three-dimensional organotypic neoplastic tissue (7.2.6) was cut entirely into 10 µm 
thick sections with the Leica CM3050 S cryostat (Leica Biosystems) and every 7th section 
was processed as described above. Staining and analysis of sections was performed as 
described in 7.3.1 with the following modifications. Sections were fixed in a mixture of 
equal parts methanol and acetone, blocking was done with 10% goat serum (Thermo Fisher 
Scientific) and 0.1% Triton X-100 in PBS, antibodies (see Table 6 and Table 7) were diluted 
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in 1% goat serum (Thermo Fisher Scientific) and 0.1% Triton X-100 in PBS and washing 
steps were performed with 0.1% Triton X-100 in PBS. After the final washing step, Triton 
X-100 was removed by washing with PBS (twice, 5 min, RT) sections were air dried and 
instead of a Hoechst staining, nuclei were stained by using Duolink In Situ Mounting 
Medium with DAPI (Sigma-Aldrich). Pictures were obtained as described in 7.3.1 and all 
measurements were done with the AxioVision software (Carl Zeiss). 
Invasion of keratinocytes into the dermal matrix is a hallmark of biologic malignancy in 90% 
of human cancers and thus can be used for evaluation of neoplasia onset154. For this reason, 
the invasion depth of keratinocytes (visualized by keratin 5 staining) into the dermal matrix 
was measured for each picture at five fixed and independent locations and the mean as well 
as the standard deviation were calculated and plotted across all three biological replicates 
per timepoint. Furthermore, the epidermis thickness above the invasion sites was also 
determined and the ratio of epidermis thickness to invasion depth was calculated and plotted 
as described above. 
7.4 In vivo experiments 
6-8 weeks old immunodeficient mice (CBySmn.CB17-Prkdcscid/J, obtained from The 
Jackson Laboratory (Bar Harbor, USA)) were used and all experiments were performed 
according to an approved experimental protocol by the Stanford Panel on Laboratory Animal 
Care. 
7.4.1 In vivo imaging of tumor size 
Tumor size was monitored in vivo by measuring the luciferase signal originating from the 
luciferase overexpressing tumor cells. To this end, mice were anesthetized with isoflurane, 
back hair was clipped and 100 µl of 30 mg/ml D-luciferin were injected intraperitoneal. After 
10 minutes, the luminescence was recorded with the IVIS 100 In Vivo Imaging System 
(PerkinElmer) and superimposed with the corresponding photographic picture. Exposure 
time, binning and distance to the camera were adjusted as required to omit saturation and 
kept constant between measuring lacZ and SPRR5_326 overexpressing tumors to allow 
cross-sample comparisons.   
Data analysis was done with the Living Image software (PerkinElmer). Briefly, the 
luminescence signal was determined for each animal individually using the automatic 
detection function of the software and the values were extracted in “Photons” mode. The 
mean and standard deviation of the resulting total flux (photons/sec in each pixel summed 
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over the region of interest area) for each group was calculated per day and plotted against 
the days after injection. Additionally, some exemplary pictures from the measurements are 
shown. 
7.4.2 In vivo tumor formation assay 
Primary keratinocytes were consecutively transduced with lentiviral particles to overexpress 
a Luciferase-YFP fusion protein for imaging, HRasG12V and Cdk4 for transformation into 
“tumorigenic keratinocytes” and SPRR5_326 or lacZ to study the potential tumor 
suppressive effect of SPRR5_326 (for details see 7.2.10 and 6.10). After detachment and 
counting of the cells (see 7.2.2 and 7.2.3), cells were washed once with PBS (5 min, RT, 
200 g) and 600,000 cells were resuspended in 100 µl PBS supplemented with 50 µl Matrigel 
(Thermo). 
Mice were anesthetized with an isoflurane/oxygen mix (PM1002 mobile anesthesia 
machine, Parkland Scientific) and the back hair was removed. For in vivo tumor generation, 
the prepared 600,000 cells were injected into the subcutaneous space on the flank of the 
mouse and for each condition (SPRR5_326 or lacZ overexpression) 4 biological replicates 
were prepared.   
Tumor growth was monitored by caliper measurements and in vivo imaging (7.4.1) once or 
twice per week. For caliper measurements, length (L), height (H) width (W) for each tumor 
was determined and the tumor volume was calculated using the formula from 
Faustino-Rocha et al.259. 
tumor volume = 
𝑊 𝑥 𝑊 𝑥 𝐿
2
 
Tomayko and Reynolds showed that the ellipsoid volume formula correlated best with the 
tumor mass and hence this formula was used to estimate the tumor mass260. 
tumor mass = 
𝜋 𝑥 𝐿 𝑥 𝑊 𝑥 𝐻
6
 
85 days after injection of tumorigenic keratinocytes, the mice were euthanized and the 
tumors were extracted and photographed (done by Dr. Zurab Siprashvili, Stanford 
University).  
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7.5 Microbiological techniques 
7.5.1 Cultivation of Escherichia coli 
Bacteria were grown overnight at 37°C on LB-agar plates (with or without antibiotics). 
Liquid bacteria cultures were inoculated in an appropriate volume of LB-Amp medium and 
incubated at 37°C with 220 rpm overnight. 
7.5.2 Preparation of chemically competent Escherichia coli 
5 ml YT-medium were inoculated with a single colony of the selected Escherichia coli strain 
and grown overnight at 37°C and 220 rpm. The next day, 50 µl from this starter culture were 
mixed with 5 ml fresh YT-medium and incubated at 37°C and 220 rpm until an OD600 of 0.8 
was reached, 100 ml YT-medium were added and the culture was grown to an OD600 of 0.5. 
Cells were spun down (2,000 rcf, 5 min, 4°C), resuspended in 20 ml ice-cold TFBI and 
incubated on ice for 10 minutes. After sedimentation of the cells (2,000 rcf, 5 min, 4°C), 
cells were resuspended in 4 ml ice-cold TFBII, divided in 100 µl aliquots, snap-frozen in 
liquid nitrogen and stored at -80°C. 
7.5.3 Transformation of chemically competent Escherichia coli 
100 µl of chemically competent cells were thawed on ice, mixed with either 50 ng of plasmid 
DNA (retransformation) or a heat inactivated ligation reaction and incubated for 30 min on 
ice. Following the heat shock required for plasmid uptake (42°C, 90 s), cells recovered 2 min 
on ice and after addition of 900 µl LB-medium (pre-warmed to 37°C), the cells were 
incubated for 1 h at 37°C and 600 rpm. Appropriate volumes of the transformation reaction 
were then spread on LB-Amp agar plates and incubated at 37 °C overnight. 
 
7.6 Molecular biological methods 
7.6.1 Annealing of siRNAs 
For annealing of siRNAs, 1 nmol of sense and antisense single siRNAs (for sequences see 
Table 17) were mixed with 5 µl siRNA annealing buffer in a 10 µl reaction and heated to 
95°C for 3 min followed by 1 hour at 37°C. 
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7.6.2 Assay for Transposase Accessible Chromatin (ATAC-Seq) 
Sample preparation for ATAC-Seq was done by Katrin Hartinger (master student under my 
supervision) in collaboration with the AG Rehli (University Hospital Regensburg) based on 
the recently published Omni-ATAC protocol from Corces et al.261. Briefly, day 4 
differentiated or undifferentiated keratinocytes with or without SPRR5 knockdown were 
harvested as described above (7.6.3 and 7.2.2). Dead cells were removed by magnetic bead 
depletion using the Annexin V MicroBead Kit (Miltenyi Biotec) according to the 
manufacturer’s instructions and 50,000 living cells were used for the transposition reaction. 
To this end, cells were pelleted (500 rcf, 5 min, 4 °C), resuspended in 50 µl ice-cold ATAC 
resuspension buffer supplemented with 0.1% NP40, 0.1% Tween-20 and 0.01% digitonin 
and incubated for 3 min on ice. Next, cells were washed (500 rcf, 5 min, 4°C) with 1 ml of 
ice-cold ATAC resuspension buffer supplemented with 0.1% Tween-20, pelleted (500 rcf, 
5 min, 4°C) and resuspended in 50 µl of transposition mixture (see Table 29, enzymes and 
buffers from the Nextera DNA Library Preparation Kit, Illumina). The transposition reaction 
took place at 37°C (30 min, 1,000 rpm).  
Table 29: Preparation of the ATAC transposition mixture 
Component volume [µl] 
2x ATAC transposition buffer  
(Nextera kit, Illumina) 
25 
Nextera Tn5 Transposase 
(Nextera kit, Illumina) 
2.5 
1% (w/v) digitonin 0.5 
10% (v/v) Tween-20 0.5 
PBS 16.5 
H2O 5 
 
After transposition, the DNA was purified with the Monarch PCR & DNA Purification Kit 
(New England Biolabs) according to the manufacturer’s instructions and recovered in 21 µl 
elution buffer. Indexes for next-generation sequencing were introduced by PCR. Therefor 
10 µl of the transposed DNA were mixed with 10 µl of 5x Phusion HF buffer, 1 U Phusion 
DNA Polymerase (New England Biolabs), 2.5 µl of the specific i5 index primer, 2.5 µl of 
the specific i7 index primer (both from the Nextera Index Kit) and brought to a final 
concentration of 0.3 mM dNTPs and 1.3 M betaine in a 50 µl reaction. The utilized thermal 
cycling conditions are given in Table 30. 
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Table 30: Cycling conditions for amplification of ATAC-Seq samples 
Step Time   
72°C 5 min   
98°C 30 s   
98°C 10 s  
11 x 63°C 30 s  
72°C 1 min  
4°C ∞   
 
Subsequent DNA purification was achieved with the Monarch PCR & DNA Purification Kit 
(New England Biolabs, first biological replicates) or AMPure XP beads (Beckman Coulter, 
second biological replicates) for size selection between 100 and 500 bp, according to the 
manufacturer´s instruction. For both purifications, DNA was eluted with 15 µl elution buffer 
from the Monarch PCR & DNA Purification Kit (New England Biolabs) and the obtained 
libraries were quantified on the Qubit 2.0 Fluorometer in combination with the Qubit dsDNA 
HS Assay Kit (both Thermo Fisher Scientific) according to the manufacturer´s instruction. 
Finally, DNA size distribution was analyzed on the TapeStation in combination with the 
High Sensitivity D1000 ScreenTape and its corresponding reagents (Agilent) and libraries 
were pooled according to the sample requirements of the Biomedical Sequencing Facility in 
Vienna, were 50 nt single-end sequencing was performed. 
7.6.3 cDNA synthesis 
For cDNA synthesis 500-1000 ng of TRIzol purified RNA (7.6.15) was first subjected to a 
DNase digest with either DNaseI or the TURBO DNA-free Kit (both Thermo), according to 
the manufacturer’s instructions, followed by cDNA synthesis with the iScript cDNA 
Synthesis Kit (Bio-Rad, following the manufacturer’s instructions). In contrast to this, RNA 
obtained with the RNeasy Plus Mini Kit was directly used for cDNA synthesis without prior 
DNase digest.  
After cDNA synthesis, H2O was added to give a final volume of 200 µl and the cDNA was 
stored at -20°C. 
7.6.4 Cellular fractionation of keratinocytes 
D3 to D6 differentiated keratinocytes (see 7.2.9) were washed twice with PBS and detached 
with 0.25% Trypsin-EDTA (Thermo Fisher Scientific) and incubation at 37°C for 4 minutes. 
Next, three volumes of DMEM+BCS were added, cells were scraped off with a cell scraper 
and singularized by resuspension and filtering through a 40 µm cell sieve (Falcon). After 
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pelleting (200 rcf, RT, 3 min), cells were resuspended in 1 ml PBS and the fractionation was 
performed with the Cytoplasmic and Nuclear RNA Purification Kit (Norgen Biotek) 
according to the manufacturer’s instructions and with several variations (lifted cells protocol 
or tissue protocol, with Accutase instead of trypsin, with or without sucrose cushion during 
centrifugation, longer incubation times), here solely the pursued protocol for the depicted 
data is given. To this end, the protocol for cells growing in suspension was pursued, however 
the nuclear RNA pellet was washed once with 200 µl ice-cold lysis buffer (1 min, 4°C, full 
speed) before RNA extraction to remove residual cytoplasmic carry-over.  
7.6.5 Chromatin Immunoprecipitation with DNA-sequencing (ChIP-Seq) 
Sample preparation for ChIP-Seq was done together with the AG Rehli (University Hospital 
Regensburg) and Katrin Hartinger (master student under my supervision). Therefor 
keratinocytes with or without SPRR5 depletion were harvested on day 4 or day 0 
(undifferentiated) of differentiation as described above (7.6.3 and 7.2.2) and formaldehyde 
crosslink was achieved by resuspending 10 million cells in 10 ml 1% (v/v) formaldehyde 
solution and incubation at room temperature for 10 minutes under constant rotation. Next, 
excess formaldehyde was quenched by addition of 1/10 volume 1.25 M glycine (5 min, RT, 
rotation) and crosslinked cells were pelleted (2,000 rcf, 4°C, 10 min), washed once with 
10 ml ice-cold PBS supplemented with 1 mM AEBSF and 10 mM sodium butyrate 
(2,000 rcf, 4°C, 10 min) and transferred to a 1.5 ml reaction tube with 750 µl ice-cold PBS 
supplemented with 1 mM AEBSF and 10 mM sodium butyrate. Following centrifugation 
(6,000 rcf, 5 min, 4°C), the liquid was removed completely, the weight of the cell pellet was 
determined, samples were flash frozen in liquid nitrogen and stored at -80°C.  
For chromatin sonication, crosslinked cells were thawed on ice and resuspended in 20 µl 
ChIP swelling buffer per 1 million crosslinked cells (the number of cells was determined by 
dividing their weight in mg by 4.5, which resulted in the millions of crosslinked cells as 
determined during preliminary experiments) but with a minimum of 500 µl swelling buffer 
per sample. Next, nuclei were extracted by incubation on ice for 10 minutes with occasional 
mixing and subsequent compression of the cells 13 times in a 2 ml douncer, pelleted 
(1,500 rcf, 5 min, 4°C) and resuspended in 1 µl ChIP RIPA buffer per 100 µg nuclei but with 
a minimum of 800 µl. Following incubation on ice for 10 minutes, the crosslinked DNA was 
sheared to fragments between 150 bp to 250 bp by sonication with the S220 
Focused-ultrasonicator (Covaris) in combination with 12x24 mm sonication tubes (Covaris, 
P/N 520056) and the indicated settings (Table 31). 
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Table 31: Settings for sonication of chromatin 
Duty cycle 20% 
Mode Freq sweeping 
Intensity 8 
Cycles of burst 200 
Water level 15 
Time 30 min 
 
After centrifugation (15,870 rcf, 5 min, 4°C), 20 µl of the supernatant were set aside, while 
from the remaining supernatant was transferred to a fresh reaction tube. A 5% (v/v) input 
sample was taken, and input and chromatin were flash-frozen and stored at -80°C. The 20 µl 
aliquot was mixed with 2 µl Proteinase K solution (20 µg/µl, Roche), incubated over-night 
at 65°C and after the addition of 10 µg RNase A (Qiagen) incubated at 37°C for 30 min. 
Following DNA extraction with the Monarch PCR & DNA Purification Kit (New England 
Biolabs, according to the manufacturer’s instructions), efficient chromatin shearing was 
verified by agarose gel electrophoresis (7.6.6).  
For chromatin immunoprecipitation, beads were washed three times with TE (pH 8.0) 
(850 rcf, 1 min, RT), resuspended in the initial volume ChIP-seq DB supplemented with 
0.5% (w/v) BSA and 20 ng/ml glycogen and incubated at RT for 2 hours or overnight at 4°C. 
Next, the chromatin corresponding to 2 million cells was thawed on ice, 1.5 volumes of 
ChIP-Seq DB and 0.25 final volumes washed Sepharose CL-4B beads were added and this 
mixture was incubated under constant rotation at 4°C for two hours. After separation of the 
preclearing beads (16,000 rcf, 5 min, 4°C), 2.5 µg antibody per 200 µl supernatant was added 
and antibody binding was achieved overnight at 4°C under constant rotation.   
The next day, 0.25 volumes of prepared nProteinA Sepharose 4 Fast Flow beads were added 
and the beads were allowed to bind the antibody for 3 hours at 4°C with constant rotation. 
Beads were washed (750 rcf, 5 min, 4°C) twice with 400 µl ice-cold ChIP-Seq WB I, 
ChIP-Seq WB II and ChIP-Seq WB III, followed by three washing steps with 400 µl ice-cold 
TE (pH 8). Eventually, DNA was eluted from the beads by addition of 110 µl ChIP-Seq 
elution buffer and incubation at room temperature for 20 minutes, and a second elution with 
100 µl ChIP-Seq elution buffer. After separation of the beads (750 rcf, 3 min, RT) the 
supernatant was combined into a fresh reaction tube, brought to a final concentration of 
250 mM sodium chloride and incubated overnight at 65°C to reverse the formaldehyde 
crosslinks. Likewise, the 5% input samples were mixed with 200 µl ChIP-Seq elution buffer, 
reverse crosslinked and from here on treated identical to the ChIP samples.  
The following day, DNA was extracted by addition of 70 µg RNAse A (Qiagen) and 
incubation for one hour at 37°C, subsequent addition of 100 µg Proteinase K (Roche) and 
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incubation for another hour at 37°C followed by purification with the Monarch PCR & DNA 
Purification Kit (New England Biolabs, according to the manufacturer’s instructions) and 
elution in 43 µl of the provided elution buffer.  
Library preparation for ChIP-Seq was performed with the NEBNext Ultra II DNA Library 
Prep Kit for Illumina (New England Biolabs) in combination with the Index Primer Set 1+2 
of the NEBNext Multiplex Oligos for Illumina (New England Biolabs). In general, the 
manufacturer’s instructions were followed, however for adapter ligation a 1:10 dilution of 
the NEBNext adapter was used and Agencourt AMPure XP beads (Beckman Coulter) were 
used for PCR clean-up as well as for size selection of DNA inserts of approximately 200 bp. 
Furthermore, instead of the recommended 5 µl only 2 µl of each index primer and the 
universal PCR primer were utilized and DNA elution after PCR clean-up was achieved with 
16 µl elution buffer from the Monarch PCR & DNA Purification Kit (New England Biolabs). 
Finally, the obtained libraries were quantified on the Qubit 2.0 Fluorometer in combination 
with the Qubit dsDNA HS Assay Kit (both Thermo Fisher Scientific) according to the 
manufacturer´s instruction. The size distribution was analyzed on the TapeStation in 
combination with the High Sensitivity D1000 ScreenTape and its corresponding reagents 
(Agilent) and libraries were pooled in an equimolar ratio. The resulting pool was sent for 
sequencing to the Biomedical Sequencing Facility in Vienna according to their sample 
requirements, were 65 nt single-end sequencing was performed on an Illumina HiSeq3000 
platform. 
7.6.6 DNA agarose gel electrophoresis 
Depending on the expected DNA size, horizontal agarose gel electrophoresis was performed 
with 0.8 – 1.4% (w/v) agarose gels (dissolved in TAE buffer, supplemented with a final 
concentration of 0.5 µg/ml ethidium bromide). To this end, samples were mixed with 1/6 
volume of DNA loading dye, loaded next to 5 µl of 1 kb Plus DNA Ladder (Thermo Fisher 
Scientific) and separation of DNA fragments was achieved by applying 90 V in gel chambers 
filled with TAE buffer. Gel documentation was done with the Transilluminator Quantum 
ST4 (PEQLAB). 
 
7.6.7 Full transcriptome RNA sequencing 
Library preparation as well as sequencing was performed by the “Kompetenzzentrum fuer 
Fluoreszente Bioanalytik” Regensburg with RNAs isolated from regenerated organotypic 
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epidermal tissue (7.6.14).  
In general, library preparation and mRNA sequencing were carried out according to the 
Illumina TruSeq Stranded mRNA Sample Preparation Guide, the Illumina HiSeq 1000 
System User Guide (Illumina), and the KAPA Library Quantification Kit - Illumina/ABI 
Prism User Guide (Kapa Biosystems), with minor modifications.  
In brief, mRNA molecules were purified using oligo-dT probes immobilized on magnetic 
beads starting with 250 ng of total RNA supplied with ERCC spike ins233. Chemical 
fragmentation of the mRNA to an average insert size of 200-400 bases was performed using 
divalent cations under elevated temperature (94°C, 4 minutes). First strand cDNA was 
produced by reverse transcription with random primers. Actinomycin D was added to 
improve strand specificity by preventing spurious DNA-dependent synthesis. Blunt-ended 
second strand cDNA was synthesized using DNA Polymerase I, RNase H and dUTP 
nucleotides. The resulting cDNA fragments were adenylated at the 3' ends, the indexing 
adapters were ligated and subsequently specific cDNA libraries were created by PCR 
enrichment. The libraries were quantified using the KAPA SYBR FAST ABI Prism Library 
Quantification Kit. Equimolar amounts of each library were used for cluster generation on 
the cBot (TruSeq SR Cluster Kit v3). The sequencing run was performed on a HiSeq 1000 
instrument using the indexed, 1x50 cycles single end protocol and TruSeq SBS v3 Reagents 
according to the Illumina HiSeq 1000 System User Guide. Image analysis and base calling 
resulted in .bcl files, which were converted into .fastq files by the CASAVA1.8.2 software 
(Bio Gist). 
7.6.8 Generation of plasmids 
The concentration of digested and purified vector and insert (see 7.6.13) was determined 
using the NanoDrop 1000 device (Thermo Fisher Scientific) and 50 ng vector were mixed 
with the designated insert in a 1:3 molar ratio with 1x T4 DNA ligase buffer (New England 
Biolabs) and 400 units T4 DNA ligase (New England Biolabs) in a 20 µl reaction. Ligation 
was achieved by incubation at room temperature for one hour or overnight at 4°C. Following 
heat inactivation (10 min, 65°C), the obtained plasmids were used for transformation of 
competent Escherichia coli cells (7.5.3). 
7.6.9 Northern blot analysis 
15 to 25 µg TRIzol purified RNA from keratinocytes at varying timepoints of differentiation 
as well as 5 µl RiboRuler High Range or Low Range RNA Ladder (Thermo Fisher Scientific) 
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were mixed with the same amount of 2x RNA loading dye, incubated at 65°C for 10 min 
and subsequently placed on ice. Ethidium bromide was added to a final concentration of  
40 µg/ml and the samples were loaded onto a formaldehyde agarose gel (1.2% agarose 
dissolved in RNA gel buffer) and separated by horizontal gel electrophoresis (running 
buffer: RNA gel buffer, 70 V) until the blue dye was 3 cm above the end of the gel. After 
shaking the gel for 30 min in 20x SSC, the RNA was transferred onto a trimmed piece of 
Amersham Hybond-N+ membrane (GE Healthcare) by upward capillary transfer using 
20x SSC as transfer buffer and incubation overnight (detailed description of the setup can 
be found here262).   
The next day, the RNA was crosslinked to the membrane with UV-light at 254 nm (auto 
crosslink function of the UV Stratalinker 2400 (Stratagene)) and successful RNA transfer as 
well as migration pattern of the RNA ladder was captured with the Transilluminator 
Quantum ST4 (PEQLAB). After prehybridization (one hour at 40-50°C with hybridization 
solution supplemented with 1 mg heat denaturated hering sperm DNA (Promega)) specific 
transcripts were detected by adding 20 pmol antisense DNA-oligos (see Table 21) that have 
been labeled in a T4 PNK reaction (Thermo Fisher Scientific) with 20 μCi 32P (20 µl total 
reaction volume, according to the manufacturer’s instructions), purified with a G-25 column 
(GE Healthcare, according to the manufacturer’s instructions) and incubation overnight at 
40-50°C under constant rotation.   
The next day, excess radioactivity was washed away (10 min each, 40-50°C, twice with NB 
wash I and once with NB wash II) and a phosphorimager screen (Kodak) was used to 
accumulate the radioactive signal. The resulting radioactive signals were read with the 
Personal Molecular Imager (Bio-Rad) and analyzed with the Quantity One software 
(Bio-Rad). Sizes for the detected transcripts were determined by superimposing the ethidium 
bromide picture with the obtained phosphorimager signals. 
7.6.10 PCR-based screening of potential SPRR5 knockout cell lines 
Screening PCRs for potential SPRR5 knockout cell lines (7.2.8) were performed as nested 
PCRs utilizing the Taq DNA polymerase (New England Biolabs) and a first set of PCRs to 
detect genomic alterations (KO allele PCR) and a second to detect remaining WT alleles 
(WT allele PCR). For PCR1 12.5 µl cell lysate (see 7.2.8) was brought to a final 
concentration of 200 µM dNTPs, 0.2 µM forward and reverse primer (see below), 1x 
ThermoPol buffer (New England Biolabs) and 1.25 units Taq DNA polymerase in a 25 µl 
reaction. After conducting the thermal cycling program, 1 µl of this first PCR was used as a 
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template for the second PCR which was also done in a 25 µl scale with the same final 
concentrations as specified for PCR1. 15 µl from PCR2 were analyzed by DNA gel 
electrophoresis (7.6.5) and selected PCR products were purified with the NucleoSpin Gel 
and PCR Clean-up Kit (Macherey-Nagel) according to the manufacturer’s instructions and 
their sequence was determined by Sanger sequencing (Macrogen) to ensure specificity of 
the employed screening approach as well as to detect genomic alterations.  
The localization of the utilized PCR primers and gRNAs can be seen in Figure 18 and the 
PCR conditions and utilized primers are listed below. 
Table 32:Thermal cycling conditions for KO allele PCRs (left) and WT allele PCRs (right) 
Step Time    Step Time   
95°C 5 min    95°C  5 min   
95°C 30 s  
25 x 
 95°C 30 s  
25 x 55°C 1 min   55°C 1 min  
68°C 3 min   68°C 1.5 min  
68°C 7 min    68°C 7 min   
10°C ∞    10°C ∞   
 
Table 33: Primer sequences for KO allele PCRs (left) and WT allele PCRs (right) 
Name Sequence (5’ to 3’)  Name Sequence (5’ to 3’) 
PCR 1  PCR 1 
KO_out_F1 CTGCATGTGTGTGTCGGTAC  WT_In_F1 CGTCCAAGCAGAAGTAAGCC 
KO_out_R1 TTACTGTCGGGTGTGTGTGT  KO_out_R1 TTACTGTCGGGTGTGTGTGT 
PCR 2  PCR 2 
KO_out_F2 CCAACTCTAAGAGAGGTAAGTATG  WT_In_F2 CCCCTCAGCTCCTGTTTTCA 
KO_out_R2 GTATGCAGTGTTTGCATAGACTGTC  KO_out_R2 GTATGCAGTGTTTGCATAGACTGTC 
 
7.6.11 Plasmid purification 
Depending on the required amount of DNA vectors, plasmid purification was done with the 
NucleoBond Xtra Maxi EF (for endotoxin-free plasmid preparations), NucleoBond Xtra 
Midi or the NucleoSpin Plasmid Kit (Macherey-Nagel) following the manufacturer’s 
instructions. The obtained DNA was dissolved in a suitable amount of H2O, the 
concentration was determined with the NanoDrop 1000 (Thermo Fisher Scientific) and the 
sequence integrity was verified by restriction enzyme digest as well as Sanger sequencing 
of the included inserts (Macrogen, sequencing primers are listed in Table 18). 
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7.6.12 Polymerase chain reaction 
For PCR amplification of DNA fragments designated for the generation of new plasmids, 
PCR was performed in a 50 µl scale using Phusion High-Fidelity DNA Polymerase (New 
England Biolabs) with 50 ng of DNA template and a final concentration of 1x HF buffer, 
200 µM dNTPs, 0.5 µM of each primer (sequences are given in Table 20), 3% DMSO and 
1 unit of Phusion DNA Polymerase in combination with the thermal cycling program given 
below. 
Table 34: Thermal cycling program for PCR with the Phusion High-Fidelity DNA Polymerase 
Step Time   
98°C 30 s   
98°C 10 s  
35 x 55-60°C 30 s  
72°C 30 s/kbp  
72°C 10 min   
4°C ∞   
 
Successful PCR amplification was verified by DNA agarose gel electrophoresis (7.6.5) and 
the desired PCR product was purified by either PCR clean-up (in case of only one PCR 
amplicon) or gel extraction, both done with the NucleoSpin Gel and PCR Clean-up Kit 
(Macherey-Nagel) according to the manufacturer’s instructions.  
7.6.13 Restriction enzyme digest 
For preparative restriction enzyme digests, 5 to 8 µg DNA vector (1 µg for analytical 
purposes) or the complete amount of purified PCR product was entirely digested with 
suitable restriction enzymes in the designated buffer according to the New England Biolabs 
guidelines and in case of vector backbone preparation for molecular cloning a 
dephosphorylation step with Antarctic phosphatase (New England Biolabs) was done 
according to the manufacturer’s instructions. Following heat inactivation of the enzymes, 
the obtained DNA fragments were analyzed by DNA agarose gel electrophoresis (7.6.5) and 
desired fragments for molecular cloning were purified via gel extraction with the NucleoSpin 
Gel and PCR Clean-up Kit (Macherey-Nagel) according to the manufacturer’s instructions. 
7.6.14 RNA extraction from organotypic tissue 
The designated portion of organotypic tissue (7.2.6 and 7.2.7) was minced and transferred 
into a Lysing Matrix D tube (MP Biomedicals) that contained 800 µl RLT Plus buffer (from 
the RNeasy Plus Mini Kit, Qiagen) supplemented with 1% β-mercaptoethanol. Cell lysis and 
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homogenization was performed with the FastPrep-24 Instrument (MP Biomedicals) for 45 s 
at 6.5 m/s. After centrifugation (2 min, 4°C, 13,000 rcf), the supernatant was transferred to 
a QIAShredder tube (Qiagen) and additionally homogenized by centrifugation (2 min, 4°C, 
13,000 rcf). The flow-through from this step was then subjected to RNA purification with 
the RNeasy Plus Mini Kit (Qiagen), following the manufacturer’s instructions, except all 
centrifugation steps were done at 4°C. The RNA was eluted in 30 µl H2O, quantified with 
the NanoDrop 1000 (Thermo Fisher Scientific) and stored at -80°C until further usage. 
7.6.15 RNA extraction with TRIzol 
Keratinocytes were washed with DPBS and directly lysed in a suitable volume of TRIzol 
Reagent (Thermo Fisher Scientific) and the RNA purification was performed according to 
the manufacturer’s instructions but with an additional chloroform extraction step. The 
obtained RNA pellet was dissolved in an appropriate amount of H2O (55°C, 900 rpm, 5 min), 
quantified with the NanoDrop 1000 (Thermo Fisher Scientific) and stored at -80°C. 
7.6.16 RT-qPCR analysis 
For RT-qPCR analysis, 7.5 µl of SsoFast EvaGreen Mix (Bio-Rad) or Takyon Mix 
(Eurogentec) were mixed with 4.5 µl H2O, 1 µl Primermix (5 µM each primer, for sequences 
see Table 19), 2 µl cDNA and analyzed in a 96-well format using the Real-Time PCR Cycler 
CFX96 (Bio-Rad) in combination with the Bio-Rad CFX Manager 3.1 (Bio-Rad) or the 
Mx3000P (Agilent Technologies) in combination with the MxPro QPCR Software (Agilent 
Technologies). Samples were at least run in duplicates and specificity of each reaction was 
monitored using a melt curve analysis for each PCR product whereas the linear amplification 
for each Primermix was ensured by testing their amplification range with a serial cDNA 
dilution series in preliminary experiments.  
Table 35: Thermal cycling program for RT-qPCR analysis 
Step Time   
95°C 3 min   
95°C 15 s  
40 x 
60°C  30 s  
72°C 30 s  
plate read   
95°C 10 s   
65°C to 95°C +0.5°C/step  5s  
melt curve 
plate read   
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Sample wise fold changes were calculated for each gene of interest (goi) in reference to the 
control from the exported Cq-values using the 2
−ΔΔCq method263 and L32 (where applicable) 
for normalization according to the following formula: 
Fold change = 2−[(𝐶𝑞 𝑠𝑎𝑚𝑝𝑙𝑒(𝑔𝑜𝑖) −𝐶𝑞 𝑐𝑜𝑛𝑡𝑟𝑜𝑙(𝑔𝑜𝑖))−(𝐶𝑞 𝑠𝑎𝑚𝑝𝑙𝑒(𝐿32)−𝐶𝑞 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝐿32))] 
 
7.7 Protein biochemistry  
7.7.1 BCA assay for protein quantification 
Protein concentration was determined using the Pierce BCA protein assay kit (Thermo 
Fisher Scientific) according to the manufacturer’s instructions in a 96-well format. Samples 
were measured in duplicates, analyzed at 562 nm and the protein concentration was 
determined using the standard curve obtained by plotting the blank-corrected A562 for the 
protein standards against their concentration. 
7.7.2 Bradford assay for protein quantification 
5x Roti-Quant (Carl Roth) was diluted 1:5 with water and 900 µl of this dilution were mixed 
with 100 µl prepared bovine serum albumin standard ranging from 0 to 150 µg/ml. 1 to 10 µl 
of protein sample were brought to a final volume of 10 µl with the respective protein lysis 
buffer and mixed with 990 µl 1x Roti-Quant. After 5 min at room temperature, the absorption 
at 595 nm was measured with a Nanophotometer (Implen) and the total protein amount for 
each sample was determined using the standard curve obtained by plotting the 
blank-corrected A595 for the protein standards against their total protein amount. The 
concentration of the protein lysate was obtained by dividing the total protein amount through 
the utilized volume of protein sample. 
7.7.3 Mass spectrometry analysis of SPRR5 
10 mg protein lysate from D5 differentiated keratinocytes was loaded onto a Vivaspin 
100 kDa cutoff column (GE Healthcare) and centrifuged two hours at 4°C with 3000 rcf. 
The flow-through was mixed with 1/5 volume 5x laemmli buffer and separated onto a 15% 
SDS-PAGE with subsequent coomassie staining (7.7.5). The edges of the gel were removed 
and it was divided horizontally into 28 stripes based on the coomassie staining and each 
stripe was divided into ten equally sized pieces. Each gel piece was minced and transferred 
into a 2 ml micro tube (Eppendorf), washed for 30 min each with 950 µl 50 mM NH4HCO3, 
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50 mM NH4HCO3/acetonitrile (3/1), 10 mM NH4HCO3/acetonitrile (3/1), 10 mM 
NH4HCO3/ acetonitrile (1/1) and lyophilized. After reduction with 300 µl 1 mg/ml DTT 
dissolved in 100 mM NH4HCO3 (50°C, 1 hour), cysteines were alkylated with 200 µl  
5 mg/ml Iodoacetamide in 50 mM NH4HCO3 (35 min, RT) and the gel pieces were washed 
and lyophilized again (see above). Next, proteins were subjected to an in gel tryptic digest 
overnight at 37°C with 1 μg Trypsin Gold mass spectrometry grade (Promega) in 50 mM 
NH4HCO3. Peptides were extracted twice with 150 µl 100 mM NH4HCO3, followed by one 
elution with 150 µl 100 mM NH4HCO3/ acetonitrile (2/1) and the obtained eluates were 
combined and lyophilized.   
Further processing of samples, mass spectrometry measurements and protein identification 
was done by the mass spectrometry facility of Biochemistry I, University of Regensburg by 
Dr. Astrid Bruckmann and Eduard Hochmuth. In brief, data obtained from samples analyzed 
on the MaXiS mass spectrometer was transferred to MASCOT 2.5.1 using the Protein-Scape 
software 3.1.3 (Bruker Daltonics). MASCOT aligned the obtained data to the annotated 
proteins of the SWISS-PROT database.  
For SRM measurements 100 fmol synthetic peptide (see Table 10) was spiked in before the 
trypsin digestion, all other steps were performed as described above but samples were 
analyzed on a QTRAP instrument. Data obtained from relative quantification of SPRR5 
protein levels were first exported to Excel and ratios of spike in peptides were compared to 
measured SPRR5 peptides and multiplied with the known amount of 100 fmol peptide spike 
in. This amount of SPRR5 protein within the sample was then divided by the number of cells 
used for sample generation, to obtain the number of SPRR5 proteins within one cell. 
7.7.4 Preparation of protein lysates from keratinocytes 
Protein lysates were prepared by collecting the cells in RIPA buffer, incubation on ice for 
15 minutes and centrifugation for 15 minutes at 4°C and full speed. The obtained supernatant 
was transferred into a new tube and this protein lysate was stored at -80°C until further use. 
For mass spectrometry analysis, day 5 differentiated keratinocytes were detached and 
singularized as described in 7.6.2. After centrifugation (7 min, 4°C, 200 rcf), cells were 
washed once with ice-cold PBS (5 min, 4°C, 200 rcf) and transferred into a clean Eppendorf 
tube with 1 ml PBS. Cells were pelleted again (400 rcf, 4°C, 7 min) the PBS was completely 
removed and the pellet was snap frozen in liquid nitrogen. Following thawing on ice, cells 
were resuspended in protein lysis buffer and incubated on ice for 20 minutes. The protein 
lysate was obtained as the supernatant after centrifugation (15 min, 4°C, full speed). 
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7.7.5 SDS-PAGE analysis and Coomassie staining 
Depending on the size of the protein of interest, proteins were separated on 10% or 15% 
SDS-polyacrylamide gels (composition see Table 36). To this end, protein samples were 
mixed with 1/5 volume of 5x laemmli buffer and denaturated at 95°C for 5 minutes. For size 
determination, 5 µl pre-stained Precision Plus Protein Standard Dual Color (Bio-Rad) was 
used and electrophoresis was performed with TGS at 100 V until the dye front reached the 
bottom of the gel.  
Gels for mass spectrometry analysis were fixed with coomassie fixative (30 min, RT) 
washed with water (5 min, RT, 3 times) and stained with Bio-Safe Coomassie Stain 
(Bio-Rad) at 4°C overnight. Destaining with water was done until protein bands became 
visible and pictures were captured with the Odyssey Imaging System (LI-COR Biosciences) 
and analyzed with the Odyssey software (LI-COR Biosciences). 
Table 36: Composition of SDS-PAGE gels 
Stacking gel (4%) Resolving gel (10%) Resolving gel (15%) Component 
2.25 ml 3.2 ml 1.9 ml Water 
- 1.9 ml 1.9 ml 4x Resolving gel buffer 
0.95 ml - - 4x Stacking gel buffer 
0.5 ml 2.6 ml 3.9 ml 
Acrylamid/Bis-solution  
30% (37.5:1) 
5 µl 4.5 µl 4.5 µl TEMED 
22.5 µl 45 µl  45 µl  10% APS 
 
7.7.6 Western Blot analysis 
7.5 to 30 µg total protein (7.7.4) from keratinocytes was separated via SDS-PAGE (7.7.5) 
and the proteins were subsequently transferred onto the Amersham Hybond-ECL membrane 
(GE Healthcare) by semi-dry blot (Bio-Rad system) using western blot transfer buffer and 
13 V for one hour. Blocking was done in 5% milk powder in TBS-T for one hour at room 
temperature and primary antibodies (Table 6) were diluted in 5% milk powder in TBS-T and 
applied for one hour at room temperature or overnight at 4°C. After washing the membrane 
three times with TBS-T (5 min each, RT), secondary antibodies were diluted in TBS-T 
supplemented with 5% milk powder, added to the membrane and incubated for one hour at 
room temperature. Following three washing steps with TBS-T (5 min, RT), the signal was 
captured with the Odyssey Imaging System (LI-COR Biosciences) and analyzed with the 
Odyssey software (LI-COR Biosciences). 
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9 Appendix 
9.1 Supplementary Figures 
 
 
Supplementary Figure 1: Long term overexpression of SPRR5_326 in primary keratinocytes 
SPRR5_326 levels in primary keratinocytes were analyzed by RT-qPCR at various timepoints after 
keratinocyte transduction (n=3). The obtained values were normalized to L32 and compared to the expression 
in lacZ overexpressing cells highlighting an adequate and long-lasting SPRR5_326 overexpression in primary 
keratinocytes. OE = overexpression 
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Supplementary Figure 2: In vivo luciferase measurements and explanted tumors 
Exemplary picture of in vivo tumor size measurement on day 16 after tumor cell injection (A). (B) depicts the 
mean luciferase signals (Total flux) and the corresponding standard deviations for in vivo tumor size 
measurements of all biological replicates. Subfigure (C) shows the explanted tumors 85 days after tumor cell 
injection. OE = overexpression, p = photon, s = second 
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Supplementary Figure 3: HaCaT cells differentiate properly but slightly different than primary KCs 
HaCaT cells exhibit slightly reduced amounts of differentiation marker transcripts compared to primary 
keratinocytes but differentiate properly (A). The relative expression of differentiation markers on day 3 and 
day 5 of differentiation was normalized to L32 expression as obtained by RT-qPCR (n=1). Exemplary pictures 
of immunofluorescence analysis from cross sections of the corresponding regenerated epidermal tissue on day 
3 (top) or day 5 (bottom) reveals no detectable loricrin protein in HaCaT cells (B, loricrin is shown in red) but 
comparable amounts of the differentiation protein keratin 1 (C, keratin 1 is shown in red). Furthermore, 
collagen VII (green) is depicted for orientation as it separates the epidermis from the beneath lying dermis and 
nuclei are shown in blue. KC = keratinocyte, prim. = primary 
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Supplementary Figure 4: SPRR5 controls epidermal tissue homeostasis on day 4 of differentiation 
Efficient depletion of SPRR5 in organotypic epidermal tissue cultures (A) results in diminished expression of 
differentiation marker mRNAs (B) as obtained by RT-qPCR analysis (n=3-4). Exemplary pictures of 
immunofluorescence analysis of cross sections from the corresponding regenerated epidermal tissue (C) 
reveals reduced amounts of the differentiation proteins loricrin and filaggrin (shown in red) in SPRR5 depleted 
tissue. Collagen VII (green) is depicted for orientation as it separates the epidermis from the beneath lying 
dermis, nuclei are shown in blue and the scale bar (white) indicates 50 µm. Diff. = differentiation, Ctrl = control 
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Supplementary Figure 5: Principal component analysis of full transcriptome sequencing samples 
Principal component analysis of the transcriptome upon SPRR5 depletion on D3 (A) and D4 (B) in regenerated 
organotypic epidermal tissue shows good clustering of control samples (siCtrl) and SPRR5 depleted tissue 
(siSPRR5) for both analyzed timepoints of differentiation. Ctrl = control, PC = principal component 
 
 
 
Supplementary Figure 6: Validation of RNA-Seq results 
DeSeq2 calculated fold changes between siSPRR5 depleted and control tissue from RNA-Seq analysis are 
plotted against fold changes obtained via RT-qPCR measurements for selected transcripts on day 3 of (A) or 
day 4 (B) of differentiation in epidermal organotypic tissue, exhibiting a decent correlation of the results  
(n=3-5). FC = fold change, Ctrl = control 
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Supplementary Figure 7: Comparison of ChIP-Seq reads and called peaks with results from Bao et al. 
Obtained mapped reads (top) and called peaks (bottom) for siCtrl ChIP-Seq samples on day 4 of differentiation 
(blue) were loaded into IGV and compared to already analyzed and published data from Bao et al. (red) for 
H3K4me1 (A), H3K27ac (B) and H3K27me3 (C), showing a good correlation between both datasets. 
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9.2 Sequences 
9.2.1 SPRR5_326 sequence 
5’AAGTTCCTTCTGGGCCAGCATCTTACACTCCACAGGCCAAGCAAAGCCCTGCTCACCAGTGCTTCTGGATGCAGCCACA
CTTCACACTTGCAGGAGAGGCAGCACCAGGCTGGCAGCTGGCGGCTTCCTCGAGCTCTACTCTTCTTAATTAGCAGCTGCA
GTTTCCATCTCAGACAAGGATCTGGTTCTAAACTATCTAATCATCTTTCCTGACATGCATCTACATTGCCCTGCTGGAAAC
ATGAGCGGCATGCACAGGCATCTTCTCCTACCACGCTTCCCCTCAGCTCCTGTTTTCAAACAATTAAAACAGAATTCCTCT
GGCA 3‘ 
9.2.2 SPRR5 transcript sequence and genomic localization 
5’AAACCCCTCCACACCTATCTGCTCCAGTCGCTGGTGAACCTTGTTGCAAGTCCAGCCCAGAATGTCTCAGCAGAAGCAG
AAGCAGTGTGCTCCCCCGCAGCAGTGCTGCCCCCCACCCCAGCAGCGCTGCCCCCCACCCCAGCAGTGCTGCCCCCCGCCT
CAACAGTGCTGCCCCCCACCCCAGCAGTGCTGCCCGCCGCCTCAACAATGCTGCCCCCCTCCCCAGCAGTGCTGTCCCCCA
CCCCAGCAGTGCTGCCCTCCACCTCAGCAGTACTGCCCCCCACCCCAACAGACCAAGCAGCCTTGCCAGCCCCCACCCAAG
TGCCAGGAGCCCTGTGCCCCCAAGTGCCCACCCCCTCAGCAGTGCCAGACGTCCAAGCAGAAGTAAGCCCTGGGCATGTGA
TCAGAGGCGAACCCCCAGGAAAAACAGAGCATGAAGTTCCTTCTGGGCCAGCATCTTACACTCCACAGGCCAAGCAAAGCC
CTGCTCACCAGTGCTTCTGGATGCAGCCACACTTCACACTTGCAGGAGAGGCAGCACCAGGCTGGCAGCTGGCGGCTTCCT
CGAGCTCTACTCTTCTTAATTAGCAGCTGCAGTTTCCATCTCAGACAAGGATCTGGTTCTAAACTATCTAATCATCTTTCC
TGACATGCATCTACATTGCCCTGCTGGAAACATGAGCGGCATGCACAGGCATCTTCTCCTACCACGCTTCCCCTCAGCTCC
TGTTTTCAAACAATTAAAACAGAATTCCTCTGGCA 3‘ 
 
Table 37: Genomic localization of SPRR5 (hg38) 
 Chromosome Strand Start End 
Exon1 1 + 152947206 152947248 
Intron 1 + 152947249 152948536 
Exon2 1 + 152948537 152949255 
 
9.2.3 SPRR5 protein sequence and peptides for mass spectrometry 
The protein sequence of the predicted human SPRR5 protein is given and the sequences of 
the four heavy labelled peptides for the SRM mass spectrometry approach are indicated in 
colors. Only the peptide indicated in green could be successfully detected via mass 
spectrometry and was used for protein quantification. 
MSQQKQKQCAPPQQCCPPPQQRCPPPQQCCPPPQQCCPPPQQCCPPPQQCCPPPQQCCPP 
PQQCCPPPQQYCPPPQQTKQPCQPPPKCQEPCAPKCPPPQQCQTSKQK 
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9.3 Lists of significantly altered genes upon SPRR5 depletion 
Only those genes with -0.5 > log2(fold change) > 0.5 and an adjusted p-value < 0.05 are 
shown here. 
9.3.1 SPRR5 regulated genes on day 3 in organotypic epidermis 
Ensembl identifier baseMean log2FoldChange p-value adjusted p-value gene symbol 
ENSG00000283227 513.874134 -5.03141714 2.24E-114 4.11E-110 SPRR5 
ENSG00000243627 12.1594968 -4.99622056 4.25E-08 1.50E-05 KCNE1 
ENSG00000186207 41.8926237 -4.66514271 7.49E-13 1.10E-09 LCE5A 
ENSG00000198854 342.418464 -4.03563816 1.76E-18 5.39E-15 C1orf68 
ENSG00000187170 14.6175526 -3.67702734 4.47E-07 0.00010783 LCE4A 
ENSG00000221878 37.2595988 -3.66566427 3.37E-14 6.18E-11 PSG7 
ENSG00000124920 89.1559031 -3.66158625 6.28E-10 4.11E-07 MYRF 
ENSG00000125571 149.659943 -3.57769005 2.90E-08 1.06E-05 IL37 
ENSG00000180332 120.510814 -3.55744864 2.57E-22 1.18E-18 KCTD4 
ENSG00000186226 660.621615 -3.50168296 4.71E-09 2.27E-06 LCE1E 
ENSG00000187180 1414.49716 -3.49980149 1.17E-09 6.90E-07 LCE2C 
ENSG00000187223 735.573059 -3.47860806 7.70E-09 3.28E-06 LCE2D 
ENSG00000187173 940.33126 -3.46497331 3.94E-09 1.95E-06 LCE2A 
ENSG00000235942 619.505669 -3.4485924 2.67E-12 3.49E-09 LCE6A 
ENSG00000247011 9.7089836 -3.44278242 0.00011371 0.00993143 NA 
ENSG00000176075 111.94385 -3.39795461 8.17E-11 7.35E-08 NA 
ENSG00000159455 2178.89237 -3.34218831 2.58E-08 9.64E-06 LCE2B 
ENSG00000243349 18.4093612 -3.31337165 8.16E-06 0.00121126 NA 
ENSG00000240386 1084.01822 -3.28091094 6.72E-08 2.28E-05 LCE1F 
ENSG00000244057 53.9550545 -3.26579291 5.34E-16 1.40E-12 LCE3C 
ENSG00000172155 388.542911 -3.25807433 2.73E-07 7.27E-05 LCE1D 
ENSG00000214491 31.9734555 -3.23706075 6.39E-12 7.82E-09 SEC14L6 
ENSG00000177243 151.443432 -3.186702 3.07E-24 2.81E-20 DEFB103B 
ENSG00000185962 315.045005 -3.15423796 7.45E-10 4.71E-07 LCE3A 
ENSG00000215183 6.99525492 -3.13290739 0.00083908 0.04824319 MSMP 
ENSG00000168952 25.7267698 -3.12873467 1.79E-10 1.43E-07 STXBP6 
ENSG00000042062 55.7964831 -3.11053046 3.42E-15 7.84E-12 FAM65C 
ENSG00000186844 1628.34182 -3.11029258 1.83E-07 5.08E-05 LCE1A 
ENSG00000105143 8.01004631 -3.01050399 0.00048389 0.031472 SLC1A6 
ENSG00000118137 11.2682561 -2.99693043 3.78E-06 0.00064225 APOA1 
ENSG00000203786 5644.59336 -2.9743959 1.53E-07 4.59E-05 KPRP 
ENSG00000263429 12.9688611 -2.95835945 5.43E-07 0.00012618 LINC00675 
ENSG00000196734 2406.54552 -2.93286619 3.32E-07 8.45E-05 LCE1B 
ENSG00000162399 8.61030677 -2.8017844 0.00037386 0.02587521 BSND 
ENSG00000168703 1914.52298 -2.75023529 1.21E-14 2.46E-11 WFDC12 
ENSG00000197084 2987.16501 -2.74213045 1.35E-07 4.28E-05 LCE1C 
ENSG00000019102 13.1589975 -2.71164387 0.00010484 0.00938 VSIG2 
ENSG00000273008 13.1133029 -2.62184407 0.00013062 0.01093888 NA 
ENSG00000185966 2968.35942 -2.5496997 7.32E-09 3.20E-06 LCE3E 
ENSG00000165799 1831.03649 -2.52981706 1.47E-08 5.62E-06 RNASE7 
ENSG00000214313 183.629185 -2.510299 8.36E-07 0.00018478 AZGP1P1 
ENSG00000136449 11.6208583 -2.45016881 4.97E-05 0.0052717 MYCBPAP 
ENSG00000283376 30.2596033 -2.44775058 6.16E-08 2.13E-05 NA 
ENSG00000233005 7.98194161 -2.44488673 0.00075574 0.04442631 NA 
ENSG00000232679 25.8411909 -2.36776703 4.50E-06 0.0007233 NA 
ENSG00000231672 40.6818906 -2.36135736 2.13E-13 3.55E-10 NA 
ENSG00000163202 6984.72841 -2.27748273 3.58E-07 9.01E-05 LCE3D 
ENSG00000160862 3790.91231 -2.26880303 2.97E-07 7.67E-05 AZGP1 
ENSG00000172005 728.459707 -2.23362638 0.00061678 0.03783388 MAL 
ENSG00000100302 43.4334226 -2.22032481 5.92E-05 0.00609651 RASD2 
ENSG00000125355 24.4733055 -2.20829738 2.15E-06 0.00041404 TMEM255A 
ENSG00000170054 43.8936574 -2.17245917 1.28E-07 4.12E-05 SERPINA9 
ENSG00000224614 47.7805588 -2.1600126 4.13E-10 2.81E-07 NA 
ENSG00000104327 30.4703162 -2.13004147 3.72E-10 2.73E-07 CALB1 
ENSG00000102962 54.394796 -2.02846862 6.49E-09 3.03E-06 CCL22 
ENSG00000094963 56.9429352 -1.98661688 1.41E-06 0.00028172 FMO2 
ENSG00000174945 19.0782755 -1.98526116 3.81E-05 0.00423681 AMZ1 
ENSG00000100167 12.688576 -1.97982956 0.00030271 0.02203167 SEPT3 
ENSG00000145879 123.319464 -1.97385456 7.78E-05 0.00783644 SPINK7 
ENSG00000131969 263.005535 -1.95755787 7.78E-13 1.10E-09 ABHD12B 
ENSG00000181652 407.50275 -1.90093625 4.95E-05 0.0052717 ATG9B 
ENSG00000169509 5322.98824 -1.85744307 3.49E-10 2.67E-07 CRCT1 
ENSG00000164283 17.118721 -1.84289744 0.00085984 0.04921412 ESM1 
ENSG00000185873 36.1534951 -1.78202614 0.00073671 0.04344696 TMPRSS11B 
ENSG00000115488 39.2119949 -1.77503721 2.57E-06 0.00047187 NEU2 
ENSG00000160360 484.526814 -1.77470658 5.93E-22 2.18E-18 GPSM1 
ENSG00000073737 762.969632 -1.77399801 4.64E-23 2.84E-19 DHRS9 
ENSG00000100292 2371.71075 -1.72362536 7.21E-07 0.00016318 HMOX1 
ENSG00000183760 1235.17771 -1.71521881 3.78E-06 0.00064225 ACP7 
ENSG00000110675 336.936545 -1.71202166 2.43E-05 0.00289689 ELMOD1 
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ENSG00000165495 43.6527979 -1.61326983 7.42E-05 0.00752237 PKNOX2 
ENSG00000198691 44.5882514 -1.54304894 3.88E-05 0.00426125 ABCA4 
ENSG00000183018 2637.04055 -1.52824071 4.35E-06 0.00070595 SPNS2 
ENSG00000165091 20.5657198 -1.52422433 0.00020699 0.01601865 TMC1 
ENSG00000164120 2401.66385 -1.51409686 4.64E-06 0.00074049 HPGD 
ENSG00000237330 211.638197 -1.48760193 5.29E-11 5.39E-08 RNF223 
ENSG00000244617 19016.2928 -1.48620801 0.00032795 0.02331385 ASPRV1 
ENSG00000166105 180.75797 -1.47602632 7.13E-09 3.19E-06 GLB1L3 
ENSG00000143536 3643.4723 -1.46502781 8.53E-05 0.00827934 CRNN 
ENSG00000114854 38.5968371 -1.44218597 0.00031839 0.02290001 TNNC1 
ENSG00000234478 31.821916 -1.4331129 1.83E-05 0.00227245 NA 
ENSG00000197249 84.1911676 -1.42846432 1.55E-07 4.60E-05 SERPINA1 
ENSG00000159899 180.478159 -1.42262795 1.66E-11 1.90E-08 NPR2 
ENSG00000101443 22.2411063 -1.4185134 0.00071803 0.04289712 WFDC2 
ENSG00000075673 7385.2923 -1.37920244 8.67E-07 0.00018826 ATP12A 
ENSG00000261572 22.2935538 -1.378175 0.00047931 0.03128448 NA 
ENSG00000163209 11418.8295 -1.36916956 4.58E-05 0.00491688 SPRR3 
ENSG00000115590 479.246471 -1.36213215 9.87E-09 4.02E-06 IL1R2 
ENSG00000197948 2320.26077 -1.34453354 1.12E-10 9.37E-08 FCHSD1 
ENSG00000271573 22.2955124 -1.33763701 0.00027494 0.02048478 NA 
ENSG00000154274 46.2106948 -1.33519099 1.20E-05 0.00170114 C4orf19 
ENSG00000130751 164.744222 -1.31555802 1.47E-07 4.48E-05 NPAS1 
ENSG00000178597 1622.73713 -1.29188729 0.00035677 0.02497517 PSAPL1 
ENSG00000213904 91.873446 -1.28300954 2.08E-07 5.68E-05 LIPE-AS1 
ENSG00000123689 113.314208 -1.27052753 9.51E-05 0.0087776 G0S2 
ENSG00000204538 231.324728 -1.26407324 3.82E-07 9.40E-05 PSORS1C2 
ENSG00000103056 4479.72834 -1.25036953 8.59E-05 0.00829472 SMPD3 
ENSG00000096006 169.679239 -1.22337481 3.72E-05 0.00415999 CRISP3 
ENSG00000106484 176.164652 -1.21240147 9.57E-07 0.00019953 MEST 
ENSG00000204539 13611.3822 -1.20441971 5.01E-05 0.0052775 CDSN 
ENSG00000185499 277.625812 -1.18962572 5.84E-07 0.00013393 MUC1 
ENSG00000095637 45.0271788 -1.18077482 0.0005075 0.03243231 SORBS1 
ENSG00000099822 45.3169922 -1.15953072 3.60E-05 0.00405442 HCN2 
ENSG00000138678 163.113427 -1.14573701 4.11E-10 2.81E-07 GPAT3 
ENSG00000167755 19407.6797 -1.13973624 7.89E-05 0.00790911 KLK6 
ENSG00000276900 80.399488 -1.1330729 0.00015031 0.01219877 NA 
ENSG00000158220 520.741592 -1.12915878 3.97E-06 0.00066114 ESYT3 
ENSG00000196549 65.7502692 -1.12030302 1.44E-05 0.00189569 MME 
ENSG00000185168 73.2856637 -1.10535611 0.00018183 0.01449962 NA 
ENSG00000129437 119.49664 -1.10461539 1.21E-05 0.00170114 KLK14 
ENSG00000072201 185.483973 -1.10063003 3.65E-09 1.91E-06 LNX1 
ENSG00000179859 359.066158 -1.09805558 1.20E-07 3.93E-05 LOC284023 
ENSG00000170961 283.020574 -1.09437712 2.98E-05 0.0034179 HAS2 
ENSG00000088386 1553.16477 -1.08958191 6.60E-09 3.03E-06 SLC15A1 
ENSG00000066735 33.5360524 -1.08833573 0.00026019 0.01955784 KIF26A 
ENSG00000240891 124.053678 -1.08498199 0.00013831 0.01132459 PLCXD2 
ENSG00000163803 219.164174 -1.08461901 3.32E-06 0.00057979 PLB1 
ENSG00000236263 33.8403849 -1.07444381 0.00010322 0.00928034 NA 
ENSG00000254966 57.8679958 -1.06431572 0.00086677 0.04937087 NA 
ENSG00000119125 370.366937 -1.05281545 5.18E-07 0.00012173 GDA 
ENSG00000166920 263.784621 -1.05218484 4.09E-06 0.00067654 C15orf48 
ENSG00000130475 251.594059 -1.04896736 9.26E-05 0.00869217 FCHO1 
ENSG00000105825 665.040185 -1.03391214 1.06E-08 4.21E-06 TFPI2 
ENSG00000238266 78.7081231 -1.01851775 2.60E-06 0.00047246 LINC00707 
ENSG00000151117 3315.16386 -1.01120508 2.81E-07 7.36E-05 TMEM86A 
ENSG00000146674 407.192089 -1.00569462 9.97E-05 0.00909973 IGFBP3 
ENSG00000144834 195.363505 -0.98733782 6.82E-08 2.28E-05 TAGLN3 
ENSG00000036672 501.451051 -0.98722765 1.41E-07 4.38E-05 USP2 
ENSG00000177628 2573.03642 -0.98609951 3.43E-11 3.71E-08 GBA 
ENSG00000253125 174.046833 -0.98547045 0.00023626 0.01805531 NA 
ENSG00000175352 57.4104737 -0.9796569 0.00057586 0.03592473 NRIP3 
ENSG00000160766 626.793421 -0.95477444 1.64E-09 9.40E-07 GBAP1 
ENSG00000122643 463.17592 -0.95122771 1.11E-09 6.77E-07 NT5C3A 
ENSG00000173926 397.278437 -0.95074763 2.50E-05 0.00295054 MARCH3 
ENSG00000159516 3222.29042 -0.90712328 1.25E-08 4.87E-06 SPRR2G 
ENSG00000213492 69.1360923 -0.90653145 1.43E-05 0.00189569 NA 
ENSG00000171476 7257.99242 -0.90402513 1.38E-05 0.00189569 HOPX 
ENSG00000274276 66.3224885 -0.89832109 9.29E-05 0.00869217 CBSL 
ENSG00000157368 280.223859 -0.88764079 5.45E-05 0.00567685 IL34 
ENSG00000138623 630.023455 -0.87470739 8.19E-06 0.00121126 SEMA7A 
ENSG00000184148 1596.9211 -0.87461564 8.72E-07 0.00018826 SPRR4 
ENSG00000149328 276.145628 -0.84681181 0.0001201 0.01029329 GLB1L2 
ENSG00000122042 756.411871 -0.82954603 9.35E-06 0.00136161 UBL3 
ENSG00000204618 1046.37417 -0.82734807 2.15E-05 0.0025917 RNF39 
ENSG00000135821 5089.88469 -0.82466367 8.24E-11 7.35E-08 GLUL 
ENSG00000088826 549.149267 -0.82287093 2.51E-05 0.00295054 SMOX 
ENSG00000035862 1356.79083 -0.82232271 4.70E-07 0.00011189 TIMP2 
ENSG00000026025 4409.40616 -0.81166276 0.00041763 0.02775285 VIM 
ENSG00000268307 347.770148 -0.8051815 2.54E-05 0.00297107 NA 
ENSG00000108244 5044.55271 -0.80251717 3.84E-07 9.40E-05 KRT23 
ENSG00000180667 690.793459 -0.79422615 0.00068434 0.04142399 YOD1 
ENSG00000187210 176.932739 -0.79243759 0.00083211 0.04799303 GCNT1 
ENSG00000173846 858.450962 -0.78566642 3.52E-09 1.90E-06 PLK3 
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ENSG00000116741 167.147564 -0.7826287 8.34E-05 0.00817244 RGS2 
ENSG00000167779 2096.67669 -0.77862704 2.45E-09 1.36E-06 IGFBP6 
ENSG00000150471 96.2327106 -0.77753359 0.00039483 0.02682092 ADGRL3 
ENSG00000236824 152.63427 -0.77336052 0.00041693 0.02775285 BCYRN1 
ENSG00000175315 2879.58924 -0.76722472 0.00038474 0.02642888 CST6 
ENSG00000162040 346.101646 -0.7558579 0.00010233 0.00928034 HS3ST6 
ENSG00000137033 314.684776 -0.74407009 0.00056366 0.03528336 IL33 
ENSG00000091428 100.574973 -0.74133426 0.00027587 0.02048478 RAPGEF4 
ENSG00000159871 3016.11459 -0.72397918 0.00023833 0.01808303 LYPD5 
ENSG00000047346 742.845322 -0.72280876 2.32E-05 0.00278589 FAM214A 
ENSG00000166828 132.101477 -0.72115269 0.00033537 0.02373809 SCNN1G 
ENSG00000128510 3714.24773 -0.72095526 4.16E-06 0.00068091 CPA4 
ENSG00000059804 152.528818 -0.71789709 8.15E-05 0.00803722 SLC2A3 
ENSG00000148346 8492.37768 -0.71105145 0.00012571 0.010674 LCN2 
ENSG00000100889 1015.4049 -0.70798278 1.35E-06 0.00027457 PCK2 
ENSG00000103811 3398.2072 -0.70548201 1.70E-05 0.00213183 CTSH 
ENSG00000172478 2777.20801 -0.70213032 1.47E-05 0.00192131 C2orf54 
ENSG00000198853 492.367792 -0.6957467 1.60E-07 4.61E-05 RUSC2 
ENSG00000246100 84.1336163 -0.69327602 0.00032676 0.02331385 NA 
ENSG00000137962 865.311892 -0.68898797 0.00058799 0.03655729 ARHGAP29 
ENSG00000006652 710.396428 -0.67617755 0.00012968 0.01091011 IFRD1 
ENSG00000162852 457.580945 -0.67386283 9.27E-05 0.00869217 CNST 
ENSG00000102312 951.884337 -0.66880518 7.33E-06 0.00112102 PORCN 
ENSG00000102879 169.360979 -0.66609702 0.00018929 0.01496463 CORO1A 
ENSG00000255501 2374.57461 -0.66282544 0.00040185 0.0270966 CARD18 
ENSG00000069011 1329.72135 -0.65608318 0.00050572 0.03243231 PITX1 
ENSG00000005001 866.47503 -0.64898823 9.53E-07 0.00019953 PRSS22 
ENSG00000142623 523.197329 -0.64567236 1.41E-05 0.00189569 PADI1 
ENSG00000189433 1066.9903 -0.6403917 1.68E-06 0.00033037 GJB4 
ENSG00000101132 163.424112 -0.64031647 0.00019848 0.01555682 PFDN4 
ENSG00000155324 828.778307 -0.63041973 2.41E-07 6.49E-05 GRAMD3 
ENSG00000130818 488.155397 -0.62665279 8.85E-05 0.00849919 ZNF426 
ENSG00000228903 260.712979 -0.6257139 0.0001282 0.01083593 NA 
ENSG00000241794 2746.21293 -0.62238799 0.00010644 0.00947687 SPRR2A 
ENSG00000164294 316.088318 -0.62084145 5.73E-05 0.00594201 GPX8 
ENSG00000243137 149.609177 -0.62082158 0.00060455 0.03720812 PSG4 
ENSG00000143845 310.389168 -0.61710272 5.25E-05 0.00550589 ETNK2 
ENSG00000057657 1262.42699 -0.61685601 0.00028237 0.02079875 PRDM1 
ENSG00000142227 841.058036 -0.60239327 9.67E-05 0.00886868 EMP3 
ENSG00000143369 4379.1028 -0.58940462 1.86E-05 0.00228696 ECM1 
ENSG00000164442 1598.79926 -0.58731186 7.96E-05 0.00793182 CITED2 
ENSG00000158158 968.605702 -0.58448369 0.00024881 0.01877961 CNNM4 
ENSG00000151498 889.302904 -0.57349128 3.89E-06 0.00065491 ACAD8 
ENSG00000169715 590.515775 -0.57044187 0.00077482 0.04540225 MT1E 
ENSG00000175121 3087.23372 -0.56371228 0.00044741 0.02941182 WFDC5 
ENSG00000104783 248.813138 -0.56149299 0.00072765 0.04305114 KCNN4 
ENSG00000135069 1348.93701 -0.55987074 0.00021479 0.01655238 PSAT1 
ENSG00000177406 173.149081 -0.55931081 0.00030716 0.02226727 LOC100049716 
ENSG00000136840 632.952461 -0.55001 3.28E-06 0.0005777 ST6GALNAC4 
ENSG00000136943 6827.53223 -0.54727274 0.00060228 0.03719308 CTSV 
ENSG00000070669 573.242 -0.54128676 0.00012569 0.010674 ASNS 
ENSG00000261068 772.807209 -0.53007623 1.43E-05 0.00189569 NA 
ENSG00000104267 4119.18146 -0.52801134 6.30E-06 0.00097119 CA2 
ENSG00000177427 434.512944 -0.51431702 8.38E-05 0.00817244 MIEF2 
ENSG00000150782 2052.10969 -0.50697654 3.00E-06 0.0005391 IL18 
ENSG00000183696 2636.8153 -0.50288994 1.14E-05 0.00163169 UPP1 
ENSG00000146477 663.870801 0.5002563 0.00017356 0.01396161 SLC22A3 
ENSG00000179403 1541.51448 0.51352792 1.41E-06 0.00028172 VWA1 
ENSG00000185507 1562.78856 0.51653243 5.41E-06 0.0008559 IRF7 
ENSG00000143819 1077.19323 0.5215535 8.28E-06 0.00121485 EPHX1 
ENSG00000172456 258.611804 0.52242949 0.00042631 0.02822702 FGGY 
ENSG00000149260 163.380044 0.53586928 0.00069581 0.04197956 CAPN5 
ENSG00000025708 11429.792 0.54897168 6.07E-06 0.00094395 TYMP 
ENSG00000120149 215.075765 0.57370349 0.00080254 0.04672834 MSX2 
ENSG00000158106 159.772803 0.60546325 0.000555 0.0348606 RHPN1 
ENSG00000168016 581.446296 0.61378149 0.00039648 0.02683353 TRANK1 
ENSG00000104722 393.712129 0.61994355 0.00027032 0.02023634 NEFM 
ENSG00000139629 4693.40961 0.62605537 1.32E-05 0.00183658 GALNT6 
ENSG00000205978 2940.29952 0.63629516 2.34E-06 0.0004422 NYNRIN 
ENSG00000261150 2767.02193 0.64252751 4.21E-05 0.00457346 EPPK1 
ENSG00000147883 8539.40571 0.64343688 0.0003378 0.02373809 CDKN2B 
ENSG00000135218 1997.65758 0.66570355 0.0001334 0.01102686 CD36 
ENSG00000185215 2133.26067 0.6664111 4.06E-08 1.46E-05 TNFAIP2 
ENSG00000127954 2329.66337 0.68886045 1.40E-05 0.00189569 STEAP4 
ENSG00000184371 159.796742 0.7033708 7.82E-06 0.00117629 CSF1 
ENSG00000183486 764.814869 0.72060939 1.61E-07 4.61E-05 MX2 
ENSG00000138606 979.872692 0.72163074 4.27E-05 0.00460813 SHF 
ENSG00000105357 3950.88025 0.74732363 8.41E-11 7.35E-08 MYH14 
ENSG00000125285 160.52706 0.7644877 0.00010297 0.00928034 SOX21 
ENSG00000114812 527.398531 0.76776521 1.63E-05 0.00208952 VIPR1 
ENSG00000158966 295.016632 0.76873403 1.48E-05 0.00192148 CACHD1 
ENSG00000064655 66.4398786 0.88879888 0.00064292 0.03904556 EYA2 
ENSG00000105523 101.777971 0.91976755 0.00050646 0.03243231 FAM83E 
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ENSG00000167972 53.6955493 0.9653959 0.00061969 0.03788557 ABCA3 
ENSG00000138798 85.590101 0.98302478 4.12E-05 0.00450006 EGF 
ENSG00000188613 170.404737 1.00732483 3.21E-06 0.00057168 NANOS1 
ENSG00000243284 156.515732 1.09311829 1.22E-05 0.00170114 VSIG8 
ENSG00000112394 62.4966976 1.14292158 0.00011959 0.01029329 SLC16A10 
ENSG00000132854 295.377735 1.18899439 2.05E-05 0.00250158 KANK4 
ENSG00000172867 6782.94035 1.21204235 3.78E-09 1.93E-06 KRT2 
ENSG00000231574 47.5220821 1.21622261 1.65E-05 0.00209949 KCCAT211 
ENSG00000159450 437.808533 1.28111414 9.72E-09 4.02E-06 TCHH 
ENSG00000167157 127.69851 1.29487775 0.00029359 0.02145349 PRRX2 
ENSG00000064886 36.875197 1.32706917 8.14E-05 0.00803722 CHI3L2 
ENSG00000169116 193.343707 1.42100733 9.34E-07 0.00019923 PARM1 
ENSG00000002745 16.2110806 1.80108235 0.00020048 0.0155802 WNT16 
9.3.2 SPRR5 regulated genes on day 4 in organotypic epidermis 
Ensembl identifier baseMean log2FoldChange p-value adjusted p-value gene symbol 
ENSG00000283227 513.874134 -3.52298464 4.90E-101 8.65E-97 SPRR5 
ENSG00000241717 12.5709246 -2.882494 1.47E-05 0.00166099 NA 
ENSG00000276241 15.8355602 -2.41705731 2.45E-05 0.00244803 NA 
ENSG00000084674 14.5669241 -2.32229112 4.27E-05 0.00371816 APOB 
ENSG00000124920 89.1559031 -2.32198659 5.54E-06 0.00085138 MYRF 
ENSG00000110799 297.703255 -2.18280648 6.62E-07 0.00017723 VWF 
ENSG00000100341 70.1883166 -1.94433734 0.00075354 0.0266826 PNPLA5 
ENSG00000247011 9.7089836 -1.91520194 0.00172691 0.04866732 NA 
ENSG00000101049 42.6212109 -1.82589092 0.00179577 0.0499739 SGK2 
ENSG00000186912 20.5864765 -1.81720002 0.00139605 0.04177176 P2RY4 
ENSG00000186207 41.8926237 -1.7345105 3.37E-06 0.00056793 LCE5A 
ENSG00000204195 12.0344511 -1.69067923 0.00115233 0.03649044 AWAT1 
ENSG00000104327 30.4703162 -1.64243628 1.90E-07 6.72E-05 CALB1 
ENSG00000094963 56.9429352 -1.63069487 1.15E-06 0.00027123 FMO2 
ENSG00000266274 9.94559428 -1.60897033 0.00141376 0.04205584 NA 
ENSG00000073737 762.969632 -1.60730037 2.29E-24 2.02E-20 DHRS9 
ENSG00000243627 12.1594968 -1.56556206 0.00035991 0.01605963 KCNE1 
ENSG00000214491 31.9734555 -1.55158262 1.67E-05 0.00180649 SEC14L6 
ENSG00000140678 89.1101808 -1.5125636 0.00082082 0.02838344 ITGAX 
ENSG00000198691 44.5882514 -1.50592218 6.22E-07 0.00016901 ABCA4 
ENSG00000215853 4219.94309 -1.46893694 3.88E-08 2.29E-05 RPTN 
ENSG00000235091 14.426802 -1.45896818 0.0008342 0.02873369 NA 
ENSG00000168952 25.7267698 -1.44687893 6.78E-05 0.00522861 STXBP6 
ENSG00000178597 1622.73713 -1.43189091 6.63E-06 0.00096772 PSAPL1 
ENSG00000019102 13.1589975 -1.41747737 0.00119659 0.03742243 VSIG2 
ENSG00000167046 37.0673009 -1.41223095 2.79E-05 0.00267723 NA 
ENSG00000214456 40.2181842 -1.40402265 0.00093385 0.03084324 PLIN5 
ENSG00000276317 42.9526497 -1.39927405 0.00038227 0.01673211 NA 
ENSG00000230102 10.080814 -1.39692844 0.00087014 0.02934239 LOC285389 
ENSG00000185873 36.1534951 -1.38678281 4.16E-05 0.00370175 TMPRSS11B 
ENSG00000183166 18.9273537 -1.37520096 0.00043251 0.01828334 CALN1 
ENSG00000172164 178.681825 -1.34370582 4.25E-05 0.00371571 SNTB1 
ENSG00000249307 14.2818237 -1.32812432 0.0007132 0.02556252 NA 
ENSG00000082397 63.7529462 -1.32790744 1.13E-06 0.00027053 EPB41L3 
ENSG00000118160 17.173707 -1.32127809 0.00057079 0.02210877 SLC8A2 
ENSG00000255173 84.992939 -1.32089199 1.57E-05 0.00174229 NA 
ENSG00000279693 53.0659157 -1.31826876 0.00014886 0.00878874 NA 
ENSG00000283376 30.2596033 -1.30534995 0.00041646 0.01777497 NA 
ENSG00000158014 27.7030009 -1.30521812 0.00121937 0.03783549 SLC30A2 
ENSG00000007237 1307.95128 -1.29232872 1.20E-11 2.36E-08 GAS7 
ENSG00000143520 34458.6098 -1.27006184 7.47E-05 0.00553187 FLG2 
ENSG00000125355 24.4733055 -1.26336506 0.00062969 0.02349715 TMEM255A 
ENSG00000163209 11418.8295 -1.23447676 2.87E-05 0.00274321 SPRR3 
ENSG00000197046 33.1024134 -1.22527797 0.00021345 0.01113551 SIGLEC15 
ENSG00000113739 339.737227 -1.2196126 0.00020539 0.01083364 STC2 
ENSG00000119457 298.261118 -1.21562788 0.00055696 0.02180801 SLC46A2 
ENSG00000112303 38.9028275 -1.21475454 2.60E-06 0.00049404 VNN2 
ENSG00000119915 182.198162 -1.21353617 0.00103098 0.03324334 ELOVL3 
ENSG00000230628 37.540418 -1.21110241 3.15E-06 0.00054073 NA 
ENSG00000224614 47.7805588 -1.20744124 3.28E-05 0.00308577 NA 
ENSG00000166105 180.75797 -1.19908626 5.81E-08 2.93E-05 GLB1L3 
ENSG00000168703 1914.52298 -1.19412949 0.00012224 0.00779751 WFDC12 
ENSG00000119125 370.366937 -1.18797255 1.47E-10 1.74E-07 GDA 
ENSG00000277496 205.244401 -1.1806761 5.88E-06 0.00089486 NA 
ENSG00000182261 917.255682 -1.16301754 4.26E-10 4.70E-07 NLRP10 
ENSG00000271573 22.2955124 -1.16161623 7.34E-05 0.00553185 NA 
ENSG00000108578 1498.92205 -1.16038456 6.08E-05 0.0048165 BLMH 
ENSG00000205363 378.365549 -1.15055165 1.94E-12 4.89E-09 C15orf59 
ENSG00000278952 324.699909 -1.14392128 0.00075239 0.0266826 NA 
ENSG00000181577 44.3718918 -1.1436787 1.14E-05 0.00139273 C6orf223 
ENSG00000167769 1712.69513 -1.132983 0.00011371 0.00752528 ACER1 
ENSG00000224721 50.0125041 -1.13022085 0.00026459 0.01298703 LOC102724153 
ENSG00000258689 26.9410759 -1.11654291 0.00053612 0.02119289 LINC01269 
ENSG00000244057 53.9550545 -1.10561843 5.32E-05 0.00434881 LCE3C 
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ENSG00000136010 185.550825 -1.0962911 9.60E-09 6.52E-06 ALDH1L2 
ENSG00000234478 31.821916 -1.09500955 4.30E-05 0.00372032 NA 
ENSG00000183091 244.778047 -1.07046776 2.19E-05 0.00223298 NEB 
ENSG00000108830 68.9619276 -1.06688844 0.00023834 0.01203292 RND2 
ENSG00000135917 174.916841 -1.06102983 2.73E-05 0.0026533 SLC19A3 
ENSG00000103740 401.663782 -1.05733956 1.52E-06 0.00033469 ACSBG1 
ENSG00000188100 237.86449 -1.05712793 0.00070597 0.02546623 FAM25A 
ENSG00000171476 7257.99242 -1.05542329 7.77E-09 5.49E-06 HOPX 
ENSG00000103056 4479.72834 -1.05524626 0.00016093 0.00929276 SMPD3 
ENSG00000221878 37.2595988 -1.05402921 0.00026779 0.01303551 PSG7 
ENSG00000084710 105.343343 -1.05186365 8.04E-06 0.00108466 EFR3B 
ENSG00000183479 678.815826 -1.04865851 0.00067885 0.02483493 TREX2 
ENSG00000268601 99.0395579 -1.04662294 8.73E-07 0.00022049 NA 
ENSG00000090512 495.387459 -1.04294039 1.81E-06 0.00038047 FETUB 
ENSG00000185168 73.2856637 -1.04130514 6.63E-05 0.00514194 NA 
ENSG00000188051 27.5558842 -1.03498169 0.00070649 0.02546623 TMEM221 
ENSG00000184459 1714.29598 -1.0326541 5.58E-08 2.93E-05 BPIFC 
ENSG00000126233 2400.69116 -1.03264763 0.00016385 0.00940019 SLURP1 
ENSG00000143536 3643.4723 -1.02711876 0.00170811 0.04840647 CRNN 
ENSG00000160200 129.506232 -1.02388358 2.12E-06 0.00042501 CBS 
ENSG00000180332 120.510814 -1.02190088 4.20E-05 0.0037098 KCTD4 
ENSG00000088053 18.7413241 -1.0203505 0.0009963 0.03236142 GP6 
ENSG00000102962 54.394796 -1.01844101 7.16E-05 0.00547343 CCL22 
ENSG00000088386 1553.16477 -1.00703759 1.08E-09 1.00E-06 SLC15A1 
ENSG00000106302 151.894984 -0.99730188 0.00016616 0.00944664 HYAL4 
ENSG00000254951 36.7381632 -0.98975661 0.00015779 0.00918673 LOC283299 
ENSG00000173926 397.278437 -0.98723731 7.46E-07 0.00019388 MARCH3 
ENSG00000151117 3315.16386 -0.98184685 1.34E-08 8.48E-06 TMEM86A 
ENSG00000185499 277.625812 -0.97960625 4.11E-06 0.00066609 MUC1 
ENSG00000189377 37.4349211 -0.97514591 0.00029016 0.01384258 CXCL17 
ENSG00000128165 185.777317 -0.97048878 9.36E-08 4.24E-05 ADM2 
ENSG00000136697 92.1102446 -0.9702897 1.75E-07 6.43E-05 IL1F10 
ENSG00000139438 58.7409761 -0.9694445 3.28E-05 0.00308577 FAM222A 
ENSG00000075673 7385.2923 -0.96418263 8.96E-05 0.00631686 ATP12A 
ENSG00000159871 3016.11459 -0.96309555 2.77E-08 1.69E-05 LYPD5 
ENSG00000253125 174.046833 -0.95584632 7.37E-05 0.00553185 NA 
ENSG00000135678 1913.84923 -0.95079813 0.00012826 0.00797992 CPM 
ENSG00000179477 4166.84704 -0.95054422 0.00019571 0.01044776 ALOX12B 
ENSG00000136696 182.027696 -0.94817105 0.00016449 0.00940603 IL36B 
ENSG00000130475 251.594059 -0.94472845 7.48E-05 0.00553187 FCHO1 
ENSG00000254966 57.8679958 -0.94333673 0.0003731 0.01642081 NA 
ENSG00000136695 3542.98192 -0.94297217 5.29E-09 4.25E-06 IL36RN 
ENSG00000130751 164.744222 -0.93816482 7.34E-06 0.00104598 NPAS1 
ENSG00000169026 130.643406 -0.93308035 0.00016321 0.00939375 MFSD7 
ENSG00000099960 63.3117146 -0.93014997 3.41E-05 0.00313871 SLC7A4 
ENSG00000184060 535.599272 -0.92198644 9.30E-06 0.00119916 ADAP2 
ENSG00000186115 67.322133 -0.9209359 0.00022615 0.01154921 CYP4F2 
ENSG00000131969 263.005535 -0.91065581 0.00010914 0.00733293 ABHD12B 
ENSG00000188373 1813.12752 -0.90992978 1.48E-07 5.82E-05 C10orf99 
ENSG00000263823 118.673433 -0.90867887 1.02E-05 0.00128423 NA 
ENSG00000189090 68.9723657 -0.90863726 8.93E-06 0.00115975 FAM25G 
ENSG00000240891 124.053678 -0.90530708 0.00024507 0.01226734 PLCXD2 
ENSG00000162040 346.101646 -0.90240678 9.65E-08 4.26E-05 HS3ST6 
ENSG00000186806 3712.46855 -0.90077543 2.68E-06 0.0005038 VSIG10L 
ENSG00000173239 796.873851 -0.89903995 0.00068663 0.0250159 LIPM 
ENSG00000103569 2065.16433 -0.8821354 6.24E-08 2.98E-05 AQP9 
ENSG00000204539 13611.3822 -0.88210267 0.00072234 0.02575331 CDSN 
ENSG00000105427 13390.0567 -0.88008507 0.00043658 0.01832405 CNFN 
ENSG00000163221 1528.94304 -0.87512587 2.29E-07 7.36E-05 S100A12 
ENSG00000182489 542.511261 -0.87484192 3.36E-07 9.73E-05 XKRX 
ENSG00000204175 153.909115 -0.86950286 1.28E-06 0.00029333 GPRIN2 
ENSG00000106327 46.7176389 -0.8684959 9.15E-05 0.00641395 TFR2 
ENSG00000204421 3930.82629 -0.86441024 2.74E-06 0.00050485 LY6G6C 
ENSG00000171812 33.874487 -0.85831757 0.00071923 0.0257262 COL8A2 
ENSG00000213963 183.603614 -0.85562272 1.21E-05 0.00143864 LOC100130691 
ENSG00000146192 82.9910417 -0.85542677 1.58E-05 0.00174631 FGD2 
ENSG00000269855 322.702607 -0.85262452 0.00010854 0.00732036 RNF225 
ENSG00000171711 56.6438482 -0.84723865 0.00032032 0.01484644 DEFB4A 
ENSG00000169896 205.272045 -0.84485662 0.00021364 0.01113551 ITGAM 
ENSG00000283167 126.832279 -0.84373593 0.00013337 0.00812877 NA 
ENSG00000179388 816.375548 -0.84352611 5.09E-05 0.0042343 EGR3 
ENSG00000169509 5322.98824 -0.83998888 0.0012205 0.03783549 CRCT1 
ENSG00000140479 2270.3876 -0.83769404 4.91E-11 7.89E-08 PCSK6 
ENSG00000106484 176.164652 -0.83218157 0.00011723 0.00768425 MEST 
ENSG00000101577 273.071642 -0.83064922 7.62E-06 0.00105827 LPIN2 
ENSG00000198948 926.376416 -0.82914287 0.00127608 0.03921444 MFAP3L 
ENSG00000167759 5482.17759 -0.82851382 0.00058828 0.02235449 KLK13 
ENSG00000204618 1046.37417 -0.8275039 1.19E-06 0.00027685 RNF39 
ENSG00000276430 245.514883 -0.8260823 1.29E-12 4.56E-09 FAM25C 
ENSG00000152137 4289.16382 -0.82342086 1.19E-07 4.89E-05 HSPB8 
ENSG00000108309 523.927312 -0.82307847 7.73E-06 0.00105827 RUNDC3A 
ENSG00000134242 262.166068 -0.82203027 2.76E-05 0.00266935 PTPN22 
ENSG00000170426 3286.79961 -0.82104654 1.98E-06 0.00040613 SDR9C7 
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ENSG00000132170 84.7686778 -0.82051657 0.00077732 0.02714489 PPARG 
ENSG00000170423 4001.51057 -0.81908496 9.87E-06 0.00125529 KRT78 
ENSG00000137878 187.556643 -0.81366268 0.00167295 0.04781409 GCOM1 
ENSG00000283270 57.945824 -0.80755779 0.00013063 0.00809878 NA 
ENSG00000213904 91.873446 -0.80368946 0.00018044 0.01008969 LIPE-AS1 
ENSG00000179148 2150.66911 -0.80318487 2.82E-06 0.00051346 ALOXE3 
ENSG00000081181 276.498296 -0.79788461 0.00022481 0.01152167 ARG2 
ENSG00000069535 56.1485512 -0.7968147 0.00162143 0.04702765 MAOB 
ENSG00000073910 308.966697 -0.79592596 0.00018161 0.01009156 FRY 
ENSG00000184702 2020.60014 -0.79377698 1.11E-10 1.40E-07 SEPT5 
ENSG00000231672 40.6818906 -0.79302077 0.00044377 0.01840707 NA 
ENSG00000188089 9747.47179 -0.7914321 7.71E-06 0.00105827 PLA2G4E 
ENSG00000179859 359.066158 -0.78368578 1.19E-05 0.00143107 LOC284023 
ENSG00000177243 151.443432 -0.77966286 0.00069951 0.0253804 DEFB103B 
ENSG00000108839 249.557648 -0.77157434 3.16E-05 0.0030037 ALOX12 
ENSG00000229035 318.201074 -0.76507981 4.38E-07 0.00012491 NA 
ENSG00000274276 66.3224885 -0.76196596 0.00012136 0.0077695 CBSL 
ENSG00000176194 1096.08785 -0.75842045 7.77E-05 0.00567344 CIDEA 
ENSG00000148798 476.31571 -0.75719315 1.34E-07 5.37E-05 INA 
ENSG00000162444 265.125694 -0.75701048 7.48E-11 1.02E-07 RBP7 
ENSG00000204538 231.324728 -0.75095919 0.00063385 0.02351062 PSORS1C2 
ENSG00000069667 1241.23344 -0.74635599 0.00015805 0.00918673 RORA 
ENSG00000179913 895.464824 -0.74615557 3.69E-13 1.63E-09 B3GNT3 
ENSG00000175121 3087.23372 -0.73731343 1.69E-07 6.34E-05 WFDC5 
ENSG00000072954 213.970487 -0.73569194 0.0003835 0.01673211 TMEM38A 
ENSG00000173221 933.472085 -0.73479442 0.00038594 0.01674194 GLRX 
ENSG00000150471 96.2327106 -0.7285214 0.00048198 0.01966866 ADGRL3 
ENSG00000092295 11319.7318 -0.71999895 6.52E-05 0.0050716 TGM1 
ENSG00000269741 2122.38047 -0.71742276 0.00013511 0.00820414 KLK9 
ENSG00000102886 999.640387 -0.7161523 1.14E-05 0.00139273 GDPD3 
ENSG00000159958 96.4132669 -0.71257223 0.00120801 0.03764642 TNFRSF13C 
ENSG00000255501 2374.57461 -0.71066529 1.62E-05 0.00177405 CARD18 
ENSG00000166828 132.101477 -0.70978713 8.82E-05 0.00626092 SCNN1G 
ENSG00000100889 1015.4049 -0.7086388 4.87E-08 2.77E-05 PCK2 
ENSG00000188001 814.191268 -0.70849709 8.80E-06 0.00115196 TPRG1 
ENSG00000149328 276.145628 -0.70655603 0.00023091 0.01175843 GLB1L2 
ENSG00000135114 674.783418 -0.70112737 7.48E-06 0.00104957 OASL 
ENSG00000111319 3699.13668 -0.69825182 3.20E-06 0.0005441 SCNN1A 
ENSG00000143412 1993.46922 -0.69713954 0.00012628 0.00794106 ANXA9 
ENSG00000167914 3408.25825 -0.69612722 0.00043644 0.01832405 GSDMA 
ENSG00000158220 520.741592 -0.69127497 0.00128079 0.03929077 ESYT3 
ENSG00000182040 87.0928916 -0.68645802 0.0002069 0.01085063 USH1G 
ENSG00000069011 1329.72135 -0.68622372 3.36E-05 0.00312214 PITX1 
ENSG00000179846 1091.93165 -0.68433173 1.56E-05 0.00174143 NKPD1 
ENSG00000060982 910.805475 -0.68062986 0.00013311 0.00812877 BCAT1 
ENSG00000186474 1175.97246 -0.67825105 1.21E-05 0.00143864 KLK12 
ENSG00000203785 8623.65197 -0.67612988 1.68E-07 6.34E-05 SPRR2E 
ENSG00000022567 482.102587 -0.67330246 0.00077688 0.02714489 SLC45A4 
ENSG00000261175 105.730542 -0.67011847 7.83E-05 0.00569715 LOC102724344 
ENSG00000072952 61.6556608 -0.67006417 0.00113981 0.03615887 MRVI1 
ENSG00000108244 5044.55271 -0.66373969 1.77E-06 0.0003763 KRT23 
ENSG00000241794 2746.21293 -0.66358261 2.72E-06 0.00050485 SPRR2A 
ENSG00000275880 272.512208 -0.66338464 7.39E-05 0.00553185 NA 
ENSG00000259581 70.9867833 -0.66334985 0.00108459 0.03478164 NA 
ENSG00000280587 90.774473 -0.66047256 0.00150839 0.04442212 NA 
ENSG00000197580 67.071225 -0.65858028 0.00139862 0.04177176 BCO2 
ENSG00000180155 5430.49867 -0.65855937 5.86E-09 4.50E-06 LYNX1 
ENSG00000129521 689.749124 -0.65757055 0.00026577 0.0129958 EGLN3 
ENSG00000182378 2433.78009 -0.65696922 1.52E-05 0.00170768 PLCXD1 
ENSG00000118402 3420.45053 -0.65495378 6.03E-05 0.00479662 ELOVL4 
ENSG00000104055 940.039568 -0.65374843 6.38E-05 0.00503045 TGM5 
ENSG00000188277 462.41795 -0.65172371 0.00090067 0.02997147 C15orf62 
ENSG00000100368 121.162019 -0.64976468 0.00059992 0.02269937 CSF2RB 
ENSG00000259153 280.466467 -0.64953206 3.13E-07 9.36E-05 NA 
ENSG00000182749 4013.38672 -0.64923205 6.30E-09 4.64E-06 PAQR7 
ENSG00000185052 90.0202632 -0.64635358 0.00022496 0.01152167 SLC24A3 
ENSG00000171954 5727.90711 -0.64471021 0.00053736 0.02119437 CYP4F22 
ENSG00000157368 280.223859 -0.64331379 0.00084254 0.02885217 IL34 
ENSG00000103888 502.460984 -0.6426779 1.75E-06 0.00037611 CEMIP 
ENSG00000237499 168.065878 -0.64130758 0.0008995 0.02997147 LOC100130476 
ENSG00000100170 2707.53724 -0.63989566 8.46E-07 0.00021654 SLC5A1 
ENSG00000036672 501.451051 -0.63961913 8.52E-05 0.0060931 USP2 
ENSG00000014257 871.41059 -0.63937138 0.00013284 0.00812877 ACPP 
ENSG00000133401 1142.31268 -0.63926113 0.00049888 0.0200804 PDZD2 
ENSG00000070669 573.242 -0.63897125 2.10E-07 6.99E-05 ASNS 
ENSG00000136840 632.952461 -0.6377598 9.51E-10 9.33E-07 ST6GALNAC4 
ENSG00000180316 843.974492 -0.63609499 0.00043563 0.01832405 PNPLA1 
ENSG00000236824 152.63427 -0.63376792 0.00171794 0.04856967 BCYRN1 
ENSG00000198478 1292.46644 -0.63373919 0.00018132 0.01009156 SH3BGRL2 
ENSG00000126878 636.418581 -0.63217066 4.35E-09 3.66E-06 AIF1L 
ENSG00000145283 402.39556 -0.63041058 0.00012339 0.00781458 SLC10A6 
ENSG00000105889 160.774856 -0.63018235 1.09E-06 0.00026798 STEAP1B 
ENSG00000158786 706.216336 -0.62669783 0.00039025 0.01685977 PLA2G2F 
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ENSG00000255138 909.080055 -0.62488652 0.00017645 0.00992951 NA 
ENSG00000197191 2342.43047 -0.62380953 0.00013341 0.00812877 CYSRT1 
ENSG00000006625 5621.43316 -0.62189542 0.00094801 0.03113638 GGCT 
ENSG00000169213 79.7631689 -0.62076173 0.00063064 0.02349715 RAB3B 
ENSG00000198885 64.6885461 -0.6196484 0.00107902 0.03466594 ITPRIPL1 
ENSG00000142677 2598.83165 -0.61928527 8.60E-06 0.00114233 IL22RA1 
ENSG00000156675 4376.72631 -0.6189653 2.45E-07 7.74E-05 RAB11FIP1 
ENSG00000108379 234.678786 -0.61739579 0.00025931 0.0127988 WNT3 
ENSG00000196542 1252.27912 -0.61692836 0.00030791 0.01454766 SPTSSB 
ENSG00000105289 227.067392 -0.61592177 2.43E-05 0.00243892 TJP3 
ENSG00000196805 764.811964 -0.61452343 6.95E-07 0.00018326 SPRR2B 
ENSG00000116741 167.147564 -0.61385043 0.00033072 0.01513961 RGS2 
ENSG00000124429 3884.18843 -0.61369446 4.23E-05 0.00371571 POF1B 
ENSG00000168140 891.968887 -0.61190753 0.00168478 0.047939 VASN 
ENSG00000130707 1127.15772 -0.61109251 5.57E-05 0.004512 ASS1 
ENSG00000163082 2179.70383 -0.60790471 0.00011509 0.00758834 SGPP2 
ENSG00000133048 139.138601 -0.60769443 0.00014238 0.00856217 CHI3L1 
ENSG00000170775 93.9171891 -0.60316721 0.00083883 0.02883609 GPR37 
ENSG00000184368 102.103273 -0.60086148 0.00088137 0.02960056 MAP7D2 
ENSG00000136153 1769.57186 -0.59802619 8.74E-06 0.00115196 LMO7 
ENSG00000233381 101.047522 -0.59618351 0.00106314 0.03421809 NA 
ENSG00000174502 185.746056 -0.59569578 0.0006064 0.02289536 SLC26A9 
ENSG00000196407 1366.53002 -0.59445611 0.00011011 0.00736969 THEM5 
ENSG00000166123 1721.06167 -0.59372136 1.06E-05 0.00131536 GPT2 
ENSG00000101096 394.234529 -0.59264292 0.00080201 0.02778736 NFATC2 
ENSG00000112033 5288.87242 -0.59256805 3.70E-12 8.17E-09 PPARD 
ENSG00000064270 1076.5338 -0.59232183 0.00125854 0.03881043 ATP2C2 
ENSG00000101849 1339.20421 -0.58916869 1.10E-07 4.62E-05 TBL1X 
ENSG00000064300 198.676688 -0.58718227 0.00031482 0.01476491 NGFR 
ENSG00000155324 828.778307 -0.58503049 5.02E-08 2.77E-05 GRAMD3 
ENSG00000173212 263.096427 -0.58370961 0.00110841 0.03548122 MAB21L3 
ENSG00000173083 1348.5552 -0.58258443 0.00019468 0.01044776 HPSE 
ENSG00000188505 11806.869 -0.57978795 6.54E-06 0.00096351 NCCRP1 
ENSG00000089723 1738.42677 -0.57938197 6.72E-06 0.00097367 OTUB2 
ENSG00000167767 13435.985 -0.57929441 0.00016627 0.00944664 KRT80 
ENSG00000141655 389.107419 -0.57823448 0.00043907 0.01834116 TNFRSF11A 
ENSG00000169474 68783.4527 -0.57705692 3.09E-06 0.00054073 SPRR1A 
ENSG00000158158 968.605702 -0.57446609 4.17E-05 0.00370175 CNNM4 
ENSG00000197372 463.840954 -0.57369826 0.00156343 0.04593365 ZNF675 
ENSG00000189051 612.398247 -0.57355735 0.00159433 0.04648819 RNF222 
ENSG00000124102 135631.372 -0.57242148 5.97E-08 2.93E-05 PI3 
ENSG00000135709 4706.17223 -0.56926207 4.73E-05 0.00401447 KIAA0513 
ENSG00000168447 2064.89785 -0.56786773 0.0003693 0.01635451 SCNN1B 
ENSG00000057657 1262.42699 -0.56527366 0.00014921 0.00878874 PRDM1 
ENSG00000261040 943.978551 -0.56519878 7.23E-05 0.00550415 WFDC21P 
ENSG00000189433 1066.9903 -0.56270636 1.36E-06 0.00030317 GJB4 
ENSG00000135069 1348.93701 -0.56257812 2.70E-05 0.0026533 PSAT1 
ENSG00000121316 2575.3047 -0.56142905 4.33E-09 3.66E-06 PLBD1 
ENSG00000122643 463.17592 -0.56060577 5.35E-05 0.00435508 NT5C3A 
ENSG00000138678 163.113427 -0.55910744 0.00057852 0.02222257 GPAT3 
ENSG00000141574 154.127317 -0.55219749 0.00042616 0.0181015 SECTM1 
ENSG00000144452 12011.8166 -0.55017316 0.00121441 0.03777935 ABCA12 
ENSG00000071242 640.909899 -0.54861928 4.01E-06 0.00065609 RPS6KA2 
ENSG00000122694 341.097576 -0.5456174 0.00023595 0.01194618 GLIPR2 
ENSG00000134955 5481.98317 -0.54287887 0.00166857 0.04781409 SLC37A2 
ENSG00000105825 665.040185 -0.54065298 0.00084044 0.02883609 TFPI2 
ENSG00000135605 180.52257 -0.53967095 0.00038577 0.01674194 TEC 
ENSG00000243137 149.609177 -0.53915114 0.00112103 0.03575545 PSG4 
ENSG00000078900 324.900769 -0.53868345 0.00023951 0.01205746 TP73 
ENSG00000066629 697.617564 -0.53635421 3.96E-06 0.00065466 EML1 
ENSG00000129455 6500.21654 -0.53398002 2.80E-07 8.53E-05 KLK8 
ENSG00000148154 1505.45963 -0.53346948 0.00124463 0.03844855 UGCG 
ENSG00000170786 2071.38816 -0.53343487 8.20E-05 0.00594083 SDR16C5 
ENSG00000100285 168.6928 -0.53268478 0.00079579 0.02762602 NEFH 
ENSG00000197822 507.065989 -0.53186711 0.00031776 0.01481485 OCLN 
ENSG00000166396 12059.4734 -0.52999968 1.69E-06 0.00036846 SERPINB7 
ENSG00000204866 4603.72894 -0.52950877 1.69E-05 0.00180659 IGFL2 
ENSG00000101846 204.440526 -0.52753945 0.00096846 0.03169006 STS 
ENSG00000087128 919.180662 -0.52354628 4.32E-05 0.00372032 TMPRSS11E 
ENSG00000155158 1367.09542 -0.52312054 0.00093756 0.03090791 TTC39B 
ENSG00000101825 553.05157 -0.52242399 1.37E-05 0.00157713 MXRA5 
ENSG00000205488 353.335067 -0.52084878 0.00163122 0.04709737 NA 
ENSG00000184148 1596.9211 -0.52059334 0.00075979 0.0267691 SPRR4 
ENSG00000189182 975.871337 -0.52010863 6.50E-05 0.0050716 KRT77 
ENSG00000139433 39015.9653 -0.51977203 7.07E-06 0.00101613 GLTP 
ENSG00000137563 2490.17643 -0.51934203 5.05E-06 0.00079459 GGH 
ENSG00000136155 12503.0891 -0.51864667 0.00014637 0.00870823 SCEL 
ENSG00000035862 1356.79083 -0.51598786 0.00027336 0.01323741 TIMP2 
ENSG00000126903 1721.47116 -0.51578092 2.28E-07 7.36E-05 SLC10A3 
ENSG00000145934 8356.26109 -0.51409535 0.00058365 0.02229914 TENM2 
ENSG00000139988 4046.88867 -0.51345055 0.00094165 0.03098493 RDH12 
ENSG00000088002 10616.9111 -0.50967355 3.98E-05 0.00358643 SULT2B1 
ENSG00000153292 775.30613 -0.50919351 0.00041463 0.01773984 ADGRF1 
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ENSG00000137486 638.278236 -0.50879449 0.00015995 0.00926649 ARRB1 
ENSG00000162390 1871.41858 -0.50854755 2.46E-06 0.00047238 ACOT11 
ENSG00000100344 560.259883 -0.50806306 0.00047704 0.01955735 PNPLA3 
ENSG00000070159 2367.72005 -0.50797589 2.04E-07 6.92E-05 PTPN3 
ENSG00000160179 850.861419 -0.50570073 0.00133792 0.04076031 ABCG1 
ENSG00000261068 772.807209 -0.50496022 3.72E-06 0.00061955 NA 
ENSG00000244094 2183.01387 -0.50459319 3.15E-06 0.00054073 SPRR2F 
ENSG00000153246 594.788669 -0.50291983 0.00032096 0.01484644 PLA2R1 
ENSG00000237350 845.68632 -0.50188468 0.00022235 0.01145473 NA 
ENSG00000173210 665.127643 -0.50010096 1.94E-07 6.72E-05 ABLIM3 
ENSG00000162066 557.998688 0.5107202 3.11E-06 0.00054073 AMDHD2 
ENSG00000094796 1066.08115 0.51451711 0.00139926 0.04177176 KRT31 
ENSG00000147889 351.142108 0.51732486 0.00086186 0.02922193 CDKN2A 
ENSG00000198715 1018.68266 0.52209751 8.64E-05 0.00615411 GLMP 
ENSG00000137343 173.054374 0.52637175 1.73E-05 0.0018457 ATAT1 
ENSG00000171621 753.517322 0.52645727 0.00170943 0.04840647 SPSB1 
ENSG00000213366 150.786843 0.53325298 0.00011175 0.00743091 GSTM2 
ENSG00000178467 150.567376 0.54270124 2.16E-05 0.00221527 P4HTM 
ENSG00000133069 205.086057 0.55125401 0.00117235 0.03686021 TMCC2 
ENSG00000035664 271.970871 0.56104127 0.00052741 0.0209421 DAPK2 
ENSG00000115648 202.137305 0.58764872 0.00085486 0.029161 MLPH 
ENSG00000114812 527.398531 0.59570349 5.26E-05 0.00432573 VIPR1 
ENSG00000147883 8539.40571 0.60948091 0.00010532 0.00718343 CDKN2B 
ENSG00000125772 620.355603 0.62112606 0.00010413 0.00713195 GPCPD1 
ENSG00000139631 222.162215 0.62468355 7.74E-05 0.00567335 CSAD 
ENSG00000135218 1997.65758 0.65823086 1.35E-05 0.0015689 CD36 
ENSG00000111432 165.726492 0.66578083 0.00011878 0.00768425 FZD10 
ENSG00000088756 221.992909 0.66817817 0.00137975 0.04175577 ARHGAP28 
ENSG00000188883 190.415467 0.67495482 0.00161407 0.04690895 KLRG2 
ENSG00000138606 979.872692 0.69340706 5.16E-06 0.00080003 SHF 
ENSG00000182272 68.6146902 0.69606089 0.00047379 0.01951503 B4GALNT4 
ENSG00000184545 169.577824 0.71013074 6.96E-05 0.00534467 DUSP8 
ENSG00000128849 261.205746 0.71112757 7.36E-05 0.00553185 CGNL1 
ENSG00000050438 71.4982862 0.71269616 0.00126217 0.0388545 SLC4A8 
ENSG00000130600 625.665104 0.72151234 1.68E-05 0.00180659 H19 
ENSG00000170454 1235.92488 0.7354675 6.41E-05 0.0050311 KRT75 
ENSG00000129946 89.5935643 0.7370941 0.00051255 0.020537 SHC2 
ENSG00000250722 660.406622 0.75102231 2.15E-05 0.00221527 SELENOP 
ENSG00000165092 809.433746 0.75363186 5.98E-06 0.00089486 ALDH1A1 
ENSG00000100767 255.830958 0.75510461 0.00093297 0.03084324 PAPLN 
ENSG00000198832 228.097785 0.767709 4.37E-05 0.0037457 SELENOM 
ENSG00000092096 51.9518257 0.80943674 0.00011186 0.00743091 SLC22A17 
ENSG00000166405 40.1165785 0.81963125 0.00156492 0.04593365 RIC3 
ENSG00000263639 37.0216264 0.82023467 5.96E-05 0.00478964 MSMB 
ENSG00000126217 34.1288481 0.84702097 0.00170068 0.04831343 MCF2L 
ENSG00000144821 185.151601 0.85247711 0.00055677 0.02180801 MYH15 
ENSG00000016082 134.770823 0.88159942 7.89E-10 8.20E-07 ISL1 
ENSG00000104081 158.583269 0.89080707 0.00013564 0.00820826 BMF 
ENSG00000143595 24.1410857 0.93509011 0.00133239 0.04066221 AQP10 
ENSG00000197635 835.905675 0.9418402 1.75E-11 3.09E-08 DPP4 
ENSG00000186891 42.0667921 0.98970837 0.00019427 0.01044776 TNFRSF18 
ENSG00000123612 20.1001669 1.00013431 0.00150011 0.04425202 ACVR1C 
ENSG00000114013 32.2780116 1.06690818 0.00040786 0.01749244 CD86 
ENSG00000006025 45.6921496 1.08577094 6.01E-05 0.00479662 OSBPL7 
ENSG00000123095 153.782993 1.09323924 3.44E-05 0.00313871 BHLHE41 
ENSG00000137673 30.9583265 1.15400175 0.00070764 0.02546623 MMP7 
ENSG00000124875 26.0787286 1.19581501 0.00088417 0.02960056 CXCL6 
ENSG00000185634 13.6525308 1.28827026 0.00158395 0.04633845 SHC4 
ENSG00000071282 18.8189862 1.47380916 3.31E-05 0.00309227 LMCD1 
ENSG00000159674 846.686296 1.55319853 4.41E-14 2.60E-10 SPON2 
ENSG00000137507 160.788174 1.63903828 0.00113081 0.03593777 LRRC32 
ENSG00000169116 193.343707 1.66484148 1.60E-12 4.72E-09 PARM1 
ENSG00000162747 20.5353973 1.66494169 2.10E-06 0.00042501 FCGR3B 
ENSG00000065371 12.549066 1.70006403 0.00047604 0.01955735 ROPN1 
ENSG00000204136 9.428147 1.70582179 0.00012761 0.00797992 GGTA1P 
ENSG00000105664 66.2751954 2.70167068 6.07E-07 0.00016752 COMP 
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